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Abstract 
 
 Polyadenylation by the mitochondrial poly(A) polymerase (mtPAP) is a crucial 
step of post-transcriptional modification in mammalian gene expression. In human 
mitochondria, polyadenylation is required for completion of seven UAA stop codons 
following complete processing of the major polycistronic RNA unit. Patients 
homozygous for a 1432A>G mutation in the PAPD1 gene, which encodes mtPAP, suffer 
from symptoms consistent with mitochondrial disease including autosomal-recessive 
spastic ataxia and optic atrophy. The principal defect of the 1432A>G mutation is short 
adenylate tails on mt-mRNAs. Fibroblast lines from patients harboring the 1432A>G 
PAPD1 mutation were established, and analysis of mitochondrial gene expression showed 
non-uniform dysregulation. For mt-mRNAs and translation products, there is a mix of 
depletion, stabilization and no effect, leading to major deficits at steady-state protein 
levels and of respiratory complexes. To confirm the pathological nature of the mutation, a 
complementation experiment was performed, which showed that expression of the WT 
PAPD1 gene rescued the mutant phenotype. To assess whether catalytic activity was 
altered in the mutant enzyme, in vitro polyadenylation assays with WT and N478D 
recombinant mtPAP were undertaken. The N478D mtPAP was found to generate the 
short oligo(A) tails as observed in vivo. In addition, the presence of the LRPPRC/SLIRP 
complex increased the maximal poly(A) extensions generated by both WT and mutant 
mtPAP. Finally, experiments were undertaken to identify factors potential interacting 
with mtPAP. The major interacting factor was found to be ATAD3, a protein reported to 
be involved with multiple mitochondrial processes involving DNA and translation 
machinery in the form of nucleoids or mitoribosomes respectively. In summary, these 
investigations provide insights into the impact and regulation of mitochondrial 
polyadenylation, and contribute towards unraveling the complexities of post-
transcriptional maturation in human mitochondrial gene expression. 
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Introduction 
 
1.1   Mitochondria - General Background  
 
 Eukaryotic cells have long benefitted from the acquisition of the mitochondrial 
organelle from its prokaryotic ancestry. Its numerous functions in mammalian cells 
include carrying out oxidative phosphorylation, housing the Krebs cycle, playing a central 
role in apoptotic cell death pathways, calcium homeostasis, and the most highly 
conserved function: biogenesis of iron-sulfur clusters. Other than the nucleus, it is the 
only organelle in human cells that contains its own genome (mtDNA), encoding its own 
proteins, rRNA, and tRNAs. As my research has focused exclusively on human 
mitochondria any references to mitochondria in this thesis will be human-oriented unless 
specified otherwise.  
 Mitochondria exhibit a filamentous and reticular structure. The word 
mitochondrion comes from the Greek words mitos and chondrion, which mean thread and 
granule, respectively. Visible by both light and electron microscopy, the organelles range 
from 0.2-0.8um in length and 0.5-2um in width (Kaasik et al., 2007). The number of 
mitochondria present in cells is usually closely related to their metabolic demand. Thus 
highly energetic tissues such as brain, skeletal muscle, cardiac muscle, and liver are 
especially enriched in mitochondrial mass (Veltri et al., 1990). The genetic material of the 
organelle, mitochondrial DNA is a double-stranded, circular molecule encoding genes 
that are not represented in the nucleus and are located within the organelle. Each cell can 
contain hundreds to thousands of copies of mtDNA molecules, with oocytes harboring at 
least 100,000 copies (Satoh and Kuroiwa, 1991; Chinnery et al., 2000; Craven et al., 
2010).  
 Over the course of evolution, much of the mitochondrial genomic burden was 
transferred to the nuclear genome. As a result, there remain only 13 polypeptides, 2 
rRNAs, and 22 tRNAs encoded in mtDNA. All the encoded proteins are components of 
the complexes involved in oxidative phosphorylation. The remaining subunits of the 
complexes are encoded in the nuclear DNA, synthesized in the cytosol, and transported 
into mitochondria after translation is complete (Schatz, 1996). This is also the case for all 
other proteins operating in and constituting the mitochondria that are not encoded in 
mtDNA, including RNA and DNA polymerases, nucleases, and membrane proteins. 
Knowing that the estimated number of proteins necessary for a functional organelle is 
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approximately 1500, and that the mtDNA only encodes 13 proteins, it is approximated 
that mitochondria contribute ~0.1% of their own total proteome content (Taylor et al., 
2003). The mitochondrion is unique from all other human organelles in the necessity of 
this dual genome support required for function. This is in notable contrast to plants where 
in addition to mitochondria, chloroplasts contain their own DNA, and import proteins 
encoded by the nucleus for proper functioning (Soll and Schleiff, 2004).   
 
1.2   Evolutionary origins of mitochondria in eukaryotes 
  
 Mitochondria have been evolving within eukaryotic cells ever since the initial 
endosymbiotic event took place 1.5 billion years ago (Brocks et al., 1999; Gray et al., 
1999). Over this time, many changes have occurred during the complex transition from 
discrete organism to cellular organelle. There are many mitochondrial variants in 
eukaryotic cells, from human mitochondria that produce approximately 95% of cellular 
ATP, mitochondria-like organelles that generate ATP from alterative electron acceptors 
such as NO3 (Kobayashi et al., 1996) to the mitosomes of E. cuniculi that scavenge ATP 
from the cytosol of their ‘host’ (Tsaousis et al., 2008). The diverse spectrum of 
mitochondria-like organelles can broadly be categorized into three groups: classical 
mitochondria, hydrogenosomes, and mitosomes. Hydrogenosomes are anaerobic, lacking 
respiratory complexes and generating ATP through H2 production. This is accomplished 
with alternatives to mitochondrial metabolic enzymes. For example, decarboxylating 
pyruvate using pyruvate:ferredoxin oxidoreductase instead of pyruvate dehydrogenase 
(Hackstein et al., 1999). While hydrogenosomes can be viewed as the anaerobic 
counterpart to mitochondria, they notably differ in that most of them do not harbor their 
own genetic material. Mitosomes also lack organellar DNA and they do not produce 
ATP. However, all three types of mitochondria-like organelles carry out the crucial 
cellular activity of iron-sulfur cluster formation. While broad groupings may allow for 
easy comparison and contrast between the degrees of metabolic engagement of these 
related organelles, it certainly underplays the range of forms they exhibit. 
Hydrogenosome-like organelles have been identified in metazoans that live exclusively in 
conditions lacking molecular oxygen (Danovaro et al., 2010). 
 The ancestor of modern human mitochondria is thought to be an α-proteobacteria 
(Andersson et al., 1998), although many facets of the proto-mitochondria acquisition by 
the host cell are unresolved, including where in the phylogenetic tree of α-proteobacteria 
the actual endosymbiont is located. The exact conditions that initiated the endosymbiotic 
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event are also controversial. Moreover, disagreement exists over whether the host cell had 
at that point acquired a nucleus (Mans et al., 2004), or was exhibiting a less 
compartmentalized structure (Martin 2005).  
 The conventional view on the symbiotic relationship exhibited by the proto-
mitochondria is based on the benefits of ATP provided by aerobic respiration. The 
ATP/ADP transport system is not bacterially derived, but instead is a member of a larger 
eukaryotic transport family. Thus, it would be difficult for the host cell to immediately 
take advantage of the newfound ATP source (Karlberg et al., 2000). A possible 
explanation of the immediate benefit of the endosymbiont is a reduction in local oxygen 
tension via respiration (Kurland and Andersson, 2000). At the time of the endosymbiotic 
event, oxygen in the Earth's atmosphere was increasing, potentially creating a toxicity 
crisis for life forms not adapted to the high levels of oxidative exposure (Des Marais, 
1998; Brocks et al., 1999). Anaerobic organisms would be at a disadvantage in this 
setting. So acquisition of the endosymbiont to the host cell would provide substantial 
benefits in the form of protection from a relatively harsh oxidative environment. 
 Over the course of evolution with the host cell, the majority of genes from proto-
mitochondria have either been lost or transferred to the nucleus. This mixture of gene loss 
or transfer makes estimations of the size of the proto-mitochondrial genome difficult. The 
modern mitochondrial proteome results from expression of a mixture of genes derived 
from ancestral α-proteobacteria, mitochondrial genes transferred to the nucleus, and novel 
eukaryotic genes. There is wide variation of gene loss/transfer between modern α-
proteobacterial descendents, with some losing their entire genome (most hydrogenosomes 
and all mitosomes) and others keeping a subset of genes encoded on mtDNA (Hackstein 
et al., 2006). The mammalian mitochondrial proteome is becoming increasingly well 
characterized, with more than 1,100 proteins identified (Rabilloud et al., 1998; 
Catherman et al., 2013; Lotz et al., 2013). Of the identified mitochondrial proteins, 
approximately two-thirds have bacterial origins, with the remaining proteins rising from 
the eukaryotic genome (Szklarczyk and Huynen, 2010). In contrast to the mitochondrial 
proteome, mtDNA appears to have a monophyletic origin (Andersson et al., 1998). The 
continued existence of mtDNA represents a major investment of resources for the 
eukaryotic cells, as the persisting mitochondrial genome necessitates dedicated gene 
expression machinery. While requiring less maintenance than the nuclear genome, the 
investment in retaining mtDNA is still substantial enough that there is likely to be 
significant benefit to the cell. This may be tied into the fact that oxidative 
phosphorylation cannot occur without a subset of respiratory chain complex components 
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being produced inside the mitochondrion. Possible reasons for this are debated, but two 
proposed theories are the "hydrophobicity theory" (von Heijne, 1986) and the "co-
location for redox regulation theory" (Allen and Raven, 1996). The first theory proposes 
that certain genes have been retained in the mitochondrial genome due to the high degree 
of hydrophobicity of their protein products, which would make transport from the cytosol 
across the mitochondrial membranes difficult. The second theory proposes that having 
specific genes housed in the mitochondrial genome allows for the direct regulation of 
expression of those genes, based on the redox state of mitochondria. Both theories argue 
for a spatial advantage of producing mitochondrial gene products within the organelle, 
versus cytosolic translation followed by import.  
 
1.3.  Structure and dynamics of the mitochondrion 
  
 The morphology of mitochondria is dynamic, constantly undergoing fission and 
fusion. The organelle is present as a reticular network, and varies in distribution 
throughout the cell (Figure 1.1). Although previously thought to possess a discrete and 
static structure, mitochondria are currently appreciated as a population of organelles that 
are able to migrate throughout the cell, undergo processes of fusion and fission, and 
turnover in a regulated manner. This facilitates their function by enabling recruitment to 
subcellular compartments, content exchange between mitochondria, morphology changes, 
and mitochondrial quality control (Chan, 2006).  
 There are five mitochondrial compartments; the outer membrane (OMM), the 
intermembrane space (IMS), the inner membrane (IMM), cristae and the mitochondrial 
 
 
Figure 1.1. The reticulum structure of mitochondria 
Human fibroblast mitochondria stained with anti-Complex V (ATPase β) antibodies (green), the nucleus is stained with 
DAPI (blue), and visualized by fluorescent microscopy. Image used with permission of MitoSciences, Inc.  
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matrix. The outer membrane encloses the organelle, and is more permissive to the 
transport of molecules due to an array of transporters and channels. The ratio of protein to 
lipids differs between the two membranes of mitochondria, with the inner membrane 
exhibiting a 3:1 ratio, and a 1:1 ratio for the outer membrane (Hoch, 1992; Gohil and 
Greenberg, 2009). Mitochondrial membranes are particularly enriched in phospholipids. 
This phospholipid composition also differs between membranes. The inner membrane is 
composed of a higher percent of unsaturated fatty acids, including the signature 
mitochondrial lipid, cardiolipin. The presence of cardiolipin in the outer membrane has 
been a controversial topic but recent studies in yeast have shown evidence of cardiolipin 
located in the outer membrane (Gebert et al., 2009). The total phospholipid composition 
of mitochondria consists of approximately 40% phosphatidylcholine, 30% 
phosphatidylethanolamine, 10-15% cardiolipin/phosphatidylinositol, and 5% 
phosphatidic acid/phosphatidylserine (Colbeau et al., 1971; Osman et al., 2011). More 
common membrane lipids, such as sterols and sphingolipids, which are important 
components of the endoplasmic reticulum, Golgi apparatus, lysosome membranes, are 
only found in trace amounts in mitochondrial membranes (van Meer et al., 2008). 
 Both membranes house an array of protein machinery. These include porin (also 
known as voltage-dependent anion channel, VDAC), and the translocases of the 
outer/inner membrane (TOM/TIM) complexes. The machinery that facilitates fusion and 
fission are also present, with the major known players being the mitofusins 
(MFN1/MFN2) on the outer membrane and OPA1 on the inner membrane. Critical 
mediators of mitophagy are also present on the outer membrane (Liu et al., 2012). The 
outer membrane is much more permeable to ions and small molecules than the inner 
membrane that strictly controls what crosses into the matrix.  
 Areas of the inner membrane exhibit highly folded structures termed "cristae", 
allowing for a larger surface area on which enzymatic reactions can take place. The 
complexes of the electron transport chain span the matrix side of the IMM and include 
transmembrane regions. Within the matrix, the majority of biochemical reactions specific 
to mitochondria occur. These include oxidative phosphorylation as well as the citric acid 
cycle, with pyruvate generated by glycolysis in the cytosol being imported into the matrix 
to fuel the reactions. The matrix also houses the mitochondrial gene expression 
machinery: mtDNA, mt-tRNAs, mt-mRNAs, mitoribosomes, and replication and 
transcription enzymes.   
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1.4   The electron transport chain and oxidative phosphorylation 
  
 One of the main functions of human mitochondria is the generation of ATP via 
oxidative phosphorylation (OXPHOS). Four protein complexes embedded in the inner 
mitochondrial membrane, namely NADH dehydrogenase (complex I), succinate 
dehydrogenase (complex II), coenzyme Q:cytochrome c reductase (complex III), and 
cytochrome c oxidase (complex IV). With the exception of complex II, all have subunits 
that are encoded in the mitochondrial genome. Together with the ATP synthase, Complex 
V, these complexes carry out oxidative phosphorylation. The process couples ATP 
generation with oxidation of NADH and FADH2 (Figure 1.2).  
 The feeding of electrons into the ETC comes from chemical reactions making up 
the Krebs cycle. Pyruvate, generated from sugars via glycolysis in the cytosol, is 
decarboxylated by pyruvate dehydrogenase into acetyl-CoA. Acetyl-CoA is then used as 
the starting molecule for the Krebs cycle. The complete oxidation of one acetyl-CoA 
molecule produces three NADH and one FADH2, which carry the electrons to be input 
into the ETC.  
 Electrons enter into the chain through complex I with the oxidation of NADH, and 
complex II oxidizes succinate in the Krebs cycle reducing FAD+ to FADH2. Oxidation of 
NADH and FADH2 reduce Coenzyme Q (CoQ), which transfers electrons to complex III. 
 
 
Figure 1.2 The electron transport chain 
The five complexes involved in oxidative phosphorylation are shown situated in the inner mitochondrial membrane 
(IMM). The respiratory complexes and ATP synthase are illustrated with different colors: green (complex I), beige 
(complex II), orange (coenzyme Q), yellow (complex III), cytochrome c (cyan), blue (complex IV), and red (ATP 
synthase). Coenzyme Q is labeled as "Q", and cytochrome c is labeled "Cyt c". Proton translocation, as well as 
chemical reactions are shown next to the complexes. Other abbreviations are NAD: nicotinamide-adenine 
dinucleotide; FAD: flavin-adenine dinucleotide; ADP: adenine diphosphate; Pi: inorganic phosphate; ATP: adenine 
triphosphate; IMS: intermembrane space. 
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Complexes I, III, and IV pump protons through the IMM as electrons flow along redox 
centers in the chain, creating an electrochemical gradient across the IMM. Oxygen is the 
terminal electron acceptor of the ETC, and is reduced to water by complex IV. The 
resulting gradient forces the protons that have built up in the intermembrane space back 
across the IMM and into the matrix through a fifth complex, ATP synthase. This 
movement of protons through ATP synthase energetically drives the conversion of ADP 
and inorganic phosphate to ATP. The ATP is then transported out of mitochondria via the 
adenine nucleotide translocator (ANT).  
 The individual respiratory complexes of the ETC are incorporated into larger 
"supercomplexes", structures composed of complexes I, II, III, IV, and the mobile 
electron carriers, Cyt c, and CoQ.  This structural organization has been proposed to 
stabilize the individual complexes, and enhance respiration through intimately 
coordinated electron flow. This interdependence is illustrated where a depletion of one 
complex can cause activity levels of another complex levels to drop (Acin-Perez et al., 
2008).  
 
 
1.5   The mitochondrial genome 
  
 At just 16,569 base pairs, the human mitochondrial genome is a fraction of the 
size of the nuclear genome. The encoded proteins, rRNAs, and tRNAs, however, are 
essential for mitochondrial gene expression. Over the course of the estimated 1500 
million years (Sicheritz-Pontén et al., 1998) of evolving in synchrony with the eukaryotic 
nuclear genome, the mitochondrial genome has become reduced from the full 
complement of genes necessary to support an independent organism to a total of just 37 
genes. All other genes were either lost over time or transferred to the nuclear genome 
through a variety of proposed mechanisms, such as gene transfer agents (GTAs) 
(McDaniel et al., 2010), transformation (Williams et al., 1997), or transduction (Jiang and 
Paul, 1998). Further evidence of the relationship to ancient α-proteobacteria is found in 
the genes that still remain in the mitochondrial DNA, via their similarity to some modern 
day α-proteobacterial genomes (Andersson et al., 1998; Georgiades and Raoult, 2011). 
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 In contrast to many mtDNA genomes, such as yeast and plants (Lang et al., 1999), 
human mtDNA possesses an economical and highly compact organization. It is also 
unlike the human nuclear genome as human mtDNA has very few non-coding regions 
and many genes are only separated by a few base pairs. The sole exception is an 
approximately 1100bp section of mtDNA termed the displacement loop, or "D-Loop". 
The D-Loop houses elements involved in regulating mtDNA replication and transcription 
initiation. It also possesses an uncommon triple-stranded helix structure. There are no 
introns in human mtDNA, making splicing machinery within the organelle unnecessary. 
Many protein-coding genes are separated by tRNA genes, but MTCOI, RNA14, 
MTND5/MTND6 and MTCYB are exceptions. 
 The mtDNA molecule is double-stranded, and contains two separate origins of 
replication, each dedicated to one strand. The strands are referred to as the heavy (H-) 
strand and the light (L-) strand, due to their separation in cesium chloride gradients 
resulting from the guanine nucleotide bias of the heavy strand. Only the MTND6 gene and 
eight tRNA genes are located on the L-strand, all other mitochondrial-encoded genes are 
found on the H-strand (Figure 1.3). The origin of replication for the H-strand is located in 
the D-Loop, while the origin of replication for the L-strand is between the tRNA 
asparagine and cysteine genes. 
 There are three promoters for the initiation of transcription, which occurs in a bi-
directional fashion. Two are located on the H-strand, termed HSP1 and HSP2, with the 
 
 
Figure 1.3 The human mitochondrial genome  
Genes and rRNAs are labeled with their names, and tRNAs are represented by circles with their single letter amino acid 
codes. The heavy and light strands are shown as separate rings. Genes belonging to specific respiratory complexes or 
rRNA are shown as boxes and labeled as follows: rRNA (red), complex I (blue), complex III (violet), complex IV (green), 
complex V (cyan). Origins of the heavy and light strand are shown with arrows marking their initiation sites and directions.  
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third found on the L-strand (LSP) (Montoya et al., 1982). HSP1 and LSP are housed in 
the D-Loop region, while HSP2 is located past the tRNA phenylalanine gene, upstream to 
the 5' end of the 12S rRNA.    
 Within an individual cell, it is possible for variants of mtDNA to exist, a condition 
termed heteroplasmy. When pathological mutations or DNA deletions occur in these 
variants, mitochondrial dysfunction can result (Holt et al., 1990). The severity of the 
clinical presentation can be dependent on the ratio of wildtype to altered mtDNA 
(Chinnery et al., 1997). Thus, heteroplasmy does not necessarily result in a clinically 
pathological condition (Kirches et al., 2001), but can lead to increasingly severe 
mitochondrial biochemical dysfunction if the percentage of the mtDNA population 
becomes too high (Rossignol et al., 1999). This is termed "the threshold effect", and 
occurs in the range of 70-90% mutant heteroplasmy (Rossignol et al., 1999). However, 
certain mutations, such as those in tRNA genes, can be functionally dominant and require 
<25% heteroplasmy levels to exert pathological effects. (Sacconi et al., 2008).  
 mtDNA molecules are organized into discrete nucleoprotein units, called 
nucleoids. The number of mtDNA molecules per nucleoid has been contested, ranging 
from one to ten (Iborra et al., 2004; Bogenhagen et al., 2008; Kukat et al., 2011). The 
exact complement of proteins packaged with the mtDNA has also been disputed, however 
the minimum necessary is the mitochondrial transcription factor A (TFAM). The number 
of TFAM molecules bound to the mtDNA has been estimated at approximately one per 
20bp (Kukat et al., 2011). There are many other factors associated with the nucleoids, 
such as those involved in replication and transcription machinery, but the exact definition 
of nucleoid components and nucleoid-associated factors is still being refined. A recurring 
issue is the conflicting composition of nucleoids and their associated factors based on 
different preparation methods (He et al., 2007; Bogenhagen et al., 2008).  
 
1.6   Replication of mitochondrial DNA 
  
 The major factors involved in mtDNA replication are a mitochondria-specific 
DNA polymerase called POLG (polymerase gamma), the helicase TWINKLE, and the 
mitochondrial single-strand binding protein (mtSSB). POLG is a heterotrimer, composed 
of a catalytic subunit (POLGA), and two accessory subunits (POLGB). TWINKLE is a 
5'-3' DNA helicase, and forms a stable hexamer or heptamer (Ziebarth et al., 2010). As its 
name suggests, mtSSB binds ssDNA, and is involved with stabilization and protection of 
the single strand during replication. The minimal complement of replication factors 
12 
 
necessary for reconstituting mtDNA replication in vitro are POLG and TWINKLE, and 
these proteins together are capable of synthesizing 2kb of ssDNA (Korhonen et al., 2004). 
With mtSSB added in, synthesis is stimulated to over 16kb (Korhonen et al., 2004). In 
vivo, the mitochondrial RNA polymerase (POLRMT) is necessary for replication of each 
strand, by generating RNA primers that initiate DNA synthesis (Fuste et al., 2010; 
Wanrooij et al., 2010). 
 There are currently at least two proposed theories on the mechanism of replication 
for mtDNA, and a third, particularly controversial theory. They are termed the 
"asynchronous strand displacement model", and the "strand coupled bidirectional 
replication model". In the first model, mtDNA replication occurs in an asymmetric 
fashion where the synthesis of DNA is initiated at the H-strand origin within the D-loop 
via RNA primers, then proceeds unidirectionally downstream. After about two-thirds of 
the H-strand has been replicated, the origin on the L-strand is exposed to the replication 
machinery, and synthesis of the L-strand begins in the opposite direction (Shadel and 
Clayton, 1997).  
 In the second model, bidirectional replication of both strands is initiated from a 
region not far downstream from the H-strand origin of replication, followed by 
progression of the dual replication fork structure around the mtDNA molecule 
(Bowmaker et al., 2003). In this scenario, the D-Loop's triple-stranded structure acts to 
stall or arrest replication, facilitating the movement of the replication fork downstream. 
Evidence exists for both models, with the possibility that both types of replication can 
occur under different physiological conditions. Mitochondrial DNA replication illustrates 
a complex process, and our understanding of the exact mechanism is far from complete. 
 The third model proposed, the controversial RITOLS (ribonucleotide 
incorporation throughout the lagging strand) model, although recently referred to as the 
"bootlace model" (Reyes et al., 2013). This model postulates that RNA transcripts are 
hybridized to the displaced strand during replication in order to stabilize and protect the 
exposed ssDNA. The role here of mtSSB proteins are minimized. This RNA 
incorporation may also serve regulatory roles in replication (Yasukawa et al., 2006). 
However, this model is particularly contested.   
 
  
1.7   Mitochondrial transcription 
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 The mitochondrial transcription machinery is entirely nuclear-encoded. During 
transcription, recruitment of a mitochondrial specific, single subunit RNA polymerase, 
POLRMT, is assisted by two transcription factors, TFAM and TFB2M. Two transcription 
factor B proteins exist, the other being TFB1M. Both have been reported to have 
transcription factor activity in vitro (Falkenberg et al., 2002), but only TFB2M was 
shown to be absolutely required for transcription. Both factors are related to rRNA 
methyltransferases, and TFB1M has been shown to be necessary for methylation of two 
adenines near the 3' end of the 12S rRNA (Metodiev et al., 2009). TFB2M is a much less 
efficient methyltransferase (Cotney and Shadel, 2006), lending credence to its role as 
more of a transcription factor. In vivo, several other accessory factors are involved in 
transcription, such as transcription elongation factor of mitochondria (TEFM) (Minczuk 
et al., 2011), and MRPL12 (Z. Wang et al., 2007). 
 From the HSP2 promoter on the H-strand and LSP promoter on the L-strand, 
mtDNA is transcribed fully into two large, polycistronic precursor RNA transcripts that 
encompass all the genes on the two respective strands. In addition, a third transcript is 
transcribed from the HSP1 promoter on the H-strand that starts at the phenylalanine mt-
tRNA gene and terminates at the 3' end of the 16S rRNA gene (Figure 1.4). This 
particular transcription event is also initiated 50-100 times more often than that on the 
larger H-strand transcript (Montoya et al., 1982; Mercer et al., 2011).  
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 Mapping the precise termination site for the transcripts of the longer polycistronic 
units has been more problematic. The known mitochondrial transcription termination 
factor mTERF1, has shown binding that mediates termination of the shorter HSP1-
initiated RNA within the tRNA
LEU
 gene (Kruse et al., 1989; Asin-Cayuela et al., 2005). 
MTERF1 functions in a bi-directional manner, particularly with POLRMT transcribing in 
the direction of the L-strand (Asin-Cayuela et al., 2005). MTERF1 has also been reported 
to aid in transcription initiation by binding the HSP1 promoter in addition to the tRNA
LEU
 
gene. This would cause a "looping out" of the DNA, and facilitate recycling of the active 
transcription apparatus (M. Martin et al., 2005). Along this line, MTERF1 has been 
posited to be involved with transcription initiation from the HSP2 promoter as well. Three 
MTERF1 paralogues exist, with MTERF2 and 3 also reported to be involved in 
transcriptional processes (Park et al., 2007; Wenz et al., 2009), and MTERF4 with 
regulation of mitochondrial translation (Camara et al., 2011).  
  
 
1.8  Transcript processing and turnover 
 
 Full length polycistronic precursor RNAs are not commonly observed 
experimentally, which suggests processing may occur alongside transcription, or at least 
very shortly thereafter (Ojala et al., 1981). The polycistronic transcripts are cleaved into 
 
 
Figure 1.4. Representation of precursor mt-RNA polycistronic units. 
The three polycistronic RNA transcription products generated from mtDNA are shown. The same labeling and 
coloring scheme is used as in Figure 1.3.  
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shorter transcription units and ultimately into the multiple mRNAs, tRNAs, and rRNAs 
by excision of tRNAs that flank the protein and rRNA coding regions. This produces 
individual discrete transcripts, and is known as the "tRNA Punctuation Model"(Ojala et 
al., 1981). Current understanding indicates that the structure of the tRNAs at their 5' end 
creates a favorable target for the endoribonuclease activity of mitochondrial RNase P 
(Holzmann et al., 2008). Cleavage at the 3' end of the tRNAs is carried out by the RNase 
Z like enzyme ELAC2 (Brzezniak et al., 2011). The obvious problem with this model is 
that not all protein-coding genes in mtDNA are punctuated by tRNA genes, for example 
MTATP6 and MTCO3. There also exist pairs of overlapping open reading frames that are 
maintained as bicistrons, namely RNA14 encoding MTATP6/8 and RNA7 encoding 
MTND4/4L. Despite all the mt-RNA units being processed from a single polycistronic 
precursor transcript, the discrete RNAs that are generated as a result are not present in 
equal amounts at steady-state (Mercer et al., 2011; Chujo et al., 2012). This emphasizes 
the need to expand our current understanding of RNA transcript turnover, particularly its 
regulation, in mitochondria.   
 Post-cleaving of the polycistronic transcripts, modifications are made at the 
resulting 3' ends. The three types of 3' modifications that can occur are listed in Table 1.1, 
although there is dispute as to whether the mt-rRNAs are oligoadenylated (Temperley et 
al., 2010b).  
 
 
The CCA modification on tRNAs is carried out by an ATP(CTP):tRNA 
nucleotidyltransferase (Nagaike et al., 2001). The mitochondrial poly(A) polymerase, 
Table 1.1 3' termini modifications of mitochondrial RNAs 
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generates the poly(A) tails on mt-mRNAs (Gallerani et al., 1976; Tomecki, 2004). The 
function of certain RNA modifications is clear. For 7 ORFs the addition of an (A) tail is 
required to complete the termination codons, and the CCA addition precedes charging 
tRNAs with their cognate amino acids. Whilst mt-rRNAs and –tRNAs do not vary in the 
3’ modification, it has become clear that mt-mRNAs exhibit a variety in regards to 
poly(A) tail length, and whether polyadenylation contributes to the completion of 
termination codons (Temperley et al., 2010b).  
 Another major aspect of RNA metabolism is degradation of transcripts. The total 
contingent of factors involved in this process is currently not known, but several 
significant players have been identified. There is hSuv3, a mitochondrial 3'-5' helicase 
(Dmochowska et al., 1999). Removal of hSuv3, or inactivation of its enzymatic activity 
causes an accumulation of both RNA degradation intermediates, and the non-coding 
"mirror RNAs" from the non-template strand transcript (Khidr et al., 2008; Szczesny et 
al., 2010), implicating its role in mt-RNA turnover. The yeast homolog (Suv1p) operates 
in concert with a catalytic unit, Dss1p, which carries out the exoribonuclease action. A 
similar 3' exoribonuclease has not been identified in human mitochondria. Another 
enzyme engaged in RNA turnover is PNPase. It was initially speculated that it might be 
potentially either the mitochondrial 3' exoribonuclease or the poly(A) polymerase, due to 
the possession of both PAP and 3'5' exoribonuclease activities. It was later reported to be 
localized in the IMS, where it is involved with RNA import (Chen et al., 2006). However, 
PNPase does co-purify with hSuv3 and vice versa, and they form a complex in vitro (D. 
D. Wang et al., 2009; Szczesny et al., 2010), which suggests that a smaller pool of 
PNPase does localize to the matrix. Depletion of PNPase causes accumulation of RNA 
degradation intermediates (particularly "mirror RNAs") and increases the half-life of 
transcripts, further implicating it in RNA turnover (Borowski et al., 2013). The only 
mitochondrial enzyme shown to have explicit deadenylase activity is PDE12, poly(A)-
specific 3' exoribonuclease. PDE12 has been shown to have deadenylase activity in vitro 
and in vivo (Rorbach et al., 2011). Depletion of the PDE12 protein unlike depletion of 
hSuv3 or PNPase does not increase mt-mRNA half-life (Chujo et al., 2012). 
Overexpression, however, has a profound effect on mt-mRNAs but this is not a uniform 
effect, as some transcripts are more stable, others less stable and others unaffected 
(Rorbach et al., 2011). Finally, an oligoribonuclease, REXO2, has been reported to exist 
in mitochondria, and may be involved with degradation of small RNA oligomers (Bruni 
et al., 2013). In total, these factors make up the current complement of enzymes known to 
be involved in RNA turnover.   
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1.9   Mitochondrial RNA binding proteins 
 
 In yeast, there exists a complement of translation activators, corresponding to 
specific mitochondrial mRNAs, which bind to the 5' UTRs and initiate translation by 
interacting with the ribosome (Towpik, 2005; Herrmann et al., 2013). In human 
mitochondria, there is only one identified translational activator, specific to COXI, 
namely TACO1 (Weraarpachai et al., 2009). The activator was identified through a 
patient harboring a mutation in the TACO1 gene displaying a substantial decrease 
exclusively in COX1 protein levels. Intriguingly MTCO1 encodes COXI but does not 
have a 5' UTR for this activator to recognize leaving the molecular mechanism 
unexplained. 
 A well characterized family of RNA binding proteins are the pentatricopeptide 
repeat (PPR) proteins The PPRs are a large family of proteins first identified in terrestrial 
plants, and are involved in a range of essential post-transcriptional functions in 
mitochondria and chloroplasts (Small and Peeters, 2000; Schmitz-Linneweber and Small, 
2008). There are seven known PPR proteins present in humans, all localized to 
mitochondria (Lightowlers and Chrzanowska-Lightowlers, 2013). These factors are 
leucine-rich PPR cassette (LRPPRC), the mitochondrial RNA polymerase (POLRMT), a 
mitochondrial ribosomal small subunit protein (MRPS27), three pentatrico- domain 
containing proteins (PTCD1, 2, and 3), and mitochondrial RNase P protein 3 (MRPP3). 
 LRPPRC was the first PPR protein to be found in man, discovered as causing a 
complex IV specific defect in the French Canadian Leigh Syndrome (Mootha et al., 
2003). Knock-down and knock-out experiments have shown that depletion of LRPPRC 
results in a general decrease of mt-mRNAs (although the reports of which specific 
transcripts show decreased levels are conflicting) (Gohil et al., 2010), dysfunction in 
protein synthesis (Ruzzenente et al., 2012; Xu et al., 2012), and intriguingly, shortening 
of the mt-mRNA poly(A) tails (Ruzzenente et al., 2012). LRPPRC has been reported to 
bind both nuclear and mt-mRNAs, although not in strictly sequence-specific manner (Mili 
and Pinol-Roma, 2003; Xu et al., 2012). It does seem to have higher affinities for 
polypyrimidine tracts. LRPPRC has been confirmed to interact with another 
mitochondrial RNA binding protein, SLIRP (steroid receptor RNA activator stem-loop-
interacting RNA-binding protein) (Sasarman et al., 2010). First identified as a nuclear 
protein (Hatchell et al., 2006), SLIRP was later shown to have the majority localize in 
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mitochondria (Baughman et al., 2009). Beyond SLIRP, the number of other reported 
interactions with LRPPRC are many, and inconsistencies abound [reviewed in 
(Lightowlers and Chrzanowska-Lightowlers, 2013)]. While LRPPRC appears to be a 
critical factor in mitochondrial function, more work is required to fully understand its 
many potential roles.  
 POLRMT carries out the polycistronic transcript synthesis and primer generation 
for mtDNA replication, as described earlier in this chapter and is therefore clearly an 
essential protein for mitochondrial DNA maintenance and expression. MRPS27 depletion 
does not result in decreases of mt-mRNAs, rather an expected decrease in translation 
efficiency, although surprisingly this effect is exacerbated for COX1 and COX2. At 
present, it is difficult to know where in the mitoribosome MRPS27 would reside as there 
are no high resolution crystal or cryo-EM structures available. The three PTCD proteins 
have been reported to be involved in different ways with translation. PTCD1 has been 
shown to influence the levels of mt-tRNA
LEU
 and may play a role in polycistronic 
processing (Rackham et al., 2009). PTCD2 disruption was reported to cause defects in 
complex III, through depletion of the mature MTCYB transcript (Xu et al., 2008). It has 
also been identified as a potential biomarker in Alzheimer's disease (Nagele et al., 2011). 
PTCD3 has also been shown to be an interactor with the mitoribosome, through 
association with the small subunit, although it does not appear to directly influence mt-
RNA processing or stability (Davies et al., 2009). The most recently discovered PPR 
protein in humans is MRPP3, which is a subunit of the RNase P complex (Holzmann et 
al., 2008). Interestingly, disruption of certain PPR proteins in mitochondria has been 
shown to influence the levels of other PPR proteins (Xu et al., 2012), perhaps suggesting 
functional connections between these factors in human mitochondria. 
 
1.10   Translation in Mitochondria 
  
 The machinery of protein synthesis in mitochondria differs from its cytosolic 
counterparts in several significant ways. The composition of the mitoribosome differs 
noticeably [described in (Chrzanowska-Lightowlers et al., 2011)]. The ratio in cytosolic 
80S particles is 70% RNA to 30% protein, and this is reversed in the mammalian 
mitochondrial ribosome. This increase of protein content causes a change in the buoyancy 
and sedimentation of the mitoribosomal monosome, with the result that the mammalian 
mitoribosome is a 55S rather than an 80S particle as in the cytosol. Included in these 
changes is the loss of rRNA that corresponds to specific regions in the bacterial 70S 
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ribosome that would interact with "E" site tRNAs (Mears et al., 2006). This indicates that 
the mitochondrial ribosomal structure does not possess what has been traditionally 
described as the "E" site, while the "P" and "A" sites remain more canonical in their 
structure (Sharma et al., 2003). The emerging understanding is that recruitment of 
mRNA, tRNA interaction, and exiting of the newly synthesized polypeptide chains must 
differ markedly in the mammalian mitochondrial ribosome than its cytosolic counterpart. 
 Currently, aspects of the assembly of the mitoribosome are still being elucidated. 
The literature only contains few reports of ribosomal proteins (MRPS16, MRPS22, 
MRPL3 and MRPL12) mutated in patients, causing mitochondrial disorders (Miller et al., 
2004; Emdadul Haque et al., 2008; Galmiche et al., 2011; Serre et al., 2013). 
Modifications must be made to mt-rRNA during the process of maturation. The 12S 
rRNA is dimethylated by TFB1M (Metodiev et al., 2009), and the MTERF4-NSUN4 
complex is critical for monosome assembly, although it is not known what/if methylation 
occurs via NSUN4 (Camara et al., 2011). For small subunit assembly, there are two 
GTPases involved, EraL1 and NOA1 (Dennerlein et al., 2010; Kolanczyk et al., 2011). In 
the case of the large subunit, two other GTPases, Mtg1 and ObgH1, have been reported to 
be associated (Kotani et al., 2013). The m-AAA protease is also required for proteolytic 
processing of the mitoribosomal subunit MRPL32, without which mitoribosome assembly 
is not completed (Nolden et al., 2005). The only protein currently shown to act as a 
chaperone-like or stabilizing factor for protein insertion into the mitoribosome is C7orf30 
(Rorbach et al., 2012; Wanschers et al., 2012), which interacts with the large subunit 
component MRPL14 (Fung et al., 2013).  
 There are proteins necessary for initiation, elongation, and termination phases of 
mitochondrial protein synthesis. Initiation of translation is mediated by mitochondrial 
initiation factor 3 (mtIF3)(Koc and Spremulli, 2002). This is accomplished by binding of 
mtIF3 to the mtSSU, which inhibits assembly of the complete monosome, although it 
may take a more active role as well in disassembly of the monosome (Christian and 
Spremulli, 2009). The second initiation factor, mtIF2, while bound to GTP, promotes 
binding of the fmet-tRNA
Met
, and generates a stable initiation complex with the mt-SSU 
and mRNA when the start codon is present (Ma and Spremulli, 1995). If the start codon is 
not present, the mt-SSU can dissociate (Christian and Spremulli, 2010). Once the 
initiation complex is formed with the mtSSU, the mtLSU can associate to form the 
complete monosome, then mtIF2 hydrolyzes GTP and the initiation factors release. 
 For the elongation action of protein synthesis in mitochondria, three factors are 
necessary: mtEFTu (Wells et al., 1995; Ling et al., 1997; Cai et al., 2000), mtEFTs (Xin 
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et al., 1995), and mtEFG1(Hammarsund et al., 2001). A second mtEFG exists, mtEFG2, 
but it has a role in ribosome recycling and lacks translocation activity (Tsuboi et al., 
2009). During elongation, mtEFTu (bound to GTP) delivers an aminoacylated-tRNA (aa-
tRNA) to the A-site of the mitoribosome. Correctly-matched codon-anticodon interaction 
between the aa-tRNA and mRNA causes hydrolysis of the GTP, and drives the release of 
mtEFTu-GDP. mtEFTs acts as a guanine exchange factor, replacing the GDP with GTP 
on mtEFTu, ready to perform the cycle again (Cai et al., 2000). Within the monosome, 
the peptidyl chain in the P site is transferred to the aa-tRNA bound in the A site via the 
catalytic action of the peptidyl-transferase center of the mtLSU, forming the new peptide 
bond. After this catalytic event, the extended peptidyl-tRNA is translocated from the A 
site to the P site, and the deacylated tRNA is released. This translocation reaction is 
driven by the hydrolysis of GTP bound to mtEFG1, via conformational changes in both 
mtEFG1 and the mitoribosome.  
 The final stage of mitochondrial protein synthesis is termination of translation. 
Once a stop codon reaches the A site, the mitochondrial release factor (mtRF1a) 
recognizes the codon, and via the GGQ domain localized to the peptidyl-transferase 
center of the ribosome, it catalyzes the release of the peptide chain (Soleimanpour-
Lichaei et al., 2007). There are also three other members assigned to the mitochondrial 
release factor family whose functions have not been fully characterized, these are mtRF1 
(the initial candidate release factor), ICT1 and C12orf65. These all possess GGQ motifs, 
but only ICT1 exhibits release activity in vitro. Recycling of the mitoribosome is carried 
out by the mitochondrial recycling factor (mtRRF) (Rorbach et al., 2008), in conjunction 
with mtEFG2 and mtIF3.  
 Notably, the codon usage in human mitochondria is altered from cytosolic, with 
AUA coding for methionine and the universal STOP codon UGA converted to coding for 
tryptophan. Until recently, it was thought that the human mitochondrial code also added 
two termination codons, AGA and AGG, which conventionally encode for arginine. 
However these two "termination codons" were shown to be involved in a frameshift 
mechanism in which the mitoribosome stalls on them due to a lack of corresponding 
tRNAs, and then shifts position -1 nucleotide upstream to create the UAG termination 
codon. This action enables utilization of just one release factor (mtRF1α) which 
recognizes the UAA and UAG codons, for translation termination and leaves the unique 
condition of AGA and AGG being unassigned codons in human mitochondria 
(Temperley et al., 2010a).  
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1.11  Mitochondrial Disease 
  
 Disruptions in the processes and functions detailed here obviously have major 
impacts on human health. Due to the multifaceted roles played by mitochondria, there is a 
wide range of clinical pathologies where mitochondrial dysfunction plays a primary role. 
The prevalence of mtDNA-based disease in the population is 9.2/100,000 people 
(Schaefer et al., 2008), with 1 in 200 people carrying potentially pathogenic mtDNA 
mutations (Elliott et al., 2008).  The majority of patients suffering from mitochondrial 
disease present with neuromuscular clinical pathologies, as neural and muscular tissues 
depend heavily on aerobic metabolism. Cells with high energy demands necessarily 
possess more mitochondrial mass. For example, a cardiomyocyte can be up to 35% 
mitochondria by volume (Barth et al., 1992).  
 Current research has implicated mitochondrial dysfunction in many other diseases, 
such as cancer (Warburg, 1956), Alzheimer's (Swerdlow et al., 2010) or Parkinson's 
(Schapira et al., 1989). Although the symptoms associated with mtDNA disease can have 
a high degree of overlap there have been a number of specific syndromes resulting from 
mtDNA mutations (Goto et al., 1990). Examples of these include MELAS (Pavlakis et 
al., 1984), MERFF (Noer et al., 1991), CPEO (Moraes et al., 1989), and Kearns-Sayre 
syndrome (Bastiaensen et al., 1982).  
 Until recently, relatively few nuclear encoded mutations that caused mitochondrial 
disease had been identified (Miller et al., 2004), but with the advent of exome sequencing 
there is a rapidly expanding catalogue of nuclear-encoded mutations (Calvo et al., 2010). 
This has facilitated identification of nuclear-encoded factors involved in mitochondrial 
function. Prior to the widespread adoption of exome sequencing technology, a more 
laborious and pedigree intensive approach, typically requiring arduous techniques such as 
linkage analysis, homozygosity mapping or positional cloning, was required to identify 
mitochondrial disease causing genes encoded in the nucleus. In this fashion a mutation in 
the gene encoding the mitochondrial poly(A) polymerase, was identified. 
Characterization of the consequences of the defect identified the first pathogenic mutation 
to affect mitochondrial mRNA maturation. At present, very little is understood about the 
fundamental physiological mechanisms and crucial role mt-mRNA maturation may play 
in human disease. 
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1.12  Mitochondrial polyadenylation and the mitochondrial  
  poly(A) polymerase 
  
 Polyadenylation is a template-independent process whereby adenine nucleotides 
are added in succession to the 3' end of mRNA transcripts. The process serves differing 
roles across organisms and throughout cellular compartments. In bacteria (Xu and Cohen, 
1995), plant mitochondria (Gagliardi and Leaver, 1999), and chloroplasts (Hayes et al., 
1999), polyadenylation serves as a signal for degradation of mRNA, aiding in the 
recruitment of exonucleases necessary for transcript turnover. Conversely, in the 
mammalian nucleus the poly(A) tail acts to stabilize the RNA transcripts (Bernstein et al., 
1989), bind poly(A)-binding protein PABP-N1 which protects from degradation (Keller 
et al., 2000), and facilitate export into the cytosol. It this compartment it is bound by 
PABP-C1, which also protects the transcript from degradation and the poly(A) tail is 
subsequently involved in initiation of translation (Gallie, 1991; Huang and Carmichael, 
1996). In yeast mitochondria, no poly(A) tail exists. Instead, transcripts have a DNA-
encoded 3' dodecamer sequence which acts as an arbiter of stability (Osinga et al., 1984). 
Trypanosome mitochondria use short poly(A) sequences to confer stability based on the 
editing status of the transcript itself (Etheridge et al., 2008). These differing roles for 
polyadenylation are summarized in Table 1.2. In human mitochondria the complete 
function of polyadenylating mt-mRNAs is less clear.  
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 Mammalian mitochondrial poly(A) polymerase (PAP) was first isolated in 1972 
from rat liver mitochondria (Jacob and Schindler, 1972). Polyadenylation activity is 
necessary for creating the UAA stop codons in seven of the thirteen mitochondrial open 
reading frames. The terminal nucleotide in these seven transcripts is uridine 5'-
monophosphate or a single adenosine 5'-monophosphate and the addition of a poly(A) tail 
creates the stop codon via further adenosine 5'-monophosphate additions. Some only 
require one "A" (MTND1, MTATP6), and the few transcripts that have 3' UTRs do not 
require polyadenylation at all for generation of their stop codons. This theme of 
heterogeneity continued as more became understood about the unique features of each 
mt-mRNA, with no two being exactly alike, as shown in table 1.3 (Temperley et al., 
2010b). The polyadenylation status of the MTND6 transcript, in particular, is unclear 
(Lightowlers lab, unpublished data). Variation in poly(A) tail length exists between cell 
types, as well as between transcripts within the same cell. MTND5 is consistently 
oligoadenylated, as opposed to polyadenylated, in most cell types (Temperley et al., 
2010b).  
 A cell line with a mtDNA microdeletion that removed the termination codon for 
the ATP8/6 bicistronic RNA unit (RNA14) indicated that deadenylation of the poly(A) tail 
on mitochondrial transcripts is translation-dependent (Temperley, 2003). The length of 
Table 1.2. The Diverse Roles of Poly(A) Tails 
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poly(A) tails were observed using a novel assay, the mitochondrial poly(A) tail assay 
(MPAT). The deletion caused steady-state levels of RNA14 to decrease, and while 
processing accuracy was not affected, and the polyadenylation profile visualized with the 
MPAT showed a prevalent truncated oligo(A) tail species of RNA14 at steady-state. 
Thiamphenicol was used to inhibit translation, and over a course of time points the 
population of oligo(A) tails disappeared in the microdeletion cell line, with the population 
of poly(A) tails increasing. It was thought that this was evidence of the oligo(A) species 
being products of deadenylation. However, when subsequent experiments were 
performed with human cells depleted of mitochondrial poly(A) polymerase via RNAi, the 
oligo(A) tails were still present. If oligo(A) tails are products of deadenylated poly(A) 
tails, then it would be expected they would disappear when mtPAP activity is suppressed. 
These results suggested that oligoadenylation could be a separate process from 
polyadenylation, and may in fact be carried out by another enzyme. 
 The human mitochondrial poly(A) polymerase (mtPAP), encoded by the PAPD1 
gene, was identified by two groups shortly after (Tomecki, 2004; Nagaike, 2005). 
Tomecki et al showed via northern blotting that the expression level of mtPAP was 
highest in heart, brain, and skeletal muscle tissue. This pattern of expression is common 
in proteins localized to mitochondria. Further confirmation came from 
immunofluorescent imaging to identify the cellular localization of c-myc-tagged mtPAP. 
This was shown to overlay with mitotracker CMXRos in HeLa cells.   
Table 1.3. Characteristics of human mt-mRNAs 
 
Gene 
5' 
leader 
ORF 3' trailer initiation termination A's needed 
MTND5 0 1811 568 AUA UAA 0 
MTCO1 3 1541 72 AUG UAG 0 
MTND4 296 1377 0 AUG UAA 2 
MTCYB 0 1140 0 AUG UAA 2 
MTND2 0 1041 0 AUU UAA 2 
MTND1 2 955 0 AUA UAA 1 
MTCO3 0 783 0 AUG UAA 2 
MTCO2 0 708 24 AUG UAG 0 
MTATP6 161 679 0 AUG UAA 1 
MTND6 0 524 
no 
consensus 
AUG UAG 0 
MTND3 0 345 0 AUA UAA 2 
MTND4L 0 296 1371 AUG UAA 0 
MTATP8 1 206 634 AUG UAG 0 
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 RNA interference was employed by both groups to deplete the mtPAP protein and 
observe the resulting effects. Knockdown of mtPAP caused changes in the population of 
poly- and oligo-adenylated transcripts, with a major shift towards oligoadenylation. 
Conflicting reports of the effect of depleting mtPAP, and thus presumably abrogating mt-
polyadenylation, has led to differing interpretations of the role of poly(A) tails in mt-
mRNA stability. Northern blotting has shown that certain transcripts are increased at 
steady-state, and others were decreased. It is unknown to what extent the unique features 
of each individual transcript play into the effects seen when the poly(A) tail is removed. 
There is one report of human mt-mRNA polyadenylation appearing to play a role in 
transcript turnover (Slomovic et al., 2005). Truncated mt-mRNAs were found with 
poly(A) tails. However, this may merely indicate polyadenylation is a ubiquitous 
transcriptional maturation event being carried out in mitochondria, and degradation 
intermediates and misprocessed transcripts are still subject to addition of the poly(A) tail.      
 Other mitochondrial parameters have been shown to be affected by mtPAP 
knockdown, such as mitochondrial morphology, O2 consumption, and mitochondrial 
membrane potential (Nagaike, 2005). siRNA depletion does not fully eliminate mtPAP 
from cells and so it is not surprising that there was some residual polyadenylation 
activity, as the population of full length poly(A) tails were decreased, but not completely 
gone. This is a problem with the siRNA method of mtPAP depletion, as residual 
polyadenylation activity exists and must be taken into account.  
 Work carried out concurrently on PNPase in mitochondria seemed to imply that it 
could potentially have a role in mt-polyadenylation, but siRNA depletion of PNPase has 
shown conflicting results on poly(A) tail lengths, and on steady-state levels of 
mitochondrial-encoded transcripts and proteins (Nagaike, 2005; Slomovic and Schuster, 
2007). PNPase has also been localized to the intermembrane space of the mitochondria, 
and is implicated in import of RNA into mitochondria, which could indicate an indirect 
role in mt-RNA metabolism (Chen et al., 2006). As mentioned earlier, despite the data 
indicating the majority of PNPase being localized to the IMS, purification of the matrix 
helicase hSuv3 revealed robust interactions with PNPase in the matrix (Szczesny et al., 
2010). Also in the report from Szczesny et al was data showing that overexpression of 
hSuv3p shortened mt-poly(A) tails, and expression of a dominant-negative mutant 
hSuv3caused lengthened poly(A) tails. The current understanding of hSuv3p and PNPase 
is that within the matrix, they form an mt-RNA degrading complex, termed the 
"degradosome". This interpretation is supported by data from multiple other groups, 
whose work details longer poly(A) tails in mitochondria via PNPase depletion (Nagaike, 
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2005; Slomovic and Schuster, 2007). So despite possessing some 5'-3' template-
independent RNA polymerization capability, PNPase is much more strongly implicated in 
3'-5' RNA degradation, and by extension, degradation of the mitochondrial poly(A) tails. 
The only other identified enzyme shown to participate in specific 3'-5' mt-RNA 
deadenylation is PDE12 (Rorbach et al., 2011). Crucially though, depletion of PDE12 
does not influence the turnover of mt-mRNAs (Chujo et al., 2012). This leaves open the 
possibility that either more RNases are active in mitochondria, or the identified ones work 
in concert.     
 The use of siRNA suppression of mtPAP is not the only technique employed to 
probe mitochondrial polyadenylation. Perturbation of mt-mRNA turnover was attempted 
by targeting a cytosolic 3' poly(A) specific ribonuclease, mtPARN, to the mitochondria, 
as well as a cytosolic poly(A) binding protein, mtPABP1 (Wydro et al., 2010). The 
results confirmed previous findings of variable effects on transcript stability. The poly(A) 
specific ribonuclease targeted to the mitochondria removed the poly(A) tails, and the 
effects on mt-mRNA stability showed that some transcripts were increased at steady state 
(MTND1, MTND2, MTND5) while others were decreased (MTCO1, MTCO2, RNA14). 
Mitochondrial protein synthesis was found to be decreased for all 13 mtDNA-encoded 
polypeptides. The targeting of mtPABP-C1 to the mitochondria exerted a significant 
negative effect on translation, but did not lead to increased transcript decay.  
 As detailed earlier, LRPPRC is a PPR protein that has been implicated in RNA 
metabolism. In 2012, Ruzzenente et al reported the results of LRPPRC knock-out in a 
mouse model (Ruzzenente et al., 2012). One of the unexpected effects of LRPPRC 
removal was a noticeable truncation in mitochondrial poly(A) tails. This results had also 
been observed in Drosophila melanogaster mitochondria, when bicoid stability factor 
(BSF, the LRPPRC homolog) was knocked-down by RNAi (Bratic et al., 2011). As 
LRPPRC is not thought to have RNase activity, this was a conspicuous consequence. The 
only other factors shown to have influence on mt-poly(A) length are PNPase, hSuv3p, 
and PDE12, all possessing 3' exoribonuclease activity. This suggested a positive role for 
LRPPRC in mitochondrial polyadenylation. This hypothesis was bolstered when in vitro 
experiments with LRPPRC and mtPAP were published in 2012 (Chujo et al., 2012). The 
presence of LRPPRC was reported to allow extension of poly(A) tails, whereas the same 
paper reported data showing mtPAP had no activity on its own. While the observation of 
LRPPRC aiding the extension of poly(A) tails was novel, the notion that mtPAP is 
incapable or nearly incapable of poly(A) extension on its own runs counter to previously 
published results of in vitro polyadenylation (Nagaike, 2005; Bai et al., 2011). In Chujo et 
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al., the addition of SLIRP to the in vitro polyadenylation reactions was also reported not 
to have an appreciable effect on poly(A) extension.   
 Currently, there is no confirmed mitochondrial poly(A) binding protein. However, 
the protein PABPC5 has recently been proposed as a candidate (He et al., 2012). 
PABPC5 can co-immunoprecipitate both LRPPRC and mtPAP. This is particularly 
notable considering the previously published work with LRPPRC and mtPAP but more 
research is necessary to elucidate the exact role of PABPC5 in mitochondria. 
 In 2011, the crystal structure of mtPAP was reported (Bai et al., 2011). Many 
notable characteristics of the polymerase were revealed by the crystal structure. A 
noncanonical poly(A) polymerase, mtPAP was shown to unexpectedly operate as a dimer, 
as opposed to the monomer status of canonical PAPs. An N-terminal region of the 
protein, C-terminal to the mitochondrial targeting sequence, contains a section similar to a 
RNP-type RNA binding domain (termed an RNA binding-like domain, or RL domain), 
which appears to aid in dimerization. Other than this region there is no obvious RNA 
binding domain. Structural similarities exist between mtPAP and canonical PAPs as it 
possesses palm and finger domains, with the active site located between the two. So while 
there is structural homology to canonical PAPs, there is very low polypeptide sequence 
homology (approximately 10-15%). mtPAP is able to utilize both ATP and UTP for 
polynucleotide extensions on RNA substrates.    
 The methods employed up to this point to disrupt mitochondrial polyadenylation 
all have their drawbacks. Artificial perturbations of a cellular system will always be an 
approximation of the actual physiological conditions of dysfunction. In a step towards 
establishing a better experimental model, an Old Order Amish family in Ohio was 
previously identified, in which four of five children are affected with an autosomal-
recessive spastic ataxia with optic atrophy (Crosby et al., 2010). A genome-wide 
microarray screen had been undertaken, and a mutation in the PAPD1 gene was found to 
segregate with the disease phenotype. The variant was a 1432A>G mutation creating a 
Human       ETLELLLKEFFEYFGNFAFDKNSINIRQGREQNKPDSSPLYIQNPFETSL 484 
Chimpanzee  ETLELLLKEFFEYFGNFAFDKNSINIRQGREQNKPDSSPLYIQNPFETSL 484 
Mouse       ETLELLIKEFFEYFGNFAFNKNSINIRQGREQNKPDSSPLYIQNPFETSL 487 
Zebrafish   DTLEKLLQEFFEFYGNFPFNKASINIRKGKEQSKPEAAALHIQNPFEATL 481 
Fly         SSLSELLLQFFEFYSQFDFHNRAISLNEGKPLSKPDHSAMYIVNPLEQLL 475 
 
Figure 1.5. Sequence alignment of the mtPAP N478 motif in various species. 
Regions of mtPAP from several species containing the highly conserved NPFE motif are shown, aligned with 
CLUSTALW software (Goujon et al., 2010). The motif is highlighted in yellow. The numbers at the end of the 
sequences indicate the peptide position ending the shown sequence. Accession numbers: human (NP_060579.3), 
chimpanzee (XP_001136690.1), mouse (NP_080433.1), zebrafish (XP_692256.3), fly (NP_569904.1).  
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N478D polypeptide substitution. This substitution is in an N-P-F-E residue sequence, 
which is a highly conserved region of the mtPAP protein (Figure 1.5). Interestingly, the 
N478D mutation does not map to a region of the protein with a known function, 
according to the published crystal structure (Bai et al., 2011). This makes the nature of its 
presumed deleterious effect much less obvious. Each affected child is homozygous for the 
mutation, while one sibling and the parents are heterozygous and do not display clinical 
pathology. The MPAT assay was used to assess the polyadenylation status of several 
mitochondrial transcripts in affected and unaffected members of the family. In the 
homozygous children, polyadenylation of mt-mRNAs is dramatically compromised, with 
an increase in the oligo(A) population of transcripts. This may be the primary 
pathological effect of the PAPD1 mutation. The mutation presents a unique physiological 
environment in which polyadenylation is compromised to a greater degree than when 
using siRNA to knockdown mtPAP. Experiments utilizing cells that harbor the 
homozygous mutation would possibly avoid the potential residual polyadenylation 
activity seen in other methods acting to artificially disrupt the poly(A) tail, or other off-
target effects. 
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1.13 Aims of this project 
  
 Over the last decade, much work has been done on mitochondrial poly(A) 
polymerase and mitochondrial polyadenylation. Unfortunately, little is understood about 
the process and the role it plays. While certain phenomena of steady-state transcript 
stabilities have been observed consistently, other results are conflicting. It is entirely 
possible, and even likely, that essential modulating factors remain to be identified. My 
project will use cell lines derived from the patients harboring the 1432A>G PAPD1 
mutation and is designed to provide crucial insights into the process and role of 
polyadenylation in mitochondria. The ablation of polyadenylation activity without an 
artificial depletion of the mtPAP enzyme or artificial disruption of mt-mRNA metabolism 
presents a physiological system ripe for exploration. Not only for elucidating the purpose 
of the poly(A) tail in mitochondria mRNA maturation, but for the understanding broader 
impacts of molecular pathologies due to mutations in nuclear genes encoding for essential 
mitochondrial functions. 
 
The specific aims of these studies are as follows: 
 
I.  
To establish cell lines as a model to investigate the effects due to the 1432A>G mutation 
in the PAPD1 gene. These will be generated using fibroblast samples from three siblings 
who possess the mutation, one of whom is heterozygous, the other two homozygous. The 
initial goal will be to "immortalize" the cells via retroviral transduction. A viral vector 
will integrate the HPV16-E6E7 region genes, allowing the cells to delay their transition 
into senescence, effectively doubling their lifespan. This immortalization of the cell lines 
will allow more in depth studying of the abrogated polyadenylation in mitochondria by 
reducing the cell division constraints commonly encountered when culturing primary cell 
lines. In addition one non-familial fibroblast line that does not harbor any form of the 
1432A>G mutation will be immortalised as a control.  
 
II. 
Using immortalized 1432A>G mutant fibroblasts as a model, rescue of the dysfunctional 
cellular phenotype will be attempted by introducing a wild-type PAPD1 gene. Expression 
of the wild-type protein will be introduced, and its compensating activity for the 
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endogenous mutant mtPAP will be assessed. This will generate evidence to establish 
whether the 1432A>G mutation in the PAPD1 gene both caused the lack of 
polyadenylation activity in the endogenous protein, and caused the downstream 
biochemical defects which contributed to the clinical pathologies exhibited by the patients 
the samples were taken from.  
 
III. 
Recombinant expression and purification of the wild-type and N478 mtPAP proteins will 
be carried out. Generation of recombinant mtPAP will be necessary to study the 
characteristics of the wild-type and mutant enzyme in vitro. The protein will be expressed 
in a bacterial system, and conditions will need to be optimized for maximizing soluble 
product. Investigations will include polyadenylation activity, substrate preferences, and 
examination of the effect of the mutation on function.  
 
IV. 
Interactions of mtPAP with other factors will be examined, utilizing co-
immunoprecipitation techniques, isokinetic sucrose gradient migration, and analysis by 
mass spectrometry.   
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Materials and methods 
 
2.1  Chemicals and Reagents 
 
All tissue culture and basic chemicals were purchased from Sigma-Aldrich, unless 
otherwise specified. 
2.2 Methods  
 
2.2.1  Mammalian cell lines 
 
Human dermal fibroblasts: The cell lines were derived from skin biopsies from 
individuals either heterozygous or homozygous for the 1432A>G mutation in the PAPD1 
gene and healthy controls. The PAPD1 lines were established in culture by collaborators 
and sent to my host laboratory. Upon receiving these cells they were immortalized at 
passage number 14 by transgenic expression of the E6E7 early region from human 
papillomavirus type 16. Expression of the E6E7 can greatly extend the life span of 
primary cells (Lochmüller et al., 1999). 
 
Flp-In
TM
 T-REx
TM
 -293 cells: Human cell line derived from human embryonic kidney 
culture and transformed with sheared adenovirus 5 DNA. This commercial derivative of 
the HEK293 line constitutively expresses the Tet repressor (continuously selected for 
using Blastocidin
S
) and has an integrated Flp recombination target (FRT) site for the 
purpose of generating stable expression of genes under the control of a tetracycline 
inducible system. For the rest of the text, this commercial cell line will simply be referred 
to as HEK293.  
 
 
2.2.2  Tissue culture  
 
All tissue culture manipulations took place in a Microflow Class II containment cabinet, 
under sterile conditions. All tissue culture plasticware was purchased from Corning. 6-
well plates were purchased from TPP. Cells were routinely inspected on a Zeiss Axiovert 
25 inverted transmitted light microscope.  
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2.2.2.1 Mammalian cell maintenance and storage 
 
Human fibroblasts and HEK293 cells were grown as monolayers at 37⁰C in vented flasks 
in humidified, 5% CO2. DMEM containing 4500mg/L glucose, 110mg/L sodium 
pyruvate, supplemented with 584mg/L L-glutamine, 10% fetal bovine serum, 50ug/ml 
Uridine, and 50U/ml Penicillin+50ug/ml Streptomycin (Gibco) was used for culture 
media. HEK293 cells had Blasticidin
S
 (Melford) added at a final concentration of 
10ug/ml every 3rd replacement of media. During culturing, cells were routinely split at 
80% confluency, and media was replaced every 2-3 days.  
 
For harvesting fibroblasts, the cells were washed once with Dulbecco’s A-PBS, then 
incubated for 2-5min in pre-warmed 1x Trypsin/EDTA (Gibco) diluted in Dulbecco’s A-
PBS at 37⁰C. They were then pipetted to make a single-cell suspension, and had media 
with 10% FBS added at a 1:1 ratio to quench the trypsin reaction. For seeding, the cells 
were then pelleted by centrifuging at 225g for 4 min, resuspended in fresh media, and 
seeded into new flasks at a 1:2 ratio. For HEK293 cells, the protocol was the same, except 
1mM EDTA in Dulbecco’s A-PBS was used in place of trypsin/EDTA.  
 
2.2.2.2 Cell counting 
 
Cells were counted using a Neubauer Hemocytometer. Cells were harvested, pelleted by 
centrifugation, then resuspended in media. 20ul of the cell suspension was pipetted under 
the glass slide on the hemocytometer, with 10ul per side. Cells were counted on two 
square grids on each side. The resulting numbers were averaged and multiplied by 10,000 
to calculate the number of cells per 1ml.  
  
2.2.2.3 Cell storage 
 
For long term storage, cells were harvested, centrifuged to pellet the cells, then 
resuspended in 1ml 90% FBS/10% DMSO and transferred into cryotubes. The cryotubes 
were then moved into a Nalgene® Mr. Frosty container at -80⁰C, which enabled cooling 
at the rate of 1⁰/min, for 24-48hrs. After at least 24hr incubation, the cryotubes were 
moved into a liquid nitrogen storage tank, and housed in the vapor phase of the nitrogen 
within.   
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2.2.2.4 Mycoplasma testing 
 
To test for the presence of mycoplasma, 1ml of media from growing cell culture flasks 
was removed, and centrifuged at 225g for 4min in order to remove unattached cells. Post-
centrifugation media was then tested using the MycoAlert
TM
 mycoplasma testing kit from 
Lonza. Contaminant mycoplasma in the media are lysed and the released enzymes react 
with the MycoAlert™ Substrate, catalyzing the conversion of ADP to ATP. The ATP 
then generates a luminescent signal via luciferase. By measuring the level of ATP in a 
sample both before (read A) and after the addition of the MycoAlert™ Substrate (read B), 
a ratio can be obtained that is indicative of the presence or absence of mycoplasma. 
Ratios of A:B of >1 indicate contamination. Contaminated cell lines were treated with 
plasmocin (Invivogen,) 25ug/ml for two weeks.  
 
2.2.3  Bacterial culturing 
 
2.2.3.1 Bacterial strains 
 
Bacterial Strain Genotype Application 
Antibiotic 
Resistance 
α-Select Bronze 
Efficiency 
(Bioline) 
F- deoR endA1 recA1 relA1 gyrA96 hsdR17(rk
-, 
mk
+) supE44 thi-1 phoA Δ(lacZYA-argF)U169 
Φ80lacZΔM15 λ- 
Propagation of 
plasmids 
None 
Rosetta (DE3) 
(Novagen) 
 F-ompT hsdSB(rB
- mB
-) gal dcm(DE3) pRARE 
(CamR)  
Expression of 
recombinant 
eukaryotic proteins 
with rare E. coli 
codons,  
Chloramphenicol 
34ug/ml 
Rosetta-gami B 
(DE3)pLysS 
(Novagen) 
 F–ompT hsdSB (rB
– mB
–) gal dcm lacY1 
ahpC (DE3) gor522::Tn10 trxB pLysSRARE (CamR, 
KanR, TetR)  
Combines features of 
Rosetta and Origami 
strains, enhanced 
disulfide bond 
formation 
Chloramphenicol 
34ug/ml,  
Kanamycin 
15ug/ml, 
Tetracycline 
12.5ug/ml 
Tuner  
(Novagen) 
F– ompT hsdSB (rB– mB–) gal dcm lacY1 
Induction by IPTG 
can be titrated 
None 
 
 
2.2.3.2 DNA vectors: 
 
Name Application Restriction Sites Used 
pcDNA5/FRT/TO 
 
Tetracycline-inducible vector for use with the Flp-
InTM T-RExTM system. Contains a hybrid 
CMV/TetO2 promoter for high-level expression. 
BamH1, NotI 
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Also contains a hygromycin resistance gene which is 
only completed by proper Flp-recombinase mediated 
integration of target gene. Encodes ampicillin 
resistance.  
 
pGEX-6P-1 
 
Generates a glutathione-S-transferase fusion protein, 
for increased soluble eukaryotic protein expression 
in E. coli. Encodes ampicillin resistance. 
 
BamH1, NotI 
pOG44 
 
Expresses the Flp recombinase to mediate 
integration of genes cloned into the 
pcDNA5/FRT/TO vector into FRT site. 
 
n/a 
pET28a 
 
The pET-28a vector carries an N-terminal 
His•Tag®/thrombin/T7•Tag® configuration plus an 
optional C-terminal His•Tag sequence. Encodes 
Kanamycin resistance. 
 
NdeI, NotI 
 
 
2.2.3.3 Bacterial media recipes 
 
LB Medium (1L) LB-agar (1L) SOC Medium (1L) 
10g Bacto tryptone 10g Bacto tryptone 20g Bacto tryptone 
5g Bacto yeast extract 5g Bacto yeast extract 5g Bacto yeast extract 
10g NaCl 10g NaCl 0.5g NaCl 
 20g Bacto agar 20ml glucose (1M) 
  5ml MgCl2 (2M) 
All Bacto products were purchased from BD. The solutions all had the pH adjusted to 7.2.  
 
2.2.3.4 Bacterial maintenance 
 
E. coli were grown on LB-agar plates and in liquid LB medium. For LB liquid media 
cells were grown in varying volumes in glass tubes or baffled flasks, shaking, at 37⁰C 
overnight (for plasmid-expression) or 20⁰C overnight (for protein expression). For 
selection on LB-agar plates, antibiotics (50ug/ml ampicillin, and strain specific antibiotic 
concentrations, see 2.2.3.1) were added prior to the LB-agar solidifying, and the LB-agar 
poured into plastic petri dishes. Bacteria were then spread on the plates and incubated 
inverted overnight at 37⁰C.   
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2.2.3.5 Bacterial storage 
 
For short term storage, LB-agar plates with bacteria were kept at 4⁰C for no more than 2 
weeks. For long term storage of bacterial strains, cells were grown on LB-agar plates with 
appropriate antibiotics, and incubated inverted overnight at 37⁰C. The following day LB 
media with 18% glycerol was pipetted onto the plates, and the bacteria suspended in 
solution. This bacterial suspension was transferred into a microtube and stored at -80⁰C.  
 
2.2.3.6 Transformation of chemically competent cells 
 
Frozen 40ul aliquots of competent bacterial cells were thawed on ice, and gently 
resuspended by flicking the tube. DNA (10ng) was added to the cell mixture, and 
incubated on ice for 30min. The cells were then subjected to a 30sec heat shock at 42⁰C, 
then incubated on ice for 2min. 1ml of SOC media pre-warmed at 37⁰C was then added, 
and incubated for maximum 1 hour at 37⁰C, shaking. The cell mixture was then 
centrifuged at 2000rpm on a Micro Centaur centrifuge (MSE) for 5min to pellet the 
bacteria. This pellet was resuspended in fresh 100ul pre-warmed SOC media, and spread 
on LB-agar plates supplemented with the appropriate antibiotics. The plates were 
incubated inverted at 37⁰C overnight.   
2.2.4  DNA handling and manipulations 
 
2.2.4.1 DNA isolation from human cells 
 
Human cultured cells were harvested from 25cm
2
 flasks and pelleted by centrifugation, 
then resuspended in 400ul low TE buffer (10mM Tris pH 8, 1mM EDTA). 50ul of 10% 
SDS and 50ul of proteinase K (20mg/ml stock) were added to give final concentrations of 
1% and 2mg/ml respectively, and the samples incubated at 37⁰C with gentle shaking 
overnight. If the sample was clear following overnight incubation, phenol/chloroform 
extraction and ethanol precipitation was carried out (see 2.2.4.4), if not then further 
proteinase k was added and the incubation extended. 
 
2.2.4.2 Plasmid DNA isolation from bacteria 
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Antibiotic-resistant colonies were used to inoculate 5ml LB media cultures that were 
incubated at 37⁰C overnight, shaking. The plasmid DNA was then extracted using the 
GeneJet plasmid prep kit (Thermo), according to manufacturer’s protocol. Purified 
plasmid DNA was then stored in deionized water at -20⁰C.  
 
2.2.4.3 Amplification of DNA by polymerase chain reaction (PCR) 
 
To amplify DNA regions of interest, polymerase chain reactions using various primers 
and polymerases were used. Reactions were performed in thick-walled 0.5ml tubes, in a 
final volume of 50ul. PCR products were purified via phenol/chloroform extraction and 
ethanol precipitated. KOD Hot Start Polymerase 10x Buffer contains MgCl2. KOD 
polymerase was utilized for cloning PCRs, as it is a proofreading enzyme. For non-
cloning PCRs, the DreamTaq (Thermo) polymerase was used. For DreamTaq PCRs, the 
MgSO4 was omitted due to its presence in the corresponding 10x buffer 
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Standard proofreading PCR reaction mix: 
Component Final Concentration in PCR 
Reaction 
10X Buffer for KOD Hot Start Polymerase 1X 
25mM MgSO4 1.5mM 
2mM dNTPs 0.2mM 
Forward Primer (10uM) 0.6uM 
Reverse Primer (10uM) 0.6uM 
Template DNA 10ng Total 
KOD Hot Start Polymerase (1 U/ul) 0.02U/ul 
Nanopure H2O Made up to 50ul 
 
Standard KOD polymerase PCR Profile:  
Step Reaction Profile Reaction Step 
1 95⁰C - 4 minutes Initial Denaturation 
2 95⁰C - 1 minute Denaturing 
3 Tm-4⁰C - 1 minute Annealing 
4 70⁰C - 2 minutes, 30 seconds Extension 
5 Back to Step 2, 35 cycles # of cycles 
6 70⁰C - 7 minutes Final Extension 
7 4⁰C - Indefinitely Hold 
 
Example DreamTaq polymerase PCR Profile:  
Step Reaction Profile Reaction Step 
1 95⁰C - 1 minute Initial Denaturation 
2 95⁰C - 30 seconds Denaturing 
3 Tm-4⁰C - 30 seconds Annealing 
4 72⁰C - 1 minute/kb Extension 
5 Back to Step 2, 35 cycles # of cycles 
6 72⁰C - 5 minutes Final Extension 
7 4⁰C - Indefinitely Hold 
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2.2.4.4 Primers used in this investigation 
Primer Name Primer Sequence Tm 
mtPAPF 5’ CACACGGATCCTTAGCAATGGCGGTTCC 3’ 52⁰C 
mtPAPFLAGR 
5’CAC ACG CGG CCG CTA CTT ATC GTC GTC ATC CTT GTA ATC TGT 
TCT CTT CCC ACT GG 3’ 
52⁰C 
mtPAP6PF 5' CACACAGGATCCAGTTGCCCAGGAACTGTG 3’ 52⁰C 
Mut-mtPAPF 5' CTC TGT ACA TTC AGG ATC CAT TTG AAA CTT C 3' 54⁰C 
Mut-mtPAPR 5' GAA GTT TCA AAT GGA TCC TGA ATG TAC AGA G 3' 54⁰C 
mtPAPR2 
5' CAC AGC GGC CGT CAT GTC TGA GTA CTA ATT GTT CTC TTC 
CCA CTG G 3’ 
54⁰C 
MPAT: DNA Linker 5' P-ATGTGAGATCATGCACAGTCATA-NH2 3' 52⁰C 
MPAT: Anti-LIGN 5' GAC TGT GCA TGA TCT CAC 3' 54⁰C 
MPAT: RNA14 5' GTG ATT ATA GGC TTT CGC 3' 50⁰C 
MPAT: RNA14 Nested 5' AGT AAG CCT CTA CCT GCA CG 3' 54⁰C 
MPAT: MTND3 5' CCG CCC GCG TCC CTT TC 3' 54⁰C 
MPAT: MTND3 Nested 5' GAC TAC AAA AAG GAT TAG ACT-3' 54⁰C 
MPAT: MTCO1 5' CAT ATT CAT CGG CGT AAA TC 3' 54⁰C 
MPAT: MTCO1 Nested 5' CAA CCC CAT GGC CTC CA 3' 54⁰C 
MPAT: MTCO3 5' TC TGC TTC ATC CGC CAA CTA 3' 54⁰C 
MPAT: MTCO3 nested 5' TGT ATG TCT CCA TCT ATT GAT 3' 54⁰C 
ND3PAP-F 5' ATT TAG GTG ACA CTA TAG AAC TAC CAC AAC TCA ACG G 3' 54⁰C 
ND3PAP-R 5' ATT CGG TTC AGT CTA ATC C 3' 54⁰C 
ND3Rev-A8 5' TTTTTTTT ATT CGG TTC AGT CTA ATC C 3' 54⁰C 
A6PAP-F 5' ATT TAG GTG ACA CTA TAG AGA AAC CAT CAG CCT ACT C 3' 54⁰C 
A6PAP-R 5' TAT GTG TTG TCG TGC AGG 3' 54⁰C 
ATP6Rev-A8 5' TTTTTTTT TAT GTG TTG TCG TGC AGG 3' 54⁰C 
pGEX-mtPAPΔN 
Sequencing ORF 5' 
5' TAC GAC AGC ATA GAG ACC 3' 54⁰C 
pGEX-mtPAPΔN 
Sequencing ORF 3' 
5' GGA AGG GAG CAA AAC AAA CC 3' 58⁰C 
pcDNA5-mtPAPFLAG 
Sequencing ORF 5' 
(CMV Forward) 
5'CGC AAA TGG GCG GTA GGC GTG 3' 60⁰C 
pcDNA5-mtPAPFLAG 
Sequencing ORF 3' (BGH 
Reverse) 
5' TAG AAG GCA CAG TCG AGG 3' 50⁰C 
MTND4 qPCR F 5' CCA TTC TCC TCC TAT CCC TCA AC 3' 59⁰C 
MTND4 qPCR R 5' CAC AAT CTGATG TTT TGG TTA AAC TAT ATT T 3' 59⁰C 
18S qPCR F 5' GTA ACC CGT TGA ACC CCA TT 3' 59⁰C 
18S qPCR R 5' CCA TCC AAT CGG TAG TAG CG 3' 59⁰C 
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2.2.4.5 Phenol/chloroform extraction and ethanol precipitation of  
  DNA  
 
DNA samples were made up to at least 100ul dH2O, then an equal volume of phenol 
(Sigma) was added. The mix was vortexed for 30 seconds, then centrifuged for 3 minutes, 
13,000rpm, at room temperature in a Micro Centaur (MSE) centrifuge. The aqueous 
phase was transferred to a fresh microtube, and mixed with an equal volume of 50% 
phenol and 50% CIAA (CIAA = 24:1 chloroform: isoamylalcohol). The mixture was 
vortexed for 30 seconds, then centrifuged as before. The aqueous phase was again moved 
to a fresh microtube, and an equal volume of CIAA added. Vortexing and centrifuging 
were done again as before. The aqueous phase was transferred to a fresh microtube, and 
1ul of linear acrylamide, 1/10th volume of 3M NaOAC pH 5.2, and 2 volumes of 100% 
ethanol were added. This mixture was then incubated at -20⁰C overnight. The next day, 
the mixture was centrifuged at 20,800g, for 30 minutes at 4⁰C in an Eppendorf 5417R 
centrifuge. The supernatant was discarded, and the DNA pellet washed once with 75% 
ethanol and once after that with 100% ethanol. The DNA pellet was then re-suspended in 
20-40ul dH2O.  
 
2.2.4.6 DNA electrophoresis and gel excision 
 
For analysis of DNA size, 100ng DNA in dH2O was mixed 1:1 with a 50% glycerol/dH2O 
mixture, and loaded onto a 0.7% agarose gel (0.35g agarose (NBS Biologicals), 50ml 1x 
TAE buffer (40mM Tris, 20mM acetic acid, 1mM EDTA, pH 8.4), and 0.2ug/ml 
ethidium bromide). For gel purification the conditions were the same but the agarose gel 
consisted of 1% low melting temperature agarose (Lonza), and the entire DNA sample 
was loaded for electrophoresis. In both types of agarose gels, the DNA was 
electrophoresed at 70V for approximately 1 hour in 1x TAE buffer. DNA was visualized 
by UV transillumination. For gel excision, specific base pair sizes were cut out of the 
agarose gel using sterile scalpel blades, reserved in a fresh microtube and then 
phenol/chloroform extracted, followed by ethanol precipitation.  
 
2.2.4.7 Restriction digests 
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Restriction endonucleases used were BamH1 (NEB), Not1 (NEB), and FspI (NEB). 
Reaction conditions for BamH1, Not1, or BamH1/Not1 double digests were 2ug DNA, 1x 
NEB buffer 3, 100ug/ml BSA, 20 Units each restriction enzyme, incubated for 3 hours at 
37⁰C. FspI digest conditions were 20ug DNA, 1x NEB buffer 4, 25 Units enzyme, 
incubated overnight at 16⁰C. Post-digestion, DNA was phenol/chloroform extracted and 
EtOH precipitated. At points in the project, High-Fidelity (HF
TM
) versions of BamH1 and 
Not1 (NEB) were used. Reaction conditions were the same as before, except both are 
100% active in Buffer 4 (NEB), and incubations were carried out at 37⁰C for 1 hour. 
Restriction digests were used for generating sticky ends of PCR fragments as well as 
linearizing plasmid DNA.  
 
2.2.4.8 Dephosphorylation of plasmid DNA  
 
Post-restriction digest, 1ul calf intestinal alkaline phosphatase (Boehringer Mannheim), 
1ul 10% SDS, and 3.5ul 1M Tris pH 9 was added to the 20ul plasmid digest. This was 
incubated at 37˚C for 30 mins, then 0.5ul of 0.5M EDTA was added to terminate the 
reaction. The dephosphorylated plasmid DNA was purified by phenol/chloroform 
extraction and ethanol precipitation prior to use in ligation reactions.   
 
2.2.4.9 Ligation of DNA 
 
Ligation reactions were carried out in 10ul volumes, using the T4 ligase (Fermentas). The 
molar ratio of restriction digested PCR fragment to vector was 3:1. The amount of insert 
DNA required in nanograms was determined with the following equation: 
 
                               
                   
                                       
 
The appropriate amount of both fragment and vector had 1ul 10x ligation buffer and 1ul 
T4 ligase added to a final volume of 10ul, and were incubated overnight at 16⁰C. After 
overnight incubation, the reaction was incubated at 65⁰C for 15min to inactivate the T4 
ligase.  
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2.2.4.10 Quantification of nucleic acids 
 
Quantifying the concentration of nucleic acids in samples was performed with a 
NanoDrop
®
 ND-1000 (Thermo) UV-Vis Spectrophotometer at a wavelength of 260nm, 
using 1ul of sample. At 260 nm, the average extinction coefficients are 40mM for RNA, 
50mM for dsDNA and 25mM for ssDNA. 
 
2.2.4.11 DNA sequencing 
 
Sequencing was carried out using a 3130xl Genetic Analyzer (Applied Biosystems), 
according to the manufacturer's instructions. The sequencing reactions were kindly 
carried out by Ms. Charlotte Alston. Primers for sequencing are listed in 2.2.4.4. Samples 
were prepared by mixing 500ng DNA with 1.5ul 5x sequencing buffer v3.1, 1 ul primer 
(stock 3.2uM), and 3ul BigDyes
®
 Terminator v3.1. Reactions were made up to 20ul, and 
cycle sequenced according to the following parameters: 
 
Step Reaction Profile Reaction Step 
1 95⁰C - 5 minutes Initial Denaturation 
2 95⁰C - 30 seconds Denaturing 
3 50⁰C - 10 seconds Annealing 
4 60⁰C - 4 minutes Extension 
5 Back to Step 2, 30 cycles # of cycles 
6 4⁰C - Indefinitely Hold 
 
The PCR products were then precipitated in a 96-well plate, and 10ul of Hi-Di added, 
followed by incubation at 95⁰C for 2 min. Samples were then loaded onto the 3130xl 
genetic analyzer. Sequencing data was analyzed using SeqScape
®
 v2.6 software (Applied 
Biosystems).  
 
2.2.5  RNA handling and manipulations 
 
2.2.5.1 RNA isolation from human cells 
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RNA was isolated from cultured human cells using Trizol (Invitrogen) following the 
manufacturer's instructions. Cells were harvested and pelleted by centrifugation. The cell 
pellet was thoroughly homogenized by pipetting in 1ml of Trizol reagent (Invitrogen). 
The suspension was incubated 5min at RT. 0.2ml chloroform per 1ml Trizol was added, 
and the tube was shaken vigorously by hand for 15sec, then incubated for 2-3min at RT. 
The sample was centrifuged at 12,000g for 15min at 4⁰C. The aqueous RNA phase was 
transferred into a fresh tube and 0.5ml of isopropyl alcohol per 1ml of Trizol added. This 
was mixed and incubated at RT for 10min, then centrifuged at 12,000g for 10min at 4⁰C. 
The supernatant was removed, and the RNA pellet washed once with 70% ethanol in 
DEPC treated H2O, and once with 100% ethanol. Then the pellet was resuspended in 20-
40ul DEPC treated H2O. The RNA was then quantified by Nanodrop
®
 analysis. 
 
2.2.5.2 In vitro transcription of RNA 
 
Generation of RNA species via in vitro transcription was accomplished using the 
Ampliscribe Sp6 kit (Epicentre
®
 Biotechnologies), following the manufacturer's 
instructions. DNA templates for in vitro transcription were PCR products with an SP6 
promoter incorporated on to the 5' end. Briefly, the transcription reaction mix was 
assembled in the following order: 
 
Amount (ul) Component 
To final vol of 20 Nuclease-free H2O 
1 50mM ATP solution 
1 50mM CTP solution 
1 50mM GTP solution 
1 50mM UTP solution 
2 10x reaction buffer 
0.1-1 DNA template 
2 100mM DTT 
2 SP6 enzyme mix 
 
Once assembled, the reaction mix was mixed thoroughly and incubated for 2 hours at 
37⁰C. Then 1ul of TURBO DNase I (2U) was added and incubated at 37⁰C for a further 
15min to remove the DNA template. RNA was recovered by phenol/chloroform 
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extraction and ethanol precipitation. The RNA pellet was washed once with 75% ethanol 
in DEPC H2O, and once in 100% ethanol, then resuspended in 20-40ul DEPC treated 
H2O. The RNA concentration was determined via Nanodrop
®
, then finally SUPERase-
In
TM
 (Ambion), an RNase inhibitor, was added to a final concentration of 1U/ul to 
prevent degradation of the RNA samples. 
 
2.2.5.3  Denaturing RNA electrophoresis  
 
Total RNA (5-10ug) was mixed in sample buffer consisting of 1x MOPS (40mM MOPS 
acid, 10mM NaOAc, 1mM EDTA pH 7.2), 15% formaldehyde, 35% formamide, 
0.1mg/ml ethidium bromide, bromophenol blue and xylene cyanol), heat denatured for 
15min at 55⁰C, then electrophoresed through a 1% agarose-formaldehyde denaturing gel 
(0.75g agarose, 1.5ml formaldehyde, 6ml 10x MOPS, 52.5ml dH2O) in 1x MOPS buffer 
at 50V for 2-3 hrs. Integrity and migration of RNA was visualized with a UV 
transilluminator after electrophoresis. For in vitro transcribed RNA, 6% 
polyacrylamide/8M Urea/1x TBE (100mM Tris, 90mM boric acid, 1mM EDTA) gels 
were used for electrophoresis. The sample buffer was 90% formamide/1x TBE. These 
gels were pre-run at constant 150V for 30-60min prior to loading RNA. Electrophoresis 
was performed at constant 150V for 1.5-2 hours. 
 
2.2.5.4  Reverse transcription  
 
For generating complementary DNA (cDNA) the Superscript II Reverse Transcription kit 
(Invitrogen) was used. RNA (5-10ug) was mixed with 1ul oligo δT primer (stock 
100uM), made up to 12ul with DEPC-treated H2O, and incubated at 70⁰C for 10min, then 
moved directly to ice for 1min. On ice, 4ul of 5x First-Strand Reaction Buffer, 2ul of 
0.1M DTT, and 1ul of 10mM dNTPs were added to the reaction mix. The reaction was 
then incubated at 42⁰C for 5min. Superscript II reverse transcriptase was then added (1ul, 
200U), the solution gently mixed, then incubation at 42⁰C was continued for 59min. The 
reverse transcriptase was inactivated by heating at 70⁰C for 15min. The resulting cDNA 
was stored at -80⁰C.  
 
2.2.5.5  Northern blotting 
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RNA was electrophoresed through agarose as described above. Gels were imaged to 
confirm RNA migration and quality, then transferred to Genescreen Plus membrane 
(Perkin Elmer) by overnight capillary transfer in 10x SSPE (3.6M NaCl, 200mM 
phosphate buffer pH 7, 20mM EDTA) any gel fragments were removed, the blot washed 
with 2x SSPE and baked at 80⁰C for 2 hrs in vacuum dryer. The membrane was then 
blocked with pre-hybridization solution containing 50% formamide, 5x SSPE, 1% SDS, 
1x Denhardts solution, rotating 2 hrs at 42⁰C. 32P-labeled DNA probes against RNA 
targets were generated using DNA templates synthesized by PCR amplification. These 
random hexamer labelling reactions (15ul) consisted of 50ng DNA template, 3ul random 
hexamer mix, 1ul (5U) DNA polymerase I (Klenow fragment, Promega), 2ul 
32P α-dCTP 
(10-20uCi, Perkin Elmer NEG513H), and incubated at 37⁰C for 1 hour. Free nucleotides 
were removed by use of an Illustra G-25 column (GE Healthcare), according to 
manufacturer's protocol. The activity of the labeled probes was estimated using a 
Cerenkov counter. The probes averaged 5000cpm/ul, and 10ul of probe was added to the 
pre-hybridization solution following blocking, and membranes were incubated overnight 
at 42⁰C with rotating. Following hybridization, membranes were washed twice with 20ml 
of 2x SSPE for 15min at RT, then once with 20ml pre-warmed 2x SSPE/2% SDS for 
15min at 65⁰C. The membrane was wrapped in SARAN wrap and exposed to Phosphor-
Imager screens, the signal was then visualized with a Typhoon FLA 9500 imaging system 
and ImageQuant software (GE Healthcare). 
 
2.2.6  Protein handling and manipulations 
 
2.2.6.1 Protein isolation from human cells 
 
Cell lysates were prepared from cultured primary and immortalized human fibroblasts, 
and HEK293 cells. Cells with confluency of approximately 80% had culture media 
refreshed the night before harvesting. Cells were detached and pelleted as described 
previously, washed once in Dulbecco’s A-PBS, pelleted again, and stored on ice until 
protein extracted. Cell pellets were suspended in chilled lysate buffer (50mM Tris pH 7.5, 
130mM NaCl, 2mM MgCl2, 1mM PMSF, 1% NP-40, with 1x EDTA-free protease 
inhibitor cocktail (Pierce)) by adding 80ul lysate buffer (per 5,000,000 cells) to cell 
pellets, and pipetting to lyse. The lysate was incubated on ice for 15min, with occasional 
mixing. The nuclear fraction of the lysate was then removed by centrifuging at 560g at 
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4⁰C for 2 minutes in an Eppendorf 5415R centrifuge. The supernatant, comprising the 
cytoplasmic fraction, was transferred to a fresh chilled tube. The protein concentration 
was then quantified via Bradford assay.  
 
2.2.6.2 Isolation of crude mitochondria from human cells 
 
Cultured human cells grown in 225cm
2
 flasks were detached and pelleted as described 
above. These cells were then suspended in 2ml of homogenization buffer (0.6M mannitol, 
10mM Tris pH 7.4, 1mM EGTA, 1mM PMSF, 0.1% BSA). This suspension of cells was 
subjected to 15 passes of homogenization in a 2 ml glass-teflon homogenizer (Glas-Col), 
followed by centrifugation at 400g, 4⁰C, for 10min in an Eppendorf 5415 R centrifuge. 
The supernatant containing the crude mitochondria was retained on ice, while the pelleted 
material was resuspended in fresh 2ml of homogenization buffer, and homogenization 
and centrifugation were repeated. The supernatant fractions were collected and 
centrifuged at 400g, 4⁰C, for 5min to further clear non-mitochondrial material. All 
cleared supernatant fractions were then centrifuged at 11,000g, 4⁰C, for 10min to pellet 
the mitochondria. The mitochondrial pellets were washed in a minimum of 300ul each of 
homogenization buffer without BSA, and combined into one tube. This combined 
mitochondrial fraction was centrifuged again at 11,000g, 4⁰C, for 5min to generate a 
single pellet of crude mitochondria. Pellets were flash-frozen in liquid nitrogen and stored 
at -80⁰C. 
 
2.2.6.3 SDS polyacrylamide gel electrophoresis 
 
Cell and mitochondrial lysates were analyzed by SDS polyacrylamide gel electrophoresis 
using either Hoefer Mighty Small
TM
 system or Bio-Rad Mini-Protean
®
 tetra cell. Stacking 
and resolving gels were prepared according to table below. 
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Component composition of SDS polyacrylamide gels 
Reagent 3.75% Stacking Gel 12% Resolving Gel 
30% polyacrylamide  
(29:1 acrylamide/bis-
acrylamide) 
0.625ml 1.998ml 
3.75M Tris-HCl pH 8.5 n/a 0.5ml 
0.5M Tris-HCl pH 6.8 1.25ml n/a 
10% SDS 50ul 50ul 
10% Ammonium Persulfate 50ul 50ul 
TEMED 5ul 5ul 
dH2O Up to 5ml Up to 5ml 
  
 
Prior to loading on to gels, samples were diluted with 5x Laemmli buffer (10% SDS, 
250mM Tris-HCl pH 6.8, 500mM DTT, 50% glycerol, and bromophenol blue). 
Especially viscous samples were incubated with 25U benzonase (Novagen) to digest any 
cellular DNA present. The samples were electrophoresed at a constant voltage of 100V 
for the Hoefer system, or 200V for the Bio-Rad system, in a running buffer consisting of 
25mM Tris, 192mM glycine, and 0.1% [w:v] SDS. The Spectra
TM
 Multicolor Broad 
Range Protein Ladder (Thermo Scientific) was loaded for protein size comparison.  
 
2.2.6.4 Coomassie blue staining 
 
Total protein content separated by electrophoresis through polyacrylamide gels was 
visualized by staining gels with Coomassie Brilliant Blue. After electrophoresis, gels 
were immersed in staining solution containing 30% methanol, 10% acetic acid, and 0.1% 
Coomassie Brilliant Blue R250 for 1 hour. The background was then removed with 
destaining solution containing 30% methanol and 10% acetic acid for at least 1 hour or 
more as necessary. Stained gels were imaged using the ChemiDoc
TM
 MP system (Bio-
Rad). 
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2.2.6.5 Silver staining 
 
Silver staining is a more sensitive method for visualizing protein content compared to 
Coomassie staining. After electrophoresis of samples, polyacrylamide gels were fixed 
overnight at RT in 50% methanol with gentle rocking. The following day the gel was 
incubated in freshly made silver staining solution (0.1% AgNO3, 10mM NH4OH, 0.36% 
NaOH) for 15min, then washed three times for 5min in dH2O. Developer solution (0.04% 
formaldehyde, 0.05% citric acid) was then added, and the gel incubated until desired 
intensity of protein signal was observed. The reaction was terminated by washing gel with 
5% acetic acid. Stained gels were imaged using the ChemiDoc
TM
 MP system (Bio-Rad).  
 
2.2.6.6 Immunoblotting 
 
Typically 40ug of total cell lysate was separated by SDS-PAGE as described above. Prior 
to transfer, PVDF membranes (Immobilon-P, Millipore) were activated by immersion in 
methanol for 20sec, and rinsed in dH2O before equilibrating in transfer buffer (25mM 
Tris, 192mM glycine, 0.02% SDS, and 15% methanol). The polyacrylamide gel and 
membrane were assembled between two pieces of Whatman 3MM filter on each side. 
Proteins were then transferred using Mini Trans-blot
TM
 module (Bio-Rad) at a constant 
100V, for 1 hr at 4⁰C in transfer buffer. Membranes were blocked in 5% milk/TBS-
Tween at for 1 hr at RT. Antibodies used for blotting are listed in 2.2.6.8. Primary 
antibody incubations were performed in 1% milk-TBST for 3 hrs at RT or overnight at 
4⁰C, and secondary antibody incubations were performed in 1% milk/TBST for 1 hr at 
RT. Blots were developed using ECL Prime (GE Healthcare), and imaged using a 
ChemiDoc
TM
 MP system (Bio-Rad).   
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2.2.6.7 Antibodies used for immunoblotting 
Primary Antibody  Species Clonality Dilution  
M2 Flag (Sigma F1804) Mouse Monoclonal 1:1000 
Cytochrome c Oxidase Subunit 1 (Mitosciences 
MS404) 
Mouse Monoclonal 1:1000 
Cytochrome c Oxidase Subunit 2 (Mitosciences 
MS405) 
Mouse Monoclonal 1:1000 
Cytochrome c Oxidase Subunit 3 (Mitosciences 
MS406) 
Mouse Monoclonal 1:1000 
Cytochrome c Oxidase Subunit 4 (Mitosciences 
MS407) 
Mouse Monoclonal 1:1000 
Succinate Dehydrogenase Subunit A 
(Mitosciences MS204) 
Mouse Monoclonal 1:5000 
Porin (Mitosciences MSA03) Mouse Monoclonal 1:10,000 
TOM20 (Santa Cruz sc-17764) Rabbit Polyclonal 1:750 
mtPAP (GeneTex GTX70156) Mouse Monoclonal 1:1000 
mtPAP (Epitomics S3295) Rabbit Polyclonal 1:500 
MRPL3 (Abcam ab39268) Goat Polyclonal 1:2000 
DAP3 (Abcam ab11928) Mouse Monoclonal 1:1000 
NDUFA9 (Mitosciences MS111) Mouse Monoclonal 1:1000 
NDUFB8 (Mitosciences MS105) Mouse Monoclonal 1:1000 
Complex V α-subunit (Mitosciences MS502) Mouse Monoclonal 1:1000 
Complex III core 2 (Mitosciences MS304) Mouse Monoclonal 1:1000 
ATP8 (Santa Cruz sc-84231) Rabbit  Polyclonal 1:200 
LRPPRC (Santa Cruz sc-66844) Rabbit Polyclonal 1:200 
ND1 (gift from A. Lombes) Rabbit Polyclonal 1:1000 
ND1 (Gift from Dr A Spinazzola) Chicken Polyclonal 1:10,000 
ATAD3 (Gift from I. Holt) Rabbit Polyclonal 1:50,000 
Secondary Antibodies Species Clonality Dilution  
Anti-Mouse, HRP-conjugated (Dako P0260) Rabbit Polyclonal 1:2000 
Anti-Rabbit, HRP-conjugated (Dako P0399) Swine Polyclonal 1:3000 
Anti-Goat, HRP-conjugated (Dako P0449) Rabbit Polyclonal 1:2000 
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Modification of the mitochondrial poly(A) tail assay to a fluorescent 
platform 
 
3.1  Introduction 
  
 Since the discovery of polyadenylation activity in thymus nuclei extracts over 50 
years ago (Edmonds and Abrams, 1960), analyzing the properties and functions of 
poly(A) tails has been a major focus of research. Characterization of nuclear and cytosolic 
polyadenylation, both in terms of molecular mechanics and functional purposes has come 
a long way. The major characteristic of polyadenylation that can confer function, is the 
chain of adenosine monophosphates added to mRNAs. Initial characterization of 
polyadenylating enzymes was primarily focused on in vitro studies, as it was difficult to 
isolate intact poly(A)+ mRNA from cells for analysis of tail lengths. These in vitro 
systems were extremely useful and much of our modern understanding of 
polyadenylation mechanics stems from those experiments.  
 There are multiple techniques that have been utilized to assess the length of 
poly(A) tails. These include RNase protection assays, northern blots, using PCR to 
amplify 3' regions of transcripts for comparison on denaturing gels, and direct sequencing 
of cDNA generated from RNA. Another common approach to assess poly(A) tail length 
is circularizing the mRNAs to capture the full tail, then reverse transcribing and PCR 
amplifying the region of interest. The amplicons can then be cloned into plasmids, and 
sequenced. This was the method undertaken in the first published description of the 
human mitochondrial poly(A) polymerase (Tomecki, 2004). As an alternative to direct 
sequencing of the PCR products, the amplicons can be radioactively labeled and 
separated by polyacrylamide-urea gel electrophoresis (Slomovic and Schuster, 2007). 
 There are benefits and drawbacks to each technique. One of the primary benefits 
of sequencing is the lack of ambiguous results of the nucleotide sequences. A major 
drawback is that many sequencing platforms have difficulty with homopolymeric tracts, 
causing distorted sequence readouts. The existence of populations of different poly(A) 
length poses a problem for sequencing based methods as well. Following PCR that will 
preferentially expand the shortest template will be of the most prevalent and will not 
allow for a broad view of differing poly(A) lengths. When using separation via 
electrophoresis to analyze tail lengths, these benefits and drawbacks are largely reversed. 
Populations of differing lengths can be observed relatively easily on the gels, but careful 
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design of size markers and clarity of detection methods are paramount for correct 
interpretation of results. 
 In 2003, our lab published a paper describing the functional consequences of a 
pathological microdeletion in the MTATP6 gene in a patient (Temperley, 2003). To 
determine poly(A) tail length this reported a modification of a technique used for 
cytosolic transcripts, and was the first published protocol for the mitochondrial poly(A) 
tail assay (MPAT). The assay allowed analysis of the lengths of poly(A) tails on 
mitochondrial mRNAs with the single nucleotide resolution. Data using this technique 
was also reported in an article on characteristics of human mitochondrial mRNAs and 
their polyadenylation status (Temperley et al., 2010b) and an investigation into the effects 
of mitochondrial poly(A) tail removal and blockage by mitochondrially-targeting the 
cytosolic deadenylase PARN and the poly(A) binding protein PABPC1 respectively 
(Wydro et al., 2010). In each of these investigations, the MPAT provided critical data on 
the poly(A) tail lengths of mt-mRNA, both the absolute tail length and the distribution of 
oligo- and polyadenylated populations present in cells. 
 The most recent use of the MPAT was in the assessment of a family harboring a 
mutation in the PAPD1 gene, which encodes the mitochondrial poly(A) polymerase, 
mtPAP (Crosby et al., 2010). Individuals homozygous for the 1432A>G mutation showed 
a short oligo(A) tail on mt-mRNAs. Heterozygous carriers did not show such a severe 
truncation, essentially reflecting the ratio of oligo- and polyadenylation observed in 
control cells. This was the extent of the characterization of this novel mutation in the 
research article. The initial impetus for this thesis work was to further our understanding 
of the function of the mitochondrial poly(A) tail in gene expression and to analysis the 
effect of the PAPD1 mutation, both in terms of downstream biochemical effects. The 
MPAT would thus be a valuable tool to employ in this research. 
 The MPAT assay was designed using standard 5’- radiolabeling of PCR primers 
in order to visualize nucleotide lengths once products had been separated by denaturing 
polyacrylamide/urea gel electrophoresis. In light of the increase in sensitivity of 
fluorescent moieties, the decision was made to convert the MPAT assay from a radiation-
based platform to a fluorescence-based one. This would have several benefits over the 
previous employments of the assay. First and foremost the 
32
P-radiolabelled primers have 
a short half life and need to be remade frequently to prevent loss of sensitivity. This 
contrasts with fluorescently tagged primers that once synthesized, retain their sensitivities 
indefinitely if corrected stored. With radiolabeled PCR products, post electrophoresis the 
gel needs to be immobilized on Whatman paper, dried for several hours, then exposed to 
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phosphorscreens for several hours up to multiple days. Fluorescent labeling again has an 
advantage as it allows immediate imaging of the gel itself, removing all the drying and 
exposure steps of autoradiography. Using radiolabeled primers means that for maximum 
sensitivity experiments must be completed within the window dictated by the isotope 
decay rate. Fluorescent-labeling of probes allows for highly sensitive, permanently 
available probes. Finally, fluorescence allows users to avoid exposure to ionizing 
radiation, while ideally maintaining or exceeding the sensitivity of radiation-based 
methods. In total, there was much to be gained by developing a fluorescent MPAT assay.  
 In this chapter, the results show that after the initial phase of optimization, I was 
able to establish the fluorescent MPAT with comparable sensitivity to the radiation-based 
MPAT results. This allowed it to be used in replacement of the radioactive assay for the 
poly(A) analysis of the PAPD1 1432A>G mutant fibroblasts. 
 
 
3.2  Methods 
 
3.2.1  Radioactive mitochondrial poly(A) tail assay 
 
This technique was performed essentially as described in (Temperley, 2003). 
 
RNA Ligation: RNA (2.5ug) isolated from cultured human cells was ligated to 20pmol 
of a universal DNA 5' phospho oligonucleotide linker (see 2.2.4.4) blocked with an NH2 
group at the 3' end. First, 10x T4 RNA Ligase buffer (NEB) was thawed and pre-warmed 
at 37⁰C and vortexed to assure it was all in solution. RNA and linker were chilled on ice, 
in a thick-walled 0.5ml microtube. This mix was then preheated at 90⁰C for 2 min, then 
transferred onto ice for a minimum of 1 min. PEG 1000 (50% stock in DEPC-treated 
H2O) (final conc. 12.5% v:v) was added whilst still on ice, and then 1ul of pre-warmed 
10x T4 RNA Ligase buffer was added. This mixture was pulsed down and 20 units T4 
RNA Ligase (NEB) added. The ligation was performed for 3 hrs at 37⁰C. After 
incubation, the reaction products were made up to 100ul with DEPC H2O, and phenol (at 
pH 6.7)/chloroform extracted and precipitated using 1/10th volume 3M sodium acetate 
pH 5.2 (made up in DEPC-treated H2O) and 2 volumes 100% ethanol.  
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Reverse Transcription and PCR Amplification: Once the RNA was precipitated, it was 
re-suspended in 11ul DEPC H2O. 5.5ul of re-suspended product was mixed with 10pmol 
of Anti-LIGN primer (appendix A). The RNA and Anti-LIGN primer were heated at 
70⁰C for 10 min, then transferred on to ice, where a master mix of 2ul of 5x Superscript 
buffer, 1ul of 100mM DTT and 0.5ul 10mM dNTPs were added. This mixture was pre-
heated at 42⁰C for 5 min, then 0.5ul (100U) Superscript II enzyme (Gibco) was added. 
Reverse transcription was performed at 42⁰C for 59min, followed by 70⁰C for 15min. 
The resulting cDNA (1ul) was used as a template in a 50ul reaction mix for a 35 cycle 
PCR reaction. This is termed the "cold PCR" reaction. The reaction mix consisted of 
34.5ul dH2O, 2.5ul 20uM Anti-LIGN primer, 2.5ul 20uM RNA14 primer (see 2.2.4.4), 3ul 
25mM MgCl2, 1ul 10mM dNTPs, 5ul 10x PCR buffer (Thermo), and finally 0.5ul (2.5U) 
Taq polymerase (Thermo) was added once the reaction mix was heated to 94⁰C. The PCR 
profile is detailed in 3.2.3. The PCR reaction products (5ul) were analyzed by agarose gel 
electrophoresis to confirm presence of correct sized product prior to precipitating. PCR 
reaction products were then ammonium acetate/ethanol precipitated by adding 1 ul linear 
acrylamide, ½ volume of 7.5M NH4OAC, and 2 volumes EtOH. This was incubated for 2 
hours at -80⁰C. The product was pelleted by centrifuging as detailed for normal EtOH 
precipitation, not washed with EtOH, but re-suspended in 10-12.5ul dH2O.  
 
Radiolabeling PCR and Sequencing Gel: Re-suspended "Cold PCR" products (2.5ul) 
were used in a 2nd PCR reaction (termed the 'hot PCR') programmed with 1 Unit Taq 
polymerase (Thermo) 1x PCR buffer (Thermo), 1.5mM MgCl2, 0.2mM dNTPs, 0.3uM 
nested radiolabelled forward primer internal to the target gene and 0.3uM Anti-LIGN 
reverse primer, in a final reaction volume of 10ul, with 30ul of mineral oil overlaid. The 
'hot PCR' profile is shown in 3.2.3, and underwent 5 cycles of amplification. The forward 
primers (5 pmol) were all 5' end-labeled by T4 polynucleotide kinase (NEB) with [γ-32P] 
dATP (3000 Ci/mmol, Perkins-Elmer), in 1x PNK buffer (NEB), for 30min at 37⁰C, and 
free radioactive nucleotides removed by overnight dialysis. The amount of radiolabeled 
primer needed per hot PCR was calculated by dividing the desired input of moles 
(0.3pmol) by the amount initially radiolabeled (5pmol) and multiplied by the recovered 
dialysis volume (ul). This gave the number of ul of labeled primer stock needed per 
reaction. As an alternative to purification by dialysis, illustra Microspin G-25 columns 
were used for removal of radioactive nucleotides from labeling reactions, according to 
manufacturers protocol. Following the PCR, 3ul aliquots of the labeled products, mixed 
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with 8ul loading buffer (1x TBE buffer, 90% [v:v] formamide, bromophenol blue, xylene 
cyanol) were separated on a pre-electrophoresed (for 30 min) 10% polyacrylamide (29:1 
ratio of bis/acrylamide), 8.2 M urea denaturing gel in 1x TBE buffer at 50W for 2-3 
hours. Bromophenol blue and xylene cyanol were used to monitor sample migration 
during electrophoresis. The gel was then transferred to Whatman paper and vacuum dried 
at 80⁰C for 2 hours. Finally the gel was exposed to a PhosphorImager cassette (Molecular 
Dynamics) and visualized by a Storm PhosphorImager.   
 
3.2.2  Fluorescent mitochondrial poly(A) tail assay 
 
The fluorescent assay follows the same procedures as the radiolabeled assay to generate 
the ‘cold’ PCR products. The remaining sections were modified and described below. 
 
Fluorescent PCR and Sequencing Gel: 2.5ul of re-suspended "Cold PCR" products 
were used in a 2nd PCR reaction (now termed the 'fluoro-PCR') programmed with 1 Unit 
Taq polymerase (Thermo) 1x PCR buffer (Thermo), 1.5mM MgCl2, 0.2mM dNTPs, 3uM 
nested Alexafluor-647 labeled forward primer internal to the target gene and 0.3uM Anti-
LIGN reverse primer, in a final reaction volume of 10ul. The "fluoro-PCR" profiles are 
shown in 3.2.3, and these reactions underwent 15 cycles of amplification. The forward 
primers used in the PCR reaction were commercially synthesized as 5' labeled with the 
Alexafluor® 647 dye (Eurogentec). Aliquots (4ul) of the labeled products, mixed with 5ul 
loading buffer (1x TBE buffer, 90% [v:v] formamide) were separated on a pre-
electrophoresed (for 30 min) 10% polyacrylamide (29:1 ratio of bis/acrylamide), 8.2 M 
urea denaturing gel at 50W for 2-3 hours. Bromophenol blue and xylene cyanol were 
used to monitor sample migration during electrophoresis. The dyes were loaded in a lane 
towards the edge of the gel, and as far from the fluorescent product lanes as feasible, due 
to their intrinsic fluorescence which interfered with sample detection. The gel was then 
transferred to acetate plastic sheets for direct imaging on a Typhoon FLA 9500 
instrument.  
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3.2.3  MPAT PCR profiles 
 
Radioactive MPAT 
Step Reaction Profile 
"Cold PCR" 
Reaction Profile 
"Hot PCR" 
Reaction Step 
1 94⁰C - 4 minutes 94⁰C - 4 minutes Initial Denaturation  
2 94⁰C - 1 minute 94⁰C - 1 minute Denaturing 
3 54⁰C - 1 minute 54⁰C - 1 minute Annealing 
4 72⁰C - 1 minute 72⁰C - 1 minute Extension 
5 Back to Step 2, 35 cycles Back to Step 2, 5 cycles # of cycles 
6 72⁰C - 7 minutes 72⁰C - 7 minutes Final Extension 
7 4⁰C - Indefinitely 4⁰C - Indefinitely Hold 
 
Fluorescent MPAT 
Step Reaction Profile 
"Cold PCR" 
Reaction Profile 
"Fluoro-PCR" 
Reaction Step 
1 94⁰C - 4 minutes 94⁰C - 4 minutes Initial Denaturation  
2 94⁰C - 1 minute 94⁰C - 1 minute Denaturing 
3 54⁰C - 1 minute 54⁰C - 1 minute Annealing 
4 72⁰C - 1 minute 72⁰C - 1 minute Extension 
5 Back to Step 2, 35 cycles Back to Step 2, 15 cycles # of cycles 
6 72⁰C - 7 minutes 72⁰C - 7 minutes Final Extension 
7 4⁰C - Indefinitely 4⁰C - Indefinitely Hold 
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3.3  Results 
 
3.3.1  Optimizing the fluorescent MPAT platform 
  
 There were two main issues to resolve with developing a fluorescent MPAT, 
namely, sensitivity and efficacy of detection of the fluorophore to be used. For maximum 
sensitivity, the Alexafluor® 647 dye was chosen, as it possessed the highest extinction 
coefficient, and thus emits most intensely with minimal crossover interference into the 
near-infrared range. At the moment, Life technologies has improved the sensitivity of 
many fluorescent moieties used in biological systems and this includes relabeling the 
Alexafluor® 647 dye as near-infrared as opposed to far-red. Although the Anti-LIGN 
reverse primer is used for all reactions, the radioactive assay radiolabels each gene-
specific nested forward primer for use in the final PCR reaction, as products did not 
resolve well if the reverse primer was labeled. However, the Anti-LIGN reverse primer 
being a universal primer also made it ideal to label with a fluorophore, as it would require 
a single labeled universal primer, for all reactions versus buying primers for each mt-
mRNA transcript individually. 
 The Anti-LIGN primer (see 2.2.4.4) labeled with the Alexa Fluor® 647 dye was 
commercially synthesized, and range of primer quantities (10 pmol to 0.01 fmol) 
electrophoresed through a 10% denaturing polyacrylamide gel (figure 3.1). The goal was 
 
Figure 3.1. Titration of Alexa Fluor® 647-labeled Primer 
To assess detection limits, a 1:10 serial dilution series of the fluorescent primer was electrophoresed through a 
10% polyacrylamide, 8.2M urea, 1x TBE gel, and imaged on a Typhoon FLA 9500 imager. Lanes are labeled with  
total amount of primer loaded. The purity of the primer was also assessed by this method. 
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to determine detection limits with the expectation that 0.01 fmol would be a viable 
sensitivity for the assay. Even if signal was only visible at 0.1 fmol, it would likely be 
sensitive enough for MPAT usage. Fortunately, fluorescent product was visualized down 
to 0.01 fmol, although the signal was fairly weak at that amount (far right lane). This 
level of detection was well within the necessary range of sensitivity. I was, therefore, 
confident that I could incorporate the fluorescent primer into the MPAT assay in 
replacement of the radiolabeled primers. 
 The first attempt at replacing 
radiolabeled primers with fluorescent-
labeled followed the radioactive MPAT 
protocol exactly. The only divergence from 
that protocol was fluorophore was 
conjugated to the reverse primer of the 
fluoro-PCR, versus radiolabeling the nested 
gene-specific forward primer. The RNA 
samples used in the assay were isolated 
from three patient cell lines, two of which 
harbored a homoplasmic 1432A>G 
mutation in the PAPD1 gene. This mutation 
causes a characteristically short 
mitochondrial (A) tail. The third cell line 
came from a relative heterozygous for the 
1432A>G mutation, who is clinically 
unaffected and does not show a 
mitochondrial oligo(A) tail. These three 
samples would act as an experimental 
control as the recognizable pattern of the 
(A) tails had already been determined using 
the radioactivity based MPAT. The latter 
demonstrated that the homoplasmic samples 
had short and the heteroplasmic samples 
had wild-type poly(A) lengths. Thus, ‘Cold PCR’ samples from these cell lines were used 
as templates for the second PCR. This second round of PCR was carried out using a 
nested primer for RNA14 and the Alexa Fluor® 647 labeled Anti-LIGN primer. The 
reaction products were then electrophoresed through a large sequencing-type 10% 
 
 
                         1 2 3 4 
 
Figure 3.2. Fluorescent MPAT on Large 
Gel 
Fluorescently-labeled samples from two homozygous 
PAPD1 mutant RNA samples (lanes 1-2), one 
heterozygote (lane 3) carrying the 1432A>G PAPD1 
mutation, and a PCR control (lane 4) were separated on a 
10% polyacrylamide/8.2M urea denaturing gel. 
Visualized on Storm PhosphorImager. 
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polyacrylamide 8.2M Urea denaturing gel, and visualized directly on a Storm 
PhosphorImager. The plastic acetate sheets the gel was transferred to in order to read it on 
the Storm Imager were not large enough to hold the entire gel, making part of the 
difficulty of visualizing the gels determining where to cut them so they fit on the plastic 
sheet. This is a step that is technically more difficult compared to transferring gels to 
Whatman paper. The gel does not adhere to plastic acetate sheets as well as the Whatman 
paper, so the user must be extremely careful when transferring the very thin, but large, gel 
onto plastic sheets for imaging. The results of this large fluorescent gel are shown in 
Figure 3.2.  
 The gel image is shown in two pieces due to the necessity of cutting the gel to fit 
onto the plastic sheets. In this initial experiment, I had not yet determined the proper areas 
to cut the gel while preserving the integrity of the fluorescent signal in the lanes. Two 
major conclusions were reached when considering this gel: the first was that when using 
fluorescence, the quality of the electrophoresis run and that of the gel itself would be 
paramount to generating clean results. That is, imperfections on the gel such as bubbles, 
fingerprints, and even dust would readily be visible. In Figure 3.2, bubbles formed when 
transferring the gel to plastic sheets are clearly visible, and issues like this would need to 
be resolved in order to produce high quality images. The second conclusion is that the 
previously observed patterns of the poly(A) tails for these patients published in (Crosby et 
al., 2010), using the radioactive MPAT, are not present. Having robustly established the 
radioactive MPAT protocol and results in the past, we knew these patterns should be 
present if the assay is operating correctly. With the fluorescently-labeled Anti-LIGN 
primer, the assay did not appear to be functioning correctly. After repeating this 
fluorescent assay protocol multiple times, and still not generating the expected results, the 
next step was to return to the radioactive-based MPAT protocol and make sure the assay 
was working correctly in my hands. 
 While switching back to the radiation-based MPAT, I accomplished two goals. 
The first was to make sure I could perform the assay correctly. The second, was to 
establish that the poly(A) phenotype observed in the PAPD1 mutant patients was present 
in RNA isolated from dermal fibroblasts. The previous published work had used RNA 
extracted from blood. My thesis project was to be largely based on work from patient 
fibroblasts, so confirming the oligo(A) phenotype was paramount. Towards this end, I 
isolated RNA from the patient fibroblast cultures, two homozygous and one heterozygous 
for the PAPD1 mutation, one from a healthy unrelated control fibroblast line, and 
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performed all stages of the MPAT assay. A gene-specific nested forward primer for 
RNA14 was radiolabeled, and used for the final hot PCR as shown in Figure 3.3.  
 In this gel, the characteristic oligo vs 
full length poly(A) tails in the mutant and wild-
type cells, respectively, was present. This was 
evidence of correct handling of the MPAT 
protocol in my hands. For the needs of the 
thesis research, the radioactive MPAT assay 
could serve as a viable tool to analyze 
mitochondrial poly(A) tails, and this was 
enough to do the necessary experiments with 
the fibroblasts. So the drive to switch the assay 
to a fluorescent platform was lessened at this 
point. However, the idea of having the Anti-
LIGN reverse primer be the labeled primer was 
still appealing, as it provide a universal primer 
that permanently retained maximal sensitivity. 
As the standard MPAT was now working in my 
hands and could be used for my thesis work, I 
concurrently attempted to repeat my results 
with the radiolabeled Anti-LIGN primer.  
 The result of switching the position of 
the radiolabeled primer was unexpected. In 
theory, either of the primers in the pair should 
be able to be labeled, and the same result 
should be observed. When the Anti-LIGN 
primer was labeled, and used with the same 
four cell line samples used in Figure 3.3, the characteristic poly(A) pattern was not 
observed. In fact, there did not appear to be a discernible pattern at all, as shown in Figure 
3.4. This result was similar to that of the fluorescently-labeled Anti-LIGN primer in the 
MPAT (figure 3.2). These outcomes from both the radioactive and fluorescent Anti-LIGN 
primer procedures provoked rethinking of labeling the reverse primer in the final PCR of 
the MPAT protocol. Instead, gene-specific nested primers conjugated to the Alexa Fluor® 
647 dye were synthesized to test in the fluorescent MPAT. 
 
Figure 3.3. Radiolabeled RNA14 
MPAT Analysis of Patient 
Fibroblasts 
RNA isolated from fibroblasts was processed for 
the MPAT using radiolabeled primers. The 
individuals were heterozygous (lane 1) or 
homozygous (lanes 2, 3) for a PAPD1 1432A>G 
mutation or control (lane 4). Controls were 
performed for the 1st (lane 5) and 2nd (lane 6) 
rounds of PCR. The signals were visualised via 
autoradiography on a Storm PhosphorImager 
and ImageQuant software.   
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 The next attempt at the 
fluorescent MPAT was with an 
RNA14-specific nested primer 
conjugated to the Alexa Fluor® 647 
dye, and it also included several 
other modifications. The standard 
radiolabeled protocol was followed 
with a parallel reaction performed 
with both an increase in the final 
concentration of the fluorescent 
primer (from 0.3uM to 3uM), and an 
increase in PCR cycles (from 5 to 15 
cycles). 
 With the use of a 
fluorescently-labeled forward 
primer, I finally saw the established 
pattern of polyadenylation from the 
PAPD1 mutant and control cells. 
Adhering to the previously used 
primer concentrations and cycle 
numbers did not produce as intense a 
signal as the higher primer concentrations and cycle numbers (Figure 3.5, panel A vs B). 
The increased primer concentration and cycle numbers produced a pattern that 
recapitulated previously observed results, and furthermore lacked much of the smeary 
signal seen with radiolabeled nucleic acids on my gels. The fluorescent MPAT was 
repeated to confirm consistency of the observed poly(A) patterns. The results also show 
that the single-nucleotide resolution obtained using the radiation-based MPAT 
experiments was maintained with the fluorescent primer. With the adjusted protocol and 
fluorescent primers, the updated MPAT appeared to have all the sensitivity and accuracy 
of the radiation based assay while adding the benefits of the long-lived primer status of 
fluorescence primer. Thus, it was adopted for use in this thesis research for analyzing 
poly(A) tails in patient fibroblasts.   
 
 
Figure 3.4. MPAT using radiolabeled Anti-
LIGN primer  
RNA isolated from fibroblasts was processed for use in the 
MPAT using radiolabeled Anti-LIGN primer. Samples were 
heterozygous (lane 1) or homozygous (lanes 2, 3) for the 
PAPD1 1432A>G mutation or control (lane 4). Controls were 
performed for the 1st (lane 5) and 2nd (lane 6) rounds of PCR. 
The signals were visualised via autoradiography on a Storm 
PhosphorImager and ImageQuant software 
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 While this thesis work was being carried out, a research group at the University of 
Tokyo published a paper investigating the role of LRPPRC, SLIRP, and PNPase in 
mitochondrial RNA metabolism and polyadenylation (Chujo et al., 2012). They 
employed a modified version of the MPAT assay, with the primary adjustment being 
electrophoresing through shorter polyacrylamide gels and visualizing the separated PCR 
products via staining with SYBR Gold (Molecular Probes). Our version of the fluorescent 
MPAT (with all the steps detailed in Figure 3.6) provides higher resolution data, as the 
Tokyo results lack single-nucleotide resolution of the poly(A) tails. Their protocol allows 
for missed observations of subtle poly(A) tail effects that may occur. For example, the 
oligoadenylation observed in PAPD1 1432A>G homozygous mutant fibroblasts, mtPAP 
siRNA knockdowns, or LRPPRC knock-outs is much more difficult to distinguish from 
naked 3' ends using their short acrylamide gels. Our MPAT allows for a more detailed 
analysis of the lengths and perturbations of poly(A) tails, and presents a superior method 
for investigations such as these.   
 
  
Figure 3.5. Assessing various PCR conditions for the fluorescent MPAT. 
A. Fluorescent MPAT of RNA14 products using 5 cycles for the final PCR separated on a 10% denaturing gel. B. 
Modified protocol for RNA14 MPAT using 15 cycles and 3uM primer concentration in final PCR. Lanes are labeled 
with cell lines used and PCR controls.     
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Figure 3.6. Steps of the fluorescent MPAT 
A cartoon depicting the steps of the fluorescent MPAT procedure. Step 1: The isolated whole cell RNA is 
ligated at the 3' end to a DNA linker oligonucleotide. Step 2: The ligated RNA-linker is used with anti-LIGN 
primer to prime a reverse transcription reaction, generating cDNA incorporating the linker, and capturing the 
poly(A) tail. Step 3: The cDNA is used as a template in a gene-specific PCR to amplify the gene of interest. 
Step 4: The gene-specific amplicon is used as a template for a nested PCR, using forward primers conjugated 
to the AlexaFluor® 647 dye with the Anti-LIGN primer, to generate a fluorescently-labeled PCR products that 
reflect the population of poly(A) tails. This known size is used for calculating where the 3' end of the 
amplicon is located upon separation via polyacrylamide/urea gel electrophoresis.   
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Chapter 4 
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Characterization of the effect of the PAPD1 1432A>G mutation on 
mitochondrial gene expression 
 
4.1  Introduction 
  
 Polyadenylation fulfills a critical role in gene expression and RNA metabolism. 
As detailed in Chapter 1, it is a 3' RNA modification that is performed in the nucleus, 
cytosol and mitochondria in mammalian cells, with nuclear and cytosolic polyadenylation 
being particularly well-characterized (Kuhn et al., 2009). Mammalian mitochondrial 
polyadenylation, in contrast, is much less well understood. The modification defies 
superficial comparison of functionality with other organisms, as the role that 
polyadenylation carries out can differ drastically. In the mammalian nucleus, 
polyadenylation acts to facilitate transport of RNA into the cytosol (Huang and 
Carmichael, 1996), protect the 3' end of mRNAs (Bernstein et al., 1989), and aid 
initiation of translation (Gallie, 1991). In bacteria, the poly(A) tail acts as a signal for 
degradation, initiating RNA turnover (Xu and Cohen, 1995). Plant chloroplasts utilize 
poly(A) tails for degradation, like bacteria (Hayes et al., 1999).  
 The trend of the poly(A) tail being able to fulfill different roles is observed in 
mitochondria from different species. Plant mitochondria use the poly(A) tail to stimulate 
mRNA degradation (Gagliardi and Leaver, 1999). In yeast mitochondria, there is no 
polyadenylation (Osinga et al., 1984). Instead, a conserved 3' dodecamer sequence acts as 
a stabilizing modification (Butow et al., 1989). The mitochondrial mRNAs of 
trypanosomes feature short poly(A) sequences to confer stability based on the editing 
status of the transcript itself (Etheridge et al., 2008). These diverse roles fulfilled by 
poly(A) tails in mitochondria of various species emphasize the difficulty of predicting the 
poly(A) function in human mitochondria. As a mutation identified in the PAPD1 gene has 
been linked to human disease (Crosby et al., 2010), it is critical to elucidate the exact role 
of the poly(A) tail in human mitochondria.   
 While it has long been known that mammalian mitochondria possess their own 
poly(A) polymerase activity (Jacob and Schindler, 1972), the human mitochondrial 
poly(A) polymerase, mtPAP, was only identified in 2003 (Tomecki, 2004). It is a 66kDa 
protein, and is a noncanonical poly(A) polymerase. It is operational as a dimer, as 
opposed to the canonical monomer (G. Martin et al., 2000). The human mitochondrial 
poly(A) tails have an average length of 50 adenine nucleotides, in contrast to the nuclear-
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encoded mRNA poly(A) tail lengths of 250 nucleotides (Kuhn et al., 2009). At the start of 
my project, the only convincing function of mitochondrial mRNA polyadenylation was 
completion of the stop codon for seven of the thirteen open reading frames coded by  
mtDNA (Ojala et al., 1981). Beyond this, the role of the poly(A) tail on human mt-
mRNAs is unclear.  
 Several groups have attempted to elucidate the function of the poly(A) tail in 
human mitochondria, utilizing a variety of methods. The current state of understanding is 
complicated by potentially conflicting data. In the initial paper identifying mtPAP, RNAi 
was used to deplete the protein levels of mtPAP, and the authors found that as a 
consequence steady-state levels of the MTND3 and RNA14 transcripts were increased 
(Tomecki, 2004). The authors speculated therefore that the poly(A) tail may not act as a 
stabilizing modification. In parallel, a group from the University of Tokyo published 
conflicting results, reporting that siRNA depletion of mtPAP caused reduction of steady-
state transcript and protein levels of mtDNA encoded gene products (Nagaike, 2005). 
Another report found that depletion of mtPAP caused a non-uniform effect on mt-mRNA, 
with some species being depleted and others increased at steady-state (Piechota et al., 
2006). The decrease in transcript levels of RNA14 was consistent with the report from 
Nagaike et al, but the increased MTND3 transcript levels were consistent with the results 
of Tomecki et al. Targeting of the cytosolic poly(A)-specific 3'-5' exoribonuclease PARN 
to mitochondria to remove the mitochondrial poly(A) tails also showed this variation of 
effects on mt-mRNA stabilities (Wydro et al., 2010). The transcripts for mtDNA-encoded 
subunits of complex I showed increased levels, while transcripts for mtDNA-encoded 
subunits of complex IV were decreased, as was the RNA14 transcript. This is consistent 
with the results of Piechota et al. In that same report from Wydro et al., the cytosolic 
enzyme PABPC1 was targeted to mitochondria, coating the mt-mRNA poly(A) tails. This 
caused a severe oxidative phosphorylation defect, a decrease in respiratory chain complex 
steady-state levels, and inhibition of mtDNA-encoded polypeptide translation. The mt-
mRNAs were not destabilized, however.  
 Another method for elucidating poly(A) tail function is the targeted depletion, 
knock-out, or overexpression of factors that have modulating effects on mitochondrial 
mRNA polyadenylation. These modulators include LRPPRC and SLIRP, proteins that 
have been shown to bind mt-mRNAs; PNPase and PDE12, which function in mt-mRNA 
exoribonuclease/deadenylase activity. There are advantages and limitations to all these 
approaches. RNAi can cause significant off-target effects, but is relatively cheap and 
convenient. Targeting modulating factors can aid in elucidating regulatory pathways, but 
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the results can be difficult to dissect into individual factor contributions. Overexpression 
can induce artifacts due to abnormally high levels of a given gene product. Generating 
knock-out animal models can be expensive and time-consuming, but robust tissue specific 
and organism specific effects can be observed. Consistently, many of these reports, 
utilizing these various methods have observed oligoadenylated mt-mRNAs in the knock-
downs and knock-out experiments.  
 In 2010, my host lab published a paper in collaboration with Professor Andrew 
Crosby of St. George's University London, identifying an Old Order Amish family 
harboring a novel 1432A>G mutation in the PAPD1 gene (Crosby et al., 2010). Their 
investigation was initiated as multiple children of the family exhibited a slowly 
progressive autosomal-recessive neuromuscular condition. The clinical features were a 
combination that was suggestive of a novel condition. These included cerebellar ataxia, 
optic atrophy, dysarthria, and learning difficulties. Using DNA extracted from blood, a 
genome-wide microarray screen was undertaken. The screen identified the 
nonsynonymous 1432A>G base change in the PAPD1 gene. The clinically affected 
children were homozygous for the mutation, while the unaffected parents and sibling 
were heterozygous. The base change was predicted to substitute an asparagine residue at 
position 478 for an aspartate. This amino acid lies within a small protein motif that is part 
of one of the most conserved regions of the mtPAP enzyme. Using RNA extracted from 
blood samples taken from multiple family members, both heterozygous and homozygous, 
the poly(A) tails on the mt-mRNAs MTCO1 and RNA14 were analyzed using the MPAT 
assay. In the patients homozygous for the mutation, the mt-mRNA adenylate tails were 
found to be only oligo(A) tails, with lengths of ≤10nt, rather than the normal 40-50nt 
range. Combined with the genetic data, this profound defect was predicted to underlie the 
neurodegenerative condition of the homozygous patients. However, as it was only 
possible to isolate nucleic acid from patient samples at this time, there was no 
confirmation that the lack of polyadenylation really caused a defect in mitochondrial gene 
expression in this initial description of the mutation. More recently, with the invaluable 
support of the affected family, colleagues in the United States were able to establish cell 
lines from several members 
 The initial goal of this thesis work was therefore to thoroughly characterize the 
downstream effects of the 1432A>G PAPD1 mutation. Through this, insights into the 
functions of mitochondrial polyadenylation would be elucidated. At the time this project 
was undertaken, the only known effect of this mutation was the dramatic shortening of 
the mitochondrial poly(A) tail on mt-mRNAs. In this chapter, I will detail the propagation 
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of dermal fibroblast cultures derived from several of these patients, their immortalization, 
and the subsequent analysis of the effect the mutation has on multiple levels of 
mitochondrial gene expression and overall mitochondrial function.  
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4.2  Materials and methods 
 
4.2.1  Culturing primary and immortalized PAPD1 1432A>G  
  fibroblasts 
 
Human fibroblasts were obtained from patient skin biopsies, and grown in a humidified 
atmosphere at 37⁰C in 5% CO2 in DMEM (Sigma) containing 4500mg/L glucose, 
110mg/L sodium pyruvate, 584mg/L L-glutamine, 1x NEAA, 10% (v:v) fetal bovine 
serum (Sigma), 50ug/ml Uridine (Sigma), and 50U/ml Penicillin+50ug/ml Streptomycin 
(Gibco).  During normal culturing, cells were routinely split at 80% confluency. For 
immortalized fibroblasts, every 3rd passage had geneticin added at a concentration of 
200ug/ml. Splitting of cells was previously described (c.f. 2.2.2.1).  
  
4.2.2  Geneticin titration 
 
For the Geneticin (G418, Gibco) titration in killing curves, heterozygous 1432A>G 
PAPD1 human fibroblasts were seeded at 50,000 cells/well in 6-well plates, and allowed 
to incubate overnight. The next day, the culture media was replaced with media 
containing geneticin. The concentration range for Geneticin killing curves were 200-
600ug/ml. Cells were grown in the presence of geneticin for 7 days, then trypsinized and 
counted on a hemocytometer. The geneticin was purchased as a powder, and a 50mg/ml 
stock solution made in H2O to be stored at -20⁰C. This stock solution was diluted in 
culture media as described above, and then added to cells at specified concentrations.  
 
4.2.3  Fibroblast immortalization 
 
The immortalization procedure was carried out by Morten Ritso (Institute of Genetic 
Medicine, Newcastle University) and myself. Retroviral constructs, carrying the E6E7 
gene region of human papillomavirus type 16, were transfected into packaging cells. 
These packaging cells (PA317) were grown to near confluence in DMEM containing 10% 
FBS; 24 h later the medium containing retroviral particles was harvested and filtered 
through a 0.4-mm filter. Retroviral titers were determined by infecting NIH/3T3 cells. 
Human fibroblasts (non-familial control line, heterozygous and two homozygous lines for 
PAPD1 1432A>G mutation) were seeded in 6-well plates in supplemented DMEM at 
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50,000 cells/well. After allowing cells to adhere overnight, cell culture media was 
removed and 1ml viral stock (retroviral vector containing E6E7 genes) mixed with 3 ml 
serum-free media and 4ug/ml polybrene was added to wells. Cells were then incubated at 
37⁰C for 2 hrs, then 5ml more serum-free media containing polybrene was added. Cells 
were incubated for a further 5 hrs after which the viral mixture was removed. The cells 
were washed once with fresh supplemented media and then fed with another aliquot of 
fresh media. Cells were cultured for two days prior to Geneticin (G418) addition at 
400ug/ml. Once selection with G418 was under way, media containing G418 was 
refreshed every other day. Selective media was used for 10 days, after which the G418-
resistant population of cells were isolated and subsequently expanded. DNA was isolated 
from immortalized fibroblasts for sequencing of the PAPD1 gene by Professor Andrew 
Crosby's lab to confirm presence of the 1432A>G mutation. 
 
4.2.4  Cell proliferation measurements 
 
Human fibroblasts were harvested and seeded 25,000 cells/well in triplicate for each time 
point in 24-well plates. For standard growth curves in media containing glucose, cells 
were harvested and counted every two days of the time course. For growth measurement 
in conditions forcing oxidative respiration, after seeding and incubating overnight, the 
standard culture media was replaced with DMEM medium lacking glucose (Sigma) 
supplemented with 10% (v:v) dialyzed FCS, 0.9 mg/ml galactose, 0.11 mg/ml sodium 
pyruvate, 1x non-essential amino acids, 50U/ml Penicillin+50ug/ml Streptomycin, and 
50ug/ml uridine. Cells were then harvested and counted every two days.  
 
4.2.5  Blue native PAGE 
 
Blue native PAGE analyses were performed by Dr. Hue Tran Hornig-Do, as described in 
(Hornig-Do et al., 2012). Briefly, crude mitochondria isolated from human fibroblasts 
(c.f. 2.2.6.2) were solubilized using n-Dodecyl β-D-maltoside at 2 g/g protein, then 
incubated for 20 min on ice. After 20 min centrifugation at 25 000g at 4⁰C, the 
supernatant was collected and mixed with Blue Native sample buffer (750mM 
aminocaproic acid, 50mM Bis-Tris/HCl pH 7.0, 0.5mM EDTA, 5% Coomassie brilliant 
blue G250). To resolve individual complexes DDM-treated mitochondrial proteins (25ug) 
were separated on 4.5–16% gradient gels at 4⁰C. After electrophoresis, the proteins were 
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transferred to PVDF membrane and sequentially probed with antibodies for respiratory 
chain complexes, and ATP synthase (c.f. 2.2.6.7).  
 
4.2.6  [
35
S]-cysteine/methionine metabolic labeling of    
  mitochondrial proteins 
 
[
35
S]-labeling was performed by Dr. Francesco Bruni and myself. All cell incubations 
were performed at 37⁰C. Fibroblasts were grown in T25 flasks until 60-70% confluence. 
The medium was then replaced with 2ml pre-warmed methionine/cysteine-free DMEM 
(Sigma) medium, and cells were incubated for 10min. This was repeated once. Then 
medium was replaced with methionine/cysteine-free medium containing 10% dialyzed 
FCS (10,000 MWCO) and 100ug/ml emetine dihydrochloride (20mg/ml in Dulbecco's A-
PBS). Cells were incubated in this medium for 1 hour. At this point, 0.5ml of the medium 
was discarded, and 20ul of [
35
S]-methionine/cysteine mix (Perkins-Elmer Easy-Tag 
express protein labeling mix, NEG-772) was added directly to the flask. The cells were 
incubated in this medium for 2 hours, with agitation of the flasks every 30min. In the case 
of pulse-chase experiments, cells were then washed with chilled standard growth medium 
supplemented with 7.5ug/ml methionine, allowed to incubate for an hour, and then 
washed again. The non-radioactive medium incubation times were extended for specific 
pulse-chase experiments. Cells were harvested with 1ml chilled 1mM EDTA in PBS, and 
pelleted by centrifugation at 250g for 4min. After washing the cell pellets 3 times with 
chilled PBS, the cells were resuspended in 30-100ul chilled PBS, containing EDTA-free 
Protease Inhibitor cocktail (Roche) and 1mM PMSF. Samples were stored at -80⁰C.  
For electrophoresis, 50ug of whole cell lysate was electrophoresed through a 15-20% 
SDS-polyacrylamide gel at 100V, the gel was then fixed over night in 3% glycerol, 10% 
acetic acid, 30% methanol. The fixed gel was vacuum-dried for 4 hours at 60⁰C, covered 
in cling film, then exposed to a PhosphorImage screen for 2 days. Results were visualized 
with a Typhoon FLA 9500 system (GE/FujiFilm).  
 
4.2.7  PicoGreen and TMRM staining 
 
Immortalized patient fibroblasts were seeded 25,000 cells/well in 1ml complete medium 
in glass bottomed dishes (WilCo) during the evening of the day prior to imaging. One 
hour prior to imaging, 3ul of PicoGreen working solution (Invitrogen) was added per ml 
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of culture medium, and cells incubated for 45min at 37⁰C, shielded from light. Next, 1ul 
TMRM (from 5uM stock in methanol) was added (final conc. 5nM), and light shielded 
incubation continued for 10min. The cells were then washed twice with KBr buffer 
(135mM NaCl, 5mM KCl, 0.4mM KH2PO4, 1mM MgSO4, 20mM HEPES, pH 7.4) 
supplemented with 5.5mM glucose, 1.3mM CaCl
 
and 5nM TMRM. The supplements for 
the KBr buffer were added fresh for each experiment. For imaging, the cells were then 
left in supplemented KBr buffer. Image acquisition was performed with an inverted 
fluorescence microscope (Axiovert 200 M, Carl Zeiss). The microscope settings used 
were GFP channel for Pico Green, 75ms exposure time, and Texas Red channel for 
TMRM, with 250ms exposure time. Transmission light brightfield images were taken 
with 400ms exposure time. The 63X objective with oil was used, and z-stack settings 
were 10 layers 0.4M apart.   
 
4.2.8  Quantitative PCR 
 
DNA was isolated from immortalized patient fibroblasts, as detailed in General Methods. 
This DNA was used for measuring mtDNA copy number, via quantitative PCR in the 
presence of SYBR Green I. The target gene was mtDNA-encoded MTND4 and the 
reference gene was nuclear-encoded ribosomal 18S DNA. Forward and reverse primers 
for each gene are listed in 2.2.4.4. For each qPCR reaction, 5ul of DNA template (50ng 
total) was pipetted in triplicate into polypropylene qPCR microtube strips. 1ul each of the 
appropriate forward and reverse primers were added, for a final reaction concentration of 
0.5uM. Nanopure H2O was added to bring reaction volume to 10ul. Finally, 10ul of 
FastStart Essential DNA Green Master (Roche) was added to each reaction. The contents 
of the microtubes were pulsed down to ensure mixing of all reagents. All qPCR reactions 
were performed in a Lightcycler
®
 Nano instrument. The reactions parameters were as 
follows: 
  
Step Reaction Profile Reaction Step 
1 95⁰C - 10 minutes Initial Denaturation 
2 95⁰C - 10 seconds (ramp 5⁰C/s) Denaturing 
3 59⁰C - 10 seconds (ramp 4⁰C/s) Annealing 
4 72⁰C - 10 seconds (ramp 5⁰C/s) Extension 
5 Back to Step 2, 45 cycles # of cycles 
6 95⁰C - 5 minutes Final Extension 
7 60⁰C to 95⁰C at 0.1⁰C/s Melting Curve 
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The Cq value (equivalent to CT) was determined using the Lightcycler
®
 Nano software. 
For analysis of quantitative PCR results, the 2
-ΔΔCq
 (Livak) method was used (Livak and 
Schmittgen, 2001). This method assumes that both the target and reference genes have an 
amplification efficiency of approximately 100%, and are within 5% of each other. The Cq 
of the target gene is normalized to the Cq of the reference gene for both the test sample 
and the calibrator sample: 
ΔCq(test) = Cq(target, test) - Cq(reference, test) 
ΔCq(calibrator) = Cq(target, calibrator) - Cq(reference, calibrator) 
Next, the ΔCq of the test sample is normalized to the ΔCq of the calibrator: 
ΔΔCq = ΔCq(test) - ΔCq(calibrator) 
Finally, the expression ratio is calculated: 
2
-ΔΔCq
 = normalized expression ratio 
 For this analysis, the test samples were the heterozygous and homozygous PAPD1 
1432A>G cells, while the calibrator sample was the control fibroblast line.  
 
4.2.9  Complex I and IV activity measurements 
 
Measurements were performed by Dr. Hue Tran Hornig-Do, as described in (Kirby et al., 
2007).  
 
4.2.10 In-gel activity assay 
 
Assay was performed by Dr. Hue Tran Hornig-Do, as described in (Hornig-Do et al., 
2012) and (Calvaruso et al., 2008).  
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4.3  Results 
 
4.3.1  Confirmation of pathological phenotype in patient   
  fibroblasts 
  
 In order to undertake investigation of the PAPD1 1432A>G mutation, a cell 
culture model was necessary. Previous work had utilized blood samples from the affected 
parents and children for experimental material. However, for this more involved project, a 
readily available source of patient material was needed. Through collaboration with 
Professor Andrew Crosby, we were able to obtain dermal fibroblast cell lines established 
from tissue biopsies from three of the family's children, one heterozygous for the 
mutation, and two that were homozygous.  
 The fibroblast lines were labeled: 
Heterozygous control (C1-Het): Heterozygous for 1432A>G mutation in PAPD1 gene, 
unaffected by clinical pathology, utilized in this work as a familial control. 
 
Patient 1 (P1): Homozygous for 1432A>G mutation in PAPD1 gene, exhibits clinical 
pathology. 
 
Patient 2 (P2): Homozygous for 1432A>G mutation in PAPD1 gene, exhibits clinical 
pathology. 
 
Control (C2) - Unrelated fibroblast line, exhibits no clinical pathology. Served as a non-
familial control line.  
  
 Upon receiving the patient cell lines seeded in T25 flasks, their condition was 
thoroughly inspected. The C-Het line showed minimal levels of cell death, as evidenced 
by detached cells, with a lack of fibroblast granularity and debris in the medium. The 
homozygous lines, however, were in quite poor condition. Much of the cell population 
had perished, accompanied by large stretches of deteriorated cell remnants. It was 
difficult to identify by light microscopy healthy cells. Due to the difficulty in obtaining 
these samples from the Amish family in Ohio, it was of the utmost importance that these 
cells be successfully cultured. In order to maximize their recovery, and trusting that there 
were viable cells present, even if not obvious under the microscope, fresh extra-enriched 
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DMEM media was used for growing the cells. Fetal calf serum was increased to 20%, and  
50ug/ml uridine, 1x non-essential amino acids supplemented, 100U/ml Penicillin and 
100ug/ml Streptomycin were added. 
 The viable homozygous cells did proliferate. After enough cells were frozen at 
early passage stocks, the immediate priority was confirming the pathological phenotype 
in these lines and subsequent immortalization of the cell lines. Fibroblasts have been 
reported as not recapitulating the biochemical defects arising from mitochondrial defects 
(Rodenburg, 2011). In these cases, alternative tissue is often required, for example 
skeletal muscle cultures. Thus, prior to immortalization of the fibroblast lines, preliminary 
examination for the presence of the defect was assessed by immunoblotting.  
 As nuclear and cytosolic 
poly(A) tails have major impacts 
on translation, a similar impact on 
mitochondrial translation would 
be predicted. As a proxy for the 
predicted mitochondrial 
dysfunction from shortened 
poly(A) tails, immunoblotting of 
cytochrome c oxidase subunit 1 
(COX1) was performed, as shown 
in Figure 4.1. The nuclear-
encoded complex II subunit 
SDHA was utilized as loading 
control. A depletion of COX1 at 
steady-state was observed in the homozygous fibroblast lines (lanes 3 and 4), as 
compared to the heterozygous fibroblasts (lane 2) and HEK293 cells (lane 1). Levels of 
SDHA did not differ between fibroblast lines, as expected. This gave the necessary 
confidence in the recapitulation in the fibroblast lines of the pathological phenotype 
observed in the patients. The cells were therefore suitable as models to analyze the 
downstream effects of the PAPD1 mutation. The advantages of this cellular system is that 
it is more physiological and is free from artificial perturbation as a result of gene knock-
out or RNAi . These lines provided a pure genetic background in which to study the 
impact of lack of the full-length mitochondrial poly(A) tail. Analysis of the downstream 
effects would hopefully help elucidate the function of polyadenylation of transcripts in 
mitochondria. 
 
 
Figure 4.1. Steady-state COX1 levels in patient 
fibroblasts 
Whole cell lysate (40ug) from patient fibroblasts and HEK293 
cells was separated by 12% SDS-PAGE and transferred to PVDF 
membrane. Respiratory chain complex subunits COX1 and SDHA 
were then immunoblotted. Lanes are HEK293 (lane H), 
heterozygous line (C1-Het, lane 1), homozygous lines (P1 and P2, 
lanes 2 and 3, respectively). 
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4.3.2  Immortalization of 1432A>G  and Control Fibroblasts 
 
 Once the patient fibroblasts were established in culture and expanded into stocks, 
immortalization of the cells was a priority. The primary goal was to significantly extend 
the lifespan of the fibroblasts, allowing a range of experiments to be performed. The 
vehicle for immortalization was a retroviral vector encoding the E6E7 early region gene 
from HPV. The particular immortalization procedure was carried in Professor Hanns 
Lochmuller’s laboratory and uses Geneticin as a selection agent. It was important to 
generate a killing curve to determine the optimal concentration to use during the selection 
process. As shown in Figure 4.2, 400ug/ml Geneticin exhibited sufficient cytotoxicity in 
the 7-day time frame to be certain non-immortalized cells would die, but not so toxic that 
immortalized cells would have difficulty surviving.  
 Once the optimal geneticin concentration was established, all three fibroblast lines 
carrying the PAPD1 mutation (homo or heterozygote) were seeded 50,000 cells/well in a 
6-well plate. Included in the immortalization cohort of cell lines was non-familial control 
fibroblast line. The control fibroblast line would be utilized as a more appropriate 
 
Figure 4.2. Determination of Geneticin Kill curve on Patient Fibroblasts 
Heterozygous PAPD1 mutant fibroblasts (C1-Het) were seeded 50,000 cells/well. The cells were then cultured in 
the presence of increasing concentrations of geneticin (G418) and counted after 7 days. Representative images are 
shown for no G418 (B), 200ug/ml (C), and 400ug/ml G418 (D).   
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comparison for differences observed in the mutant cells, as the HEK293 cells differ 
significantly from fibroblasts.   
 After treatment with the retrovirus, cells were put under geneticin selection, and 
monitored for resistant colonies. A high number of cells in each fibroblast line became 
geneticin-resistant, and were then expanded and continued to be cultured under selecting 
conditions. The only marker of "immortalization" was the continued geneticin resistance 
observed with the fibroblasts, so geneticin was kept in culture media at 200ug/ml every 
3rd feed for maintenance. Sequencing of the PAPD1 gene (Figure 4.3) was performed to 
confirm the persistence of the 1432A>G mutation post-immortalization.  
 Immunoblotting was carried out on cell lysates pre- and post-immortalization to 
assess mitochondrial protein levels. It was crucial to confirm that any defect seen in the 
primary lines was maintained, and was present to the same extent after immortalization.  
The levels of mitochondrial mtDNA and nDNA-encoded proteins would be analyzed and 
the observations compared pre- and posts-immortalization. 
 Included in the immunoblotting was the steady-state levels of mtPAP. This could 
indicate any changes from wild-type, and would identify if these changes were 
maintained in the immortalized lines. Based on the published crystal structure (Bai et al., 
2011), N478  does not appear to reside in a region of the protein that has a catalytic, 
dimerizing, or RNA binding role. It should be noted that the published crystal structure 
was not able to visualize the specific region where the mutation occurs (residue 478), 
leaving open the possibility that there is a function to this domain that has not yet been 
assigned. The N478D mutation in mtPAP could have potentially affected the stability of 
 
Figure 4.3. Sequencing confirms persistence of PAPD1 1432A>G mutation 
post-immortalization. 
DNA from both homozygous mutant fibroblast lines and the heterozygous line was isolated as detailed in 
chapter 2 and subjected to sequence analysis. Electropherograms covering the region of the mutation are 
presented for the heterozygous mutant line, and one representative homozygous mutant line.   
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the enzyme, and if so, it would be depleted at steady-state. The steady-state levels of 
mtPAP in the homozygous mutant fibroblasts were not decreased in comparison to the 
either the heterozygous fibroblasts or the non-familial fibroblasts (Figure 4.4A lanes 2,3 
and 6,7 cf. lanes 1,4 and 5,8). No difference was observed between primary and 
immortalized cells. TOM20, a mitochondrial OMM protein, served as a loading control 
for the blot.  
 A second immunoblot 
was carried out to probe for 
SDHA and COX2. The 
purpose of this blot was to 
ensure that mitochondrial 
defects exhibited by the 
mutant fibroblasts would not 
be affected by the 
immortalization process. As 
shown in Figure 4.4B, COX2 
is significantly depleted in the 
homozygous fibroblast lines 
(lanes 2,3 and 6,7 cf.1,4 and 
5,8)). The heterozygous line 
appears to possess COX2 
levels comparable to the 
control line. At least for 
steady-state levels of protein, 
the heterozygote does not 
appear to possess an intermediate phenotype between pathological and wild-type. 
Treatment with the retroviral vector did not alter the phenotypes of the patient fibroblasts, 
which provided confidence about continuing with the immortalized cells as the ongoing 
model of dysfunctional mitochondrial polyadenylation.   
 
From this point onwards, any references to the patient or control fibroblasts refers to the 
immortalized versions of the cells. 
 
  
 
 
 
Figure 4.4. Steady-state mtPAP levels pre- and 
post-immortalization. 
Whole cell lysate (40ug) from primary and immortalized fibroblasts 
were separated via 12% SDS-PAGE and following transfer the 
membrane was immunoblotted with A. anti-mtPAP, TOM20, and B. 
SDHA, and COX2 antibodies. TOM20 and SDHA were used as loading 
controls.  
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4.3.3  Analysis of fibroblast mitochondrial mRNA 3' termini by  
  MPAT 
 
 I had optimized the MPAT assay for detection via fluorescence in replacement of 
radiation (as detailed in chapter 3), and it was ready to be implemented in mt-mRNA 3' 
end analysis. C-Het, P1, P2, and C2 fibroblasts were harvested, and RNA was isolated 
from each line. Four mt-mRNAs were chosen, two of which, MTCO1 and RNA14, 
matched the transcripts analyzed previously in these patients (Crosby et al., 2010). The 
other two transcripts analyzed were MTND3 and MTCO3. Mitochondrial tRNAs and 
rRNA transcripts were not analyzed as these have been shown to not be polyadenylated 
(Temperley et al., 2010b).  
 As illustrated in Figure 4.5, the adenylation profiles for each transcript in the 
mutant cell lines match the characteristic oligo(A) lengths observed previously for the 
homozygous PAPD1 mutation. In the homozygous mutant fibroblasts, the adenylate tail 
 
 
Figure 4.5. Polyadenylation profiles of PAPD1 mutant and control fibroblasts. 
Selected mitochondrial mRNAs were analyzed using the MPAT assay, as described in chapter 3. RNA was 
isolated from heterozygous mutant (C1-Het), homozygous mutant (P1 and P2), and control (MB-I) fibroblasts. 
The fluorescently labeled reaction products were separated on a 10% polyacrylamide/urea gel, and imaged on a 
Typhoon FLA 9500 (GE/Fuji). Oligo- and polyadenylated populations were determined by using free primer size 
as a reference, and the start of the poly(A) tail is marked with A0.   
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of the analysed mt-RNA species is significantly shorter, as compared to the heterozygous 
and control fibroblasts. The majority of the transcript population exhibits a 3' terminal 
extension in the range of 4-10 adenines, versus the 40-50 adenine extensions of the 
heterozygote and control. The "full-length" poly(A) tails observed in my controls match 
previous reports of average mt-mRNA polyadenylation length for these transcripts 
(Temperley, 2003; Nagaike, 2005; Slomovic and Schuster, 2007; Wydro et al., 2010).  
 All four mRNAs examined exhibited short oligo(A) tails in the homozygous 
mutant fibroblasts, and this is consistent with the results from MPAT assays conducted 
using RNA extracted from patient blood samples (Crosby et al., 2010). The heterozygous 
cell line shows a mild intermediate phenotype with regards to polyadenylation status. The 
presence of a small proportion of oligoadenylated mt-mRNA transcripts has been 
reported as a normal occurrence (Temperley, 2003; Crosby et al., 2010; Wydro et al., 
2010). Consistent with this observation, a faint signal in the MPAT gel showing a 
minimal level of oligoadenylation for each transcript can be seen in the non-familial 
control line. The heterozygous mutant line shows a mild increase in this amount of 
oligoadenylation, which likely corresponds to the mixed PAPD1 genotype that the cells 
harbor. This slight change in ratio of adenylation lengths may not be sufficient to cause 
negative impacts downstream.   
 In summary, these results served as confirmation of the presence of the primary 
defect of shortened adenylate tails in the homozygous mutant fibroblasts. In addition, the 
diminished levels of mtDNA-encoded subunits of complex IV present evidence of 
downstream effects as a result of the PAPD1 mutation.   
 
4.3.4  Effect of PAPD1 1432A>G mutation on cell proliferation 
  
 With the oligo(A) tail defect established in the mutant fibroblasts, the planned 
experiments were concerned with characterizing in greater depth the downstream effects 
resulting from the mutation. On a gross cell level, this consisted of examining the 
differences in fibroblast growth rates in normal glucose-rich media, versus glucose-free 
media, substituting galactose as the only carbon source. This forces cells to rely heavily 
on oxidative respiration. A compromised growth rate in the homozygous mutant cells 
would indicate that the mutation causes oxidative respiration to be negatively affected. 
The panel of fibroblast lines utilized in this experiment were the heterozygous mutant 
line, both homozygous mutant lines, and the non-familial control line.  
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 Cells were seeded 25,000 per well in 24-well plates, and harvested in triplicate 
every other day for either eight or ten days. The results are shown in Figure 4.6. There are 
not large differences in growth rates between the four cell lines when cultured in glucose-
based media, although the homozygous mutant fibroblast lines (P1 and P2) do grow the 
slowest. The heterozygous line proliferates at a similar rate to the control line. When 
cultured in galactose, a more pronounced difference in growth rate between patient and 
control lines is observed. Forcing the cells to rely on oxidative metabolism has an impact 
on the growth rate for all the fibroblast lines, but the homozygous mutant cells are 
preferentially suppressed in their growth. This presents supporting evidence that the 
mtPAP mutation causes an impairment of oxidative respiration. When able to utilize 
glycolysis, the homozygous mutants can maintain growth rates relatively close to the 
heterozygous mutant and control line, although the rate is still slightly depressed. It is 
clear that in cells missing full length poly(A) tails, the capacity of oxidative respiration is 
diminished, which is in agreement with previous reports (Nagaike, 2005; Wydro et al., 
2010; Rorbach et al., 2011) each utilizing differing methods of poly(A) tail removal. 
  
 
 
4.3.5  Steady-state levels of mitochondrial mRNAs in    
  mutant fibroblasts 
 
 
Figure 4.6. Growth curves of PAPD1 1432A>G fibroblasts propagated in 
glucose or galactose media. 
Heterozygous mutant (C1-Het), homozygous mutant (P1 and P2), and control (C2) fibroblast lines were seeded 
at 25,000 cells/well in glucose or galactose-containing culture media. Cells were seeded in triplicate  and counted 
every two days. Left: Growth curves from the four fibroblast lines in standard glucose-based media. Right: 
Growth curves from all four fibroblast lines cultured in galactose-based media. Error bars represent S.D. from 
three replicates.   
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 To address the question of what direct effect polyadenylation has on mRNA 
stability, we analyzed steady-state levels of mitochondrial RNAs. Previous reports have 
generated conflicting results in terms of mRNA stability when mtPAP is knocked-
out/down, or the poly(A) tail itself is artificially removed. So the results from these cells 
free from artificial perturbation could provide clarification in a physiological 
environment. RNA was isolated from the four fibroblast panel and then analyzed via 
northern blotting. The panel of mt-mRNAs analyzed included RNA14, MTCO1 MTCO3 
and MTND3, which had been examined with the MPAT assay, and MTND1. MTRNR2 
and MTRNR1. rRNAs were included as mitochondrial-encoded loading controls, and 
nuclear-encoded 18S rRNA as an additional 
loading control. As the mt-tRNAs are not 
oligo/polyadenylated, none were included 
in this set of genes to analyze.  
 A non-uniform pattern was 
observed upon visualizing the mRNA 
steady-state levels in the fibroblast 
mitochondria. As shown in Figure 4.7, the 
mRNAs are differentially affected by 
shortening of the poly(A) tail. Three 
outcomes are observed for the mt-mRNAs: 
depletion, increase, or no effect. The 
bicistronic RNA14 transcript appears 
depleted at steady-state in the homozygous 
mutant cells.  
 The RNA14, MTCO1, and MTCO3 
transcripts in the homozygous mutant cells 
are depleted. Conversely, the steady-state 
levels of MTND1 appear to be increased in 
the homozygous mutant lines. For MTND3, 
there does not appear to be any significant 
difference in steady-state levels, with or without the shortened poly(A) tail. The faster 
migration of the MTND3 transcript allows easy visualization on the northern blot of the 
size difference that occurs as a result of polyadenylation loss. The transcript in the 
homozygous mutant cells clearly migrated further through the gel, consistent with a 
reduction in size due to a shorter adenylate tail. This is much less obvious for the larger 
 
 
Figure 4.7. Assessment of mt-mRNA 
steady-state levels in patient 
fibroblasts 
Northern blot analysis was performed using total RNA 
(4ug) extracted from heterozygous mutant (C1-Het), 
homozygous mutant (P1 and P2), and control (C2) 
fibroblast lines. RNA was separated by 
formamide/agarose gel electrophoresis and transferred 
to a nylon membrane. Membranes were hybridized 
with radiolabeled DNA probes corresponding to the 
listed RNA transcripts, and visualized by 
autoradiography.  
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mRNA transcripts. In the case of the mt-rRNAs, no changes in migration or steady-state 
levels were observed. The mt-rRNAs are not polyadenylated in HeLa cells, only having 
been reported experimentally to possess 3-4 adenine extensions (Temperley et al., 
2010b), so this was expected. The northern blots show non-uniform changes to steady-
state levels for the mt-mRNAs. There are no obvious characteristics of the mRNAs that 
might correlate with the changes in stability, such as 5' or 3' UTRs, or size of the open 
reading frames.   
 
 
4.3.6  Steady-State levels of mitochondrial proteins in mutant  
  fibroblasts 
  
 A more extensive analysis of OXPHOS complex components was performed by 
western blot. Of particular importance were the steady-state levels of mtDNA encoded 
proteins, as these transcripts are the direct substrates of mtPAP, and would be potentially 
affected by alterations in its 
activity. The mtDNA-encoded 
proteins analyzed included ND1, 
and COX1-3. There are two 
antibodies to subunits of 
complex I which are nuclear 
encoded, NDUFB8 and 
NDUFA9. NDUFB8 provides 
information pertaining to the 
assembly of the complex and 
levels are believed to reflect 
proper complex assembly, as it is 
rapidly degraded if not correctly 
integrated. Other nuclear-
encoded mitochondrial proteins 
blotted include TOM20, complex 
II subunit A, and mtPAP.  
 As shown in Figure 4.8, a 
more consistent pattern is 
 
 
Figure 4.8. Steady-state Levels of Mitochondrial 
Proteins in PAPD1 Mutant Fibroblasts 
Immunoblot analysis was performed using whole cell lysate (40ug) 
from fibroblast lines. Cell lysates were separated by 12% SDS-
PAGE, and transferred to PVDF membranes for blotting. 
Membranes were probed with antibodies against mtDNA and 
nDNA-encoded proteins, and visualized with ECL Prime (GE).  
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exhibited, compared to changes in mt-mRNA steady-state levels. Rather than the non-
uniform changes in levels of the mt-mRNA transcripts, the mtDNA-encoded respiratory 
chain complex subunits appear to be uniformly decreased at steady-state. The nuclear-
encoded complex I subunits, NDUFB8 and NDUFA9, both show decreased signal on 
immunoblotting as well. NDUFB8 is recognized as an indicator of levels of  complex I. 
With ND1 and NDUFB8 depleted on immunoblotting, this may indicate decreased levels 
of fully assembled complex I. Notably, MT-ND1 mRNA is increased at steady-state in the 
homozygous mutant fibroblasts. More transcript is present, but the protein is markedly 
depleted compared to controls. The nuclear-encoded complex II subunit, SDHA, was not 
affected by the mtPAP mutation. As previously observed, mtPAP does not appear to 
differ significantly between the cell lines. Both SDHA and TOM20 act as loading 
controls for the immunoblotting. 
 
 
4.3.7  Mitochondrial protein synthesis and turnover in PAPD1  
 mutant fibroblasts 
 
 Having observed depletion at steady-state levels for mtDNA-encoded proteins, it 
was not immediately apparent whether the cause was reduced expression, or increased 
turnover. It was therefore important to characterize any changes in de novo protein 
synthesis as a result of the PAPD1 mutation. Unlike in the nucleus or cytosol, the role of 
the poly(A) tail in mitochondria in potentially facilitating translation is unclear. As a 
consequence, it was appropriate to identify if the loss of the poly(A) tail had a direct 
effect on translation in mitochondria.  
 There is currently no in vitro system to address questions such as these pertaining 
to mitochondrial translation. Hence, Dr. Francesco Bruni and I employed a well-
established technique for analysis of  de novo synthesis of mitochondrial proteins (Ching 
and Attardi, 1982; Chomyn, 1996; Fernandez-Silva et al., 2007; Sasarman and 
Shoubridge, 2012). This technique utilizes [
35
S]-labeled methionine/cysteine to radiolabel 
newly synthesized mitochondrial polypeptides. This is performed in the presence of a 
cytosolic translational inhibitor, emetine, which allows only the mitochondrial-encoded 
proteins being synthesised to incorporate the radiolabeled amino acids. Once incubation 
with the radiolabeled amino acids was complete, a second incubation with unlabeled 
culture medium supplemented with methionine, referred to as the "chase", was 
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performed. The cells were then lysed and the radiolabeled mitochondrial translation 
products were separated by gel electrophoresis and visualized by autoradiography.   
 The initial experiments using this technique were to visualize differences in 
translation of each mtDNA-encoded polypeptide between the control fibroblast line and 
the homozygous mutant fibroblast lines. These products are identified according to their 
predicted identities based on previous reports (Chomyn, 1996). Staining of the gel with 
Comassie blue was performed for assessing any differences in protein loading. Again, 
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Figure 4.9. De novo synthesis of mitochondrial translation products in PAPD1 
mutant fibroblasts. 
To assess mitochondrial translation products, whole cell lysate (50ug) harvested from fibroblasts labeled with 
[35S]-methionine/cysteine was separated on a 15-20% SDS polyacrylamide gel. A. A representative image of 
the control and homozygous mutant de novo synthesis of mtDNA-encoded proteins. Protein identities are 
indicated to the left of the image. Comassie blue staining was used protein loading comparison. B. 
Quantification of [35S]-labeling for both homozygous mutants and control fibroblast lines (n=3 for C2 and P2 
lines, n=2 for the P1 line). Translation product intensities were quantified by densitometry using Image J. Only 
clearly discrete products were analyzed. Results were normalized to the control values. Error bars represent 
S.D. Images analyzed include the image in A, lanes 1,2, and 5 in Figure 4.10, and a third independent labeling 
experiment (data not shown).  
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there is a non-uniform pattern in the homozygous mutant cell lines compared to the non-
familial control line. The results from multiple labeling experiments are shown 
graphically in Figure 4.9B, with a representative image shown in Figure 4.9A. The 
labeling shows increases, decreases, or no change, depending on the polypeptide. The 
major translation decreases are observed for COX1, COX2, COX3 in the mutant, while 
ND5 and ATP6 appear to be increased. The rest of the labeled translation products do not 
appear to show significant changes in the mutant cells, as the levels are comparable to 
control. As with the mRNA transcripts, there are no obvious characteristics that could 
explain the changes. The ND1 and ATP6 data stand out, as their mRNA species are 
increased and decreased, respectively, but their translational products do not reflect this. 
Levels of translation of MTND1 are similar between mutant and control cells, however 
immunoblot analysis shows that the protein is severely depleted at steady-state. The 
RNA14 steady-state mRNA levels are significantly lower in the mutant cells, but its 
translation product is increased. At the time of the labeling experiments, there were not 
antibodies available for analyzing the steady-state levels of ATP6 or ATP8. A 
commercial antibody did become available for ATP8, and this result is shown and 
discussed in Chapter 5. The gel patterns of multiple independent labeling experiments 
were quantified by densitometry, and graphed for comparison (Figure 4.9B).  
 Having visualized the state of mitochondrial protein synthesis in the control and 
homozygous mutant fibroblasts, mtDNA-encoded protein turnover was examined. 
Changes in turnover rates could potentially explain the lower steady-state levels for 
respiratory chain subunits in the homozygous mutants that did not appear to have 
decreased synthesis. This pulse-chase experiment, performed by Dr. Bruni, was carried 
out over several time points in order to observe the rate of degradation of the radiolabeled 
polypeptides. As the experiment used emetine for inhibition of cytosolic translation, the 
time points only extend to eight hours. A longer time course would result in cytotoxicity 
from the emetine. Eight hours was shown to be sufficient to observe any gross changes in 
mitochondrial protein turnover in the homozygous mutant fibroblast line, compared to the 
control line. The C2 (control) and P2 (patient 2) lines were chased for multiple time 
points, while the P1 (patient 1) line was labeled for only one time point. This inclusion 
was for comparison at time zero for all three fibroblast cultures.  
 The pulse chase experiment results are shown in Figure 4.10. Time point zero for 
all three cell lines recapitulates the patterns observed in the pulse labeling experiment.  
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 Two mitochondrial polypeptides show an increased rate of turnover in the 
homozygous mutant line, these are complex I subunits ND2 and ND5. COX1 also 
appears to show an increased rate of turnover in the mutant line, but to a much lesser 
extent than the aforementioned complex I subunits (Figure 4.10B-E). The majority of the 
mitochondrial polypeptides in the homozygous mutant lines did not appear to be 
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Figure 4.10. Pulse-chase labeling of de novo protein synthesis in PAPD1 mutant 
fibroblasts. 
A. Autoradiography image of mitochondrial translation products labeled with [35S]methionine/cysteine and chased for 
0, 4, and 8 hours post-labeling. The control (C2) and homozygous mutant (P2) were labeled and chased as indicated, 
while the other homozygous mutant (P1) was labeled for a single time point. Predicted translation product identities 
are listed on the left side of the gel image. Coomassie blue staining of the gel is included for comparison of loading in 
each lane. B-E. Analysis by densitometry using Image J was performed on the gel image in A, and the resulting values 
for translation products were normalized to the 0hr time point value to graph the percent reduction in value for the 4hr 
and 8hr time points. The graphs shown are for ND5 (B), ND2 (C), COX1 (D), and ND1 (E).    
B 
A 
C 
D E 
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markedly affected in their turnover time, when compared to the control fibroblasts (data 
not shown).   
 
4.3.8  Assembly of complexes I-V in mutant PAPD1    
  fibroblasts 
 
 After observing major decreases of steady-state levels for mtDNA-encoded 
complex I and IV subunits, as well as alterations in mRNA levels and their translation, it 
was important to confirm potential disruptions to the assembly of the respiratory 
complexes. This was accomplished by isolating mitochondria from control and 
homozygous mutant fibroblasts, and analyzing by blue native polyacrylamide gel 
electrophoresis (BN-PAGE). The BN-PAGE and subsequent blotting was carried out by 
Dr. Hue-Tran Hornig-Do. This 
method preserves assembled 
complex integrity during isolation. 
n-dodecyl β-D-maltoside (DDM) 
was used for solubilization and 
Coomassie blue G-250 was added 
to the supernatant. This binds to 
proteins and introduces a shift in 
charge for the protein complexes  
 As shown in Figure 4.11, the 
assembly of all five OXPHOS 
complexes was investigated. A clear 
reduction in the amount of 
complexes I and IV in the 
homozygous mutant is observed, 
compared to control. Complexes II 
and III appear to be unaffected by 
the PAPD1 mutation, as their levels 
are equivalent between the 
homozygous mutant and control cell lines. Despite the decrease in steady-state levels of 
the RNA14 transcript, the amount of complex V present in the homozygous mutant cells 
does not differ markedly from the control cells. Complex II is also used here as a loading 
 
 
Figure 4.11. Analysis of OXPHOS 
complexes assembly. 
Control (C2) and homozygous mutant (P2) mitochondria 
(40ug) were solubilized and separated by 4.5-16% blue native 
PAGE. Separated complexes were transferred to a PVDF 
membrane and immunoblotted for each of the five OXPHOS 
complexes. Sizes of the detected complexes are indicated to the 
left of panels, and the complex identities are shown on the 
right. Primary antibody targets were NDUFA9 (CI), Core 2 
subunit (CIII), alpha subunit (CV), the holoenzyme (CIV), and 
SDHA (CII).  
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control, as its subunits are entirely nuclear-encoded and thus assembly should be not be 
affected. The specific reduction of Complexes I and IV in the homozygous mutant is 
consistent with the depletion at steady-state of mtDNA-encoded subunits. With multiple 
missing subunits, the respiratory chain complexes may not be able to fully assemble, and 
complexes I and IV seem most vulnerable to this effect. This outcome would likely 
significantly compromise the enzymatic capabilities of these two complexes. As complex 
IV is the terminal electron acceptor of the respiratory chain, the ATP production capacity 
of the mitochondria may be compromised. This is consistent with the cell proliferation 
data from culturing the homozygous mutant cells in galactose-based media.    
 
 
4.3.9  Complex I and IV activity in PAPD1 homozygous mutant  
  fibroblasts 
 
 To complement blue native data, the direct enzymatic activity of complexes I and 
IV were measured. While decreased levels of respiratory subunits is a pathological 
feature of mitochondrial dysfunction, it was important to establish the actual impairment 
in complex activity. This was performed by Dr. Hue-Tran Hornig-Do on mitochondria I 
isolated via the standard procedure. The complex activities of mitochondria from one 
homozygous mutant 
fibroblast line (P2) and one 
control line (C2) were 
assayed 
spectrophotometrically. The 
activity for complexes I and 
IV in the homozygous mutant 
line compared to the control 
line was 49.2% and 36.2%, 
respectively, compared to 
control values, as shown in 
Figure 4.12. These 
measurements represent a 
significant activity decrease 
in the mutant cells. This is 
 
Figure 4.12. Measurement of complex I and IV 
activity in PAPD1 mutant fibroblast mitochondria. 
Isolated mitochondria from control (C2) and homozygous mutant (P2) 
fibroblasts were assayed for complex I and IV activity. A) Measurement 
of complex I activity for the control and mutant samples. Activities are 
expressed as nmol rotenone sensitive NADH oxidized per min per mg 
mitochondrial protein. B) Measurement of complex IV activity for 
control and mutant samples. Activities are expressed as nmol reduced 
cytochrome c oxidized per min per mg mitochondrial protein For both 
complexes, n=2. Error bars represent S.D. ** P<0.01, ***P<0.001, 
Students t-test.  
A B 
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consistent with depletion of respiratory chain complex subunits and the reduced levels of 
assembled complex. These results also provide evidence that the major pathology in the 
homozygous mutant patients is that of an oxidative deficit resulting from a compromised 
electron transport chain.  
 
4.3.10 Examination of mitochondrial morphology in PAPD1   
  mutant fibroblasts 
 
 One of the critical parameters for proper mitochondrial function is finely regulated 
fission and fusion events. This allows for exchanges of mitochondrial material, organelle 
turnover, and mobility within the cell. I sought to examine whether the PAPD1 
homozygous mutant fibroblasts exhibited changes in mitochondrial morphology, as this 
could be indicative of perturbed fission and fusion.  
 For imaging the fibroblast mitochondria, TMRM was used, and for staining 
dsDNA in the cells PicoGreen was used. The images were acquired using an inverted 
fluorescence microscope. The PicoGreen dye stained both the nuclear DNA, and the 
mtDNA-containing nucleoids within the mitochondria. The dye is capable of binding both 
linear and supercoiled DNA, but has a lower fluorescence yield when bound to 
supercoiled DNA. TMRM is a cationic fluorescent dye that emits orange fluorescence as 
it accumulates in polarized mitochondria, and its lipophilic structure allows the dye to 
traverse cell and mitochondrial membranes. This membrane potential-driven 
accumulation in mitochondria allows for examination of membrane potential collapse or 
flux in cells. Assuming the membrane potential is not compromised, the fluorescence 
emitted by the accumulated TMRM allows for clear visualization of the mitochondrial 
reticular network in cells.  
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 For this imaging experiment, I did not set a constant value for the exposure times, 
they were calibrated by the microscope software for each image taken, resulting in 
differing exposure times. The mitochondrial morphology is easily observed. However, the 
ability to compare subtle differences in the fluorescent intensities potentially resulting 
from disruptions in the membrane potential is compromised. The clarity of the 
mitochondrial networks observed in all the imaged cell lines suggests that major 
depolarization of the mitochondrial membrane potential has not taken place. 
 As shown in Figure 4.13, gross morphological analysis does not reveal any 
discernible differences but to be certain proper quantification of networks would need to 
be measured. The nucleoid staining for the four cell lines does not appear on observation 
to differ significantly. These results imply that aspects of mitochondrial function not 
related to oxidative phosphorylation are not dramatically impaired in the homozygous 
PAPD1 mutant cells. As only respiratory chain complex subunit mRNAs are 
polyadenylated by mtPAP, this is expected.  
 
 
Figure 4.13. Examination of mitochondrial morphology via TMRM staining. 
The complete panel of fibroblast lines, control (C2), patient 1 (P1), patient 2 (P2) and heterozygous mutant (C1-
Het) were stained with TMRM and PicoGreen fluorescent dyes. TMRM staining was viewed with the Texas Red 
channel, and PicoGreen staining was viewed with the GFP channel. The mitochondrial networks are stained with 
TMRM, and nuclear and mtDNA stained with PicoGreen. The images shown here are the two channels merged 
for a single image per fibroblast line.   
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4.3.11 Assessment of mitochondrial membrane potential in PAPD1 
  mutant fibroblasts 
 
 In order to assess mitochondrial membrane potential in the homozygous mutant  
PAPD1 fibroblasts, one homozygous mutant cell line and the control line were stained 
with JC-1 dye, and imaged via fluorescent microscopy. JC-1 is a widely used dye that 
fluoresces in the green or red spectrum based on its aggregation status. As a lipophilic 
cationic dye, it 
accumulates in 
mitochondria in a 
membrane potential-
dependent fashion, 
forming oligomers. 
The transition from 
monomer to oligomer 
shifts its fluorescent 
emission from green 
(529nm) to red 
(590nm). Changes in 
the ratio of red to green 
fluorescence can be 
used as an indicator of 
compromised 
membrane potential.
 Figure 4.14 
shows the results of the 
JC-1 staining. As with 
the mitochondrial 
morphology, there did not appear to be gross differences in JC-1 oligomer red 
fluorescence as detected by staining between the control and homozygous mutant cell 
lines. There was a small difference between the two lines from the JC-1 monomer green. 
As the red fluorescent signal is driven by accumulation in the mitochondria, and does not 
change in a dramatic fashion in the mutant cells, this seemed to indicate that the PAPD1 
 
 
Figure 4.14. Membrane potential assessment via 
fluorescent microscopy. 
Control (C2) and patient 1 (P1) fibroblasts  were stained with JC-1 cationic dye. 
The monomer fluorescence was viewed with the GFP channel, and the oligomer 
fluorescence was viewed with the Texas Red channel. The left column of images 
corresponds to the control fibroblasts, and the column to the right the 
homozygous mutant fibroblasts. Brightfield images are provided for orientation 
of the cells in the viewing field.    
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mutation did not cause significant disruption to mitochondrial membrane potential. 
However, as with the TMRM/PicoGreen staining, quantitative assessment is necessary in 
order to clarify any subtle changes that are not obvious upon gross observation.  
 
4.3.12 mtDNA levels in PAPD1 mutant fibroblasts 
 
 A common pathologic feature of mitochondrial disorders is a change in the 
steady-state levels of mtDNA copy number. While polyadenylation of mt-mRNAs does 
not have a known direct connection to mtDNA metabolism and regulation, the possibility 
exists that shortening of the mt-mRNA poly(A) tails would produce some indirect 
perturbation of mtDNA levels. The mtDNA copy numbers were assessed in the mutant 
PAPD1 fibroblasts as compared to control fibroblasts to confirm that the molecular 
pathologies stemming from the mutation occur outside the context of mtDNA 
metabolism. Using quantitative PCR, the levels of mtDNA were analyzed by measuring 
the amplification of a mtDNA encoded gene relative to a nuclear gene. Previously 
validated primer pairs for the MTND4 and 18S genes were employed for this analysis. 
DNA was isolated from the four 
fibroblast cultures. 
 Figure 4.15 shows the results of 
the qPCR analysis of mtDNA levels. 
The only significant difference in 
mtDNA levels is between patient 1 and 
the control line, an average 25% 
increase of mtDNA levels. The mtDNA 
levels in the heterozygous mutant line 
and second patient line did not differ 
significantly from the control line 
(Figure 4.15, C1-Het cf. C2). This 
confirms that there is no depletion of 
mtDNA in the PAPD1 mutant lines and 
that such a depletion is not the cause of 
downstream depleted and misregulated 
respiratory chain complex subunit 
levels. These results do not rule out the 
 
 
Figure 4.15. mtDNA copy number in 
PAPD1 mutant and control fibroblasts. 
Total DNA (50ng) isolated from all four fibroblast lines 
and quantitative PCR was performed, amplifying a 
mitochondrial gene (MTND4) and a nuclear gene (18S). 
The heterozygous line (C1-Het), homozygous mutant lines 
(P1 and P2) and control line (C2) are all shown on the 
graph. The ratio of MTND4 amplification to 18S 
amplification was calculated, then normalized to the 
average ratio of the control line. Error bars refer to S.D.; 
n=3, *P>0.05, Student's t-test.  
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possibility of mtDNA deletions or alterations outside of theMTND4 gene. Major common 
deletions normally include MTND4, and these can be rules out based on these results.  
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4.4  Discussion 
 
4.4.1  Oligo(A) tails are present in PAPD1 patient fibroblasts  
  
 The aim of characterizing the PAPD1 mutant fibroblasts was to understand the 
molecular mechanisms underlying the patient pathology, and leverage those observations 
to gain insights into the natural role of the poly(A) tail in mitochondria. In the case of the 
latter, the patient fibroblast cultures benefit from the lack of an artificial intervention to 
knock down or knock out mtPAP. The sole primary molecular pathology is a specific 
shortening of the poly(A) tail on mt-mRNAs. This presented a unique model for this 
study.    
 The immortalized fibroblasts were analyzed using the MPAT assay, focusing on a 
representative panel of mt-mRNAs, MTCO1 MTCO3, RNA14 and MTND3. These three 
transcripts represented the varying degrees of polyadenylation necessary for stop codon 
completion: no adenines, one adenine, or two adenines. Each transcript recapitulated the 
characteristic oligo(A) tail described previously in (Crosby et al., 2010), when the RNA 
was extracted from blood.  
 The homozygous mutants exhibited near-complete reduction of full length 
poly(A) tails. In contrast to the homozygous cells, the heterozygous mutant fibroblasts 
exhibited a mild intermediate phenotype. The population of full length poly(A) tails 
appears comparable to wild-type levels, but the oligo(A) population of transcripts seems 
to be increased slightly compared to the non-familial control line. Some oligoadenylation 
of mt-mRNAs is consistently observed (Crosby et al., 2010; Temperley et al., 2010b), 
and increases of this population may not be pathogenic. Rather, the loss of the full length 
poly(A) tails underlies the molecular pathology. By being able to generate wild-type 
amounts of full length poly(A) tails, this is probably how the heterozygous patients are 
able to avoid the clinical pathologies exhibited by the homozygous patients.   
  
4.4.2  Oligo(A) tails cause non-uniform misregulation of   
  mitochondrial gene expression products 
 
 The immediate impact of changes to poly(A) tail length would be expected to be 
on the mt-mRNA transcripts themselves. I examined the steady-state levels of several mt-
mRNAs by northern blotting, which allowed me to observe alterations in size and quality 
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in addition to observing differences in the amount of transcripts present in each cell line. 
The results showed non-uniform changes to the steady-state levels of the transcripts 
analyzed. MTCO1, MTCO3 and the RNA14 bicistronic transcript were decreased, while 
MTND1 was elevated. MTND3 appeared unaffected by the abrogated poly(A) tail. The 
mt-rRNAs were unaffected as well, but as these are not subject to polyadenylation, no 
changes were expected.  
 The qPCR analysis of mtDNA levels ruled out the possibility of mtDNA 
depletions causing downstream decreases in transcripts, although such a decrease in 
mtDNA would not have explained the increased levels of MTND1. There appeared to be a 
small but significant (for patient 1) increase in mtDNA levels in homozygous mutant 
cells. Patient 2 and the heterozygous mutant line were not significantly different from 
control. There is no obvious evidence that mtDNA is involved in the pathological 
phenotype of the mutant cells.    
 There are no obvious characteristics of the transcripts that can account for their 
discrepant behaviors when oligoadenylated. No consistent pattern emerges, such as 
related open reading frame lengths, or the presence of 5' leader or 3' trailer transcript 
regions. The mechanisms that allow certain mRNAs to be elevated, while others are 
decreased at steady state, remain to be elucidated. MTND2 was not analyzed by northern 
blot in this work, but other reports show it to be another extra-stable mt-mRNA, alongside 
MTND1 (Piechota et al., 2006; Wydro et al., 2010; Rorbach et al., 2011). According to 
these previous reports, the other mtDNA-encoded complex I subunits are not stabilized to 
the same extent as MTND1 and MTND2. The location of the two mRNAs within the 
polycistronic RNA molecule may have some impact on their subsequent cleavage and 
polyadenylation, and may influence regulation by yet unknown factors. My experiments, 
and others reported in the literature, have not shown other mt-mRNAs besides MTND1 
and MTND2 to be stabilized by shortening or removal of their poly(A) tails. There appear 
to be factors unique to these two transcripts that cause this difference. As mentioned, 
these factors are not clear at present.  
 In my experiments, MTCO1, MTCO3 and RNA14 were decreased at steady-state. 
This agrees with most reports in the literature for MTCO1 (Nagaike, 2005; Wydro et al., 
2010; Rorbach et al., 2011). The same results exist for RNA14 in these reports, however 
the overexpression of PDE12, a putative mitochondrial deadenylase, in HEK293 cells 
showed no effect on RNA14 steady-state levels while otherwise matching the results for 
other transcripts (Rorbach et al., 2011). MTCO2 and MTCO3 have been shown in several 
of these reports to be decreased as well. This is consistent with the status of MTCO3 that I 
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observed in the homozygous mutant cells. As with the complex I subunit-encoding 
mRNAs, there is no obvious pattern to explain why the complex IV subunit-encoding 
mRNAs are specifically depleted. MTCO3 does appear to be decreased to a much more 
marked degree than MTCO1 or MTCO2. This difference could in part be explained by 
MTCO3 being the only mtDNA-encoded complex IV transcript that requires adenylation 
in order to complete its stop codon, as it possesses no 3' UTR. However, even in the 
homozygous mutant lines the transcript is oligoadenylated, thus completing the stop 
codon. Thus, the stop codon necessity of adenylation does not completely explain the 
transcript decrease. The remainder of the mt-mRNAs appear to have their steady-state 
levels unaffected when only oligoadenylated. My northern blotting analysis of MTND3, 
showed no changes in steady-state levels as a consequence of oligoadenylation.  
 These results suggest, that unlike other organisms and cellular compartments 
where polyadenylation has a primary positive or negative effect on mRNA stability, 
polyadenylation may have a more complex role in mammalian mitochondrial mRNA 
metabolism. There is no single pattern of degradation, as in bacteria, or stabilization, as in 
the human cytosol. Whether this observed complexity is a product of unknown levels of 
regulation, or mid-evolutionary transition of mt-mRNA poly(A) tail necessity, is yet to be 
elucidated.  
 
4.4.3  Translation of oligo(A) mt-mRNAs 
 
 While the variable effects on mt-mRNA stability are not easily explained, it was 
possible that the downstream effects would align in a more coherent manner. Thus, I 
sought to investigate the translation status of the oligoadenylated mt-mRNAs. Analysis of 
de novo protein synthesis presented yet another complex set of results. There were once 
again increases, decreases, and lack of change on mitochondrial mRNA translation. 
Interestingly, not all of the trends observed at the mRNA level were recapitulated at the 
translational level. For example, RNA14 is clearly depleted, yet synthesis of the ATP6 
polypeptide appears to be increased. Whilst, for MTCO1, and MTCO3, there appears to 
be a relationship as both the transcript and protein synthesis are decreased. MTND1, one 
of the several curiously extra-stabilized mt-mRNAs, does not show significant changes in 
de novo protein synthesis in the homozygous mutants, compared to control.   
 There are several possible explanations for the discrepancies observed here. The 
discovery of TACO1, a human mitochondrial translational activator for COX1, suggests 
that there may be more translational activation factors for the other mt-mRNAs, such as 
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exist in yeast (Weraarpachai et al., 2009; Herrmann et al., 2013). These activators could 
be responding to the same stimuli (short oligo(A) tails) in differential manners, thus 
producing variable translation changes. As mentioned in context of the mt-mRNA 
stability differences, the mitochondrial genes could be in varying phases of losing the 
necessity of a poly(A) tail for optimal protein synthesis. However, we know that yeast 
translational activators interact with UTRs. In human mt-mRNA only a subset of 
transcripts have sequences that correspond to a UTR. MTCO1, for example, has a 
sequence that is not cleaved off that represents the antisense of tRNA serine at the 3’ end.  
 Despite this variation at the protein synthesis level, steady-state respiratory 
subunit analysis showed a consistent trend towards depletion. I immunoblotted against 
multiple mtDNA-encoded gene products: COX1, COX2, COX3, ND1, and ATP8 (data 
shown in Chapter 4, as the ATP8 antibody was not available when this characterization 
work was being carried out. Subsequent availability allowed for expansion of analysis 
during characterization of the lentiviral-treated fibroblasts). All of these subunits were 
decreased in the homozygous mutant fibroblasts. So in a functional sense, the endpoint of 
the poly(A) truncation is loss of various mtDNA-encoded OXPHOS subunits. The 
mechanisms underlying this effect are not clear in the case of complex I. For complex IV, 
there is a logical sequence of dysfunction, with the transcripts decreased at steady-state, 
then reduced protein synthesis which causes reduced levels of steady-state proteins, 
which causes a decrease of the assembled complex. The pulse-chase experiment was 
performed in order to assess the rates of mitochondrial translation product turnover, and 
investigate whether changes in turnover rates were contributing to depleted steady-state 
subunit levels. Small differences were observed in OXPHOS protein turnover, with the 
most affected proteins being ND5 and ND2, and COX1 to a much lesser extent, but the 
rest of the translation products did not show major turnover differences between the 
homozygous mutant and control fibroblasts.  
 Interestingly, other approaches for removal of the poly(A) tail have all shown a 
uniform decrease in protein synthesis for all mitochondrial polypeptides. This includes 
overexpression of the PDE12 deadenylase, and mitochondrial targeting of either cytosolic 
PARN or PABPC1. Consistent with the results presented here, both LRPPRC knockout 
mice and human patients harboring mutations in LRPPRC show a similar non-uniform 
translation pattern (Sasarman et al., 2010; Ruzzenente et al., 2012). Important to note, 
however, is the translation products that are increased/decreased do not all match with the 
PAPD1 homozygous mutant patterns. The fact that LRPPRC has been shown to be 
involved with mt-mRNA metabolism and pro-polyadenylation strengthens the idea that 
99 
 
some underlying process may be disrupted when the protein's function is impinged upon. 
Perhaps cis-regulatory elements exist in the transcripts that require the poly(A) tail for 
functioning in the context of translation, and LRPPRC interacts with these elements.  
 Another important point is the lack of mtPAP depletion as a result of the N478D 
mutation. In other experimental systems of mtPAP suppression, such as the knock-downs, 
the enzyme is not physically present. This could cause assembly defects of a potential 
larger protein complex that mtPAP may associate with. The loss of the protein could have 
other unpredicted effects as well. The homozygous N478D mutant mtPAP fibroblasts 
provide a system where the enzyme is physically present, with only activity impaired. 
This is an ideal situation for analysis of poly(A) activity defects only, without the 
possibility of other confounding physiological perturbations, unless the mutation affects 
interactions with LRPPRC or other trans-acting factors. This possibility is investigated in 
chapters 6 and 7.  
 
 
4.4.4  The PAPD1 1432A>G mutation causes an oxidative defect        
       
 The cumulative result of the transcription and translation changes stemming from 
the homozygous PAPD1 mutation is a significant oxidative metabolism defect. Blue 
native PAGE was performed to confirm if any assembly disruption of complexes I-V had 
occurred. Specifically, complexes I and IV showed the lowest levels of fully assembled 
complex. There was not any evidence of partially assembled subcomplexes for I or IV. 
This logically follows from depletion of mtDNA-encoded subunits for each complex. 
Subsequent analysis of the activity from the complexes in isolated mitochondria 
confirmed an impairment of enzymatic activity. Considering complexes I and IV have the 
largest number of mtDNA-encoded subunits, their preferential disruption in the presence 
of the homozygous PAPD1 mutation can be rationalized. While mitochondrial 
morphology and membrane potential did not appear substantially disrupted, cell growth 
defects in galactose-based media revealed the extent of the oxidative impairment. The 
growth curves for the homozygous mutant cells mildly lags compared to the heterozygous 
and control lines in standard glucose media. Once cultured in media that forces heavier 
reliance on oxidative metabolism, the impairment of cellular proliferation is considerably 
more evident. Time permitting, it would informative to measure the levels of ATP present 
in the homozygous mutant cells and their synthesis rate.  
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 Taken together, these experimental results indicate that the respiratory defect acts 
as the source of clinical pathology in the affected patients. The decrease in COX1-3 
proteins due to transcript decreases would have a major impact on complex IV assembly. 
As complex IV is the terminal respiratory complex, disruption of its assembly and activity 
would directly cause an OXPHOS defect. Importantly, complex I is the most commonly 
involved respiratory complex in mitochondrial disease, and thus its involvement in the 
patient pathology is likely substantial. 
 Mitochondrial disorders defined by nuclear gene mutations causing mitochondrial 
translation defects are a currently expanding category. The symptoms of the homozygous 
PAPD1 1432A>G patients overlap those observed in nuclear mutation-based 
mitochondrial disease: these include autosomal-recessive ataxia, optic atrophy, 
neurological deficits. The clinical presentation of these disorders can be quite varied, but 
neurological involvement is common. The lack of mtDNA involvement only underscores 
the similarity to other nuclear mutations, which cause disorders of mitochondrial 
translation. The molecular and clinical data from these PAPD1 follow in a logical manner 
from the disruption of the respiratory chain function causing oxidative metabolism 
defects, to a neurodegenerative pathology, with ataxia as the principle component. This 
rational relationship between clinical pathology and molecular dysfunction in the PAPD1 
patients is in contrast to certain other nuclear-encoded mitochondrial factor-driven 
disorders. For example, mutations in the mitochondrial aminoacyl-tRNA synthetases, 
which would be expected to affect mitochondrial protein synthesis in all tissues, in fact 
present with highly variable phenotypes and remarkable tissue specificity depending on 
which of the synthetases is mutated (Konovalova and Tyynismaa, 2013).  
 Analyses of steady-state levels of mt-mRNAs and respiratory subunits showed the 
heterozygote to be essentially indistinguishable from control cells. The cell growth curve 
for heterozygous cells matched control in galactose media, and even exceeded the control 
in glucose media, implying the lack of an oxidative metabolism defect. There does not 
appear to be an obvious reason why the heterozygous fibroblasts would proliferate at a 
greater rate than control cells, as none of our analyses showed any gains on the molecular 
level. The cell growth results more likely fall within the normal range of rates exhibited 
by wild-type fibroblasts, and would be more apparent with the inclusion of more control 
fibroblast lines. At the time of this work, only the one immortalized non-familial control 
line I immortalized was available.  
 It is still unclear whether the mtPAP N478D monomer can heterodimerize with 
wild-type mtPAP monomer, or if they can only homodimerize. Regardless of which 
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situation occurs in the heterozygous background, there exists enough poly(A) activity to 
overcome the mutation. This is important when considering complementation 
experiments, as the expressed transgene must be able to exert an effect on the phenotype. 
Had the heterozygous cells shown the deficiencies observed in the homozygous cells, a 
rescue experiment might not be feasible if the wild-type transgene expression ratio was 
1:1 with mutant expression. Fortunately, the mutation is recessive, thus expression of 
wild-type mtPAP in the homozygous mutants to suppress the defect was a reasonable 
hypothesis.  
 
4.4.5  What is the role of the poly(A) tail? 
 
 As stated, the aim of this section of research was two-fold: to characterize the 
downstream effects of truncated poly(A) tails on mt-mRNAs by analyzing the molecular 
phenotype of the mutant fibroblasts and then to use these results to gain insight into what 
specific role the poly(A) tail plays in mitochondria. While I have completed an 
investigation of the molecular phenotype of the mutant fibroblasts, and generated some 
informative data, progress in understanding the role of mitochondrial polyadenylation has 
been complicated. The differential effects observed resulting in differing levels of gene 
expression do not clearly illustrate a single fundamental mechanism across all mtDNA-
encoded OXPHOS subunits. The effects observed on complex IV follow a trend of 
stabilization of the mRNA transcripts conferred by the poly(A) tail, but the transcripts 
encoding other OXPHOS proteins do not adhere to this paradigm. Unlike the generally 
uniform degradation or protective role found in other organisms and cellular 
compartments, human mitochondria may utilize the poly(A) tail for more than a single 
function. The specific endogenous components of the translation machinery interacting 
with the tail are not known, and whether they interact in differing manners depending on 
the mt-mRNA is also not known. In a broad fashion, without full length poly(A) tails, 
respiratory chain defects result. This interpretation is complicated in part by the lack of 
quality antibodies to examine steady-state levels of all mtDNA-encoded polypeptides. 
The closest available alternative is the information derived from labeling of de novo 
mitochondrial protein synthesis. From that experiment, there are translation products that 
appear unaffected by oligoadenylated status of their coding transcript. If they are indeed 
unaffected, what is the mechanism of differentiation between transcripts? These questions 
are difficult to answer at present. The exact degree of poly(A) tail truncation necessary to 
cause these effects is also unclear, as in the homozygous mutant fibroblasts, the 
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shortening of the tail is quite dramatic. Future work may explore whether there is a 
threshold length of poly(A) tail required for optimal mtDNA gene expression, or if the 
shortened lengths are proportional to the downstream dysfunction incurred.  
 These cell biology and biochemistry based investigations presented here have not 
uncovered a full understanding of the precise nature of the N478D mutation. As the 
enzyme domain within which the mutation is located does not currently have an exact 
function attributed, more work is needed to understand the structural or enzymatic 
dysfunction. This was the impetus for the in vitro investigations using recombinant 
proteins detailed in chapter 6.  
 In summary, this study of the heterozygous and homozygous PAPD1 1432A>G 
mutant fibroblasts has yielded valuable, if complex, insights as to the effect of 
oligoadenylated mt-mRNA transcripts. The mutation results in a shortening of the 
adenylate tail on mt-mRNAs, leading eventually to activity deficits in complexes I and 
IV, which presumably underlie the neurodegenerative condition afflicting the patients 
harboring the homozygous genotype. While their condition is tragic, it underscores the 
notion that impairment of polyadenylation is not an embryonic lethal condition and that 
cells can somewhat tolerate the mitochondrial dysfunction. The cells survive and 
proliferate, although in a hampered fashion. The use of these patient fibroblasts has been 
a critical tool, and beyond the insights gathered by my investigations, they will continue 
to serve as a valuable resource for research into mitochondrial polyadenylation.   
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Chapter 5 
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Rescue of mt-mRNA oligoadenylation by lentiviral-based wild-type 
mtPAP expression 
 
5.1  Introduction 
 
 In parallel to the characterization studies of the PAPD1 1432A>G fibroblasts, it 
was imperative to be confirm that the 1432A>G mutation was the sole effecter of the 
pathological cellular phenotype observed. The most straightforward method for 
confirming this is ectopic expression of the wild-type gene in the afflicted cells, and 
monitoring for recovery of the dysfunction. The aim of this study was therefore 
ameliorating the biochemical defects in the PAPD1 mutant fibroblasts by rescuing the 
mutant phenotype. With the data for the heterozygous mutant line, I knew that 
introduction of a similar amount of wild-type mtPAP to N478D mtPAP would be 
sufficient to recover dysfunction.  
 There are multiple techniques for introducing an exogenous transgene into 
cultured cells. These include cationic lipid based methods for delivery of DNA. 
Electroporation is another common method, harnessing an electrical discharge through 
solution that causes temporary pores to open in cell membranes through which DNA can 
move. A particularly effective approach for gene delivery is the use of viral vectors. 
Lentivirus-based transduction, specifically, has a host of benefits over other methods, as a 
high percentage of cells are transduced, a broad variety of cell types can be infected, and 
the ability to infect both non-dividing and dividing cells.  
 While the use of viral vectors was considered from the outset, the initial 
transduction strategy for this rescue experiment used lipid-based transfection methods 
with a DNA plasmid (pcDNA5/FRT/TO) typically used for HEK293 Flp-In
TM
 T-REx
TM
 
transfections to generate stable transfections in the immortalized PAPD1 mutant cells. 
The pcDNA/FRT/TO plasmid possesses a tetracycline-inducible promoter for expressing 
the gene of interest. The pcDNA6/TR plasmid, which encoded the Tet repressor, is co-
transfected into target cells in parallel with pcDNA5/FRT/TO in order to generate 
tetracycline-inducible cellular expression of the gene of interest. This strategy had the 
added benefit of producing a DNA construct that would also be suited for transfection 
into the HEK293 cells for other experiments. Unfortunately this approach proved 
unsuccessful for use in immortalized fibroblasts. I attempted to generate stable 
transfectants with the same DNA plasmids using electroporation, but this also failed.  
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 A lentiviral vector was therefore designed to deliver a wild-type FLAG-tagged 
PAPD1 gene into both the wild-type and mutant cells. In this chapter, I will describe the 
generation of the PAPD1 DNA construct, the initial attempts at transfection, then the 
implementation and results of the wild-type PAPD1 lentiviral transduction on the mutant 
fibroblasts.  
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5.2  Materials and Methods 
 
5.2.1  Generation of the pcDNA5/FRT/TO-mtPAPFLAG   
  construct 
 
Full length coding region of mtPAP was PCR amplified using single stranded cDNA 
prepared from human fibroblasts via Oligo dT as template. The forward and reverse 
primers used in the PCR reaction were mtPAPF and mtPAPFLAGR (2.2.4.4). This 
generated a C-terminal FLAG-tagged mtPAP amplicon with BamH1 and Not1 restriction 
sites at the 5' and 3' ends, respectively. The PCR reaction products were then separated 
through a 1% low melting temperature agarose gel, and the DNA band of the correct size 
was excised and purified. The purified mtPAPFLAG PCR product was then digested with 
BamH1 and Not1 to create sticky ends, followed by phenol/chloroform extraction and 
EtOH precipitation. The expression vector pcDNA5/FRT/TO (Invitrogen) was also 
digested with BamH1 and Not1, and the linear products phenol/chloroform extracted and 
EtOH precipitated, then dephosphorylated using calf intestine alkaline phosphatase 
(NEB). The mtPAPFLAG fragment was ligated into pcDNA5/FRT/TO, and then used to 
transform Bioline α-select bacterial cells (Novagen). Transformed colonies were selected 
for ampicillin resistance (100ug/ml) on LB-agar plates. Confirmed colonies harboring the 
pcDNA5-mtPAPFLAG construct were expanded into 5ml cultures and incubated at 37⁰C 
overnight shaking. The construct was then purified with GeneJet plasmid prep kit 
(Fermentas), according to manufacturers protocol. The purified construct was then 
sequenced with a 3130xl Genetic Analyzer (Applied Biosystems) to confirm correct 
ligation, orientation, and full sequence. See section 2.2.4.4 for primers, and 2.2.4.3 for 
PCR profiles and reaction mixes. 
 
5.2.2  Blasticidin
S
 titration 
 
Immortalized heterozygous PAPD1 1432A>G mutant fibroblasts (C-HET) were seeded 
50,000 cells/well in 6-well plates (Corning) in standard DMEM and incubated overnight. 
The following day, Blasticidin
S
 was added to the media in five wells at the following 
concentrations: 0, 1, 2, 5, 7, and 10ug/ml. The cells were cultured in the presence of 
Blasticidin
S
 for six days, with one media replacement at day 3. After six days, cells were 
trypsinized and counted using a Neubauer hemocytometer. 
107 
 
 
5.2.3  Lipid-based transfection of fibroblasts 
 
The pcDNA5/FRT/TO-mtPAPFLAG construct and pcDNA6/TR plasmid were linearized 
by FspI digestion. Digest reactions were then phenol/chloroform extracted, EtOH 
precipitated, and the DNA re-suspended in 20ul sterile dH2O. The immortalized human 
fibroblast cell lines were split into 6-well plate wells to achieve 30-60% confluency by 
the day of transfection. Immediately prior to transfection, linearized construct and 
plasmid were mixed in a 9:1 ratio to give a total DNA amount of 2ug (1.8ug pcDNA5-
mtPAPFLAG and 0.2ug pcDNA6/TR). This DNA mix was made up to 100ul with 
DMEM lacking serum, antibiotics, and supplements, and combined with 10ul Superfect 
(Qiagen). The solution was gently mixed by pipetting and allowed to incubate 10min at 
RT. While Superfect/DNA mixture incubated, the medium was removed and cells were 
washed twice with PBS. After 10min 1200ul of complete supplemented medium was 
added to DNA/superfect mixture, gently mixed and then transferred on to washed cells. 
The cells were incubated in for 2.5-3hrs, then transfection mix was removed, and cells 
washed twice with PBS. A second round of transfection, performed as detailed above, 
was then completed. Following the second round of transfection, cells were fed with 
normal growth medium until two days later when selection with Blasticidin
S
 at 2ug/ml 
began. 
 
5.2.4  Transfection by electroporation 
 
Immortalized fibroblasts were washed once with Dulbecco's A-PBS, then trypsinized, 
pelleted, and each cell pellet suspended at 800,000 cells in 25ul of Resuspension buffer R. 
The plasmids to be used for transfection were mixed in a 9:1 ratio, pcDNA5/FRT/TO-
mtPAPFLAG to pcDNA6/TR, in sterile TE buffer. 4ug of this 9:1 DNA mix was added to 
the 25ul cell suspension. 10ul of the suspension (~400,000 cells) was electroporated with 
a pulse voltage of 1500V, pulse width of 10, and pulse number of 3. The cells were then 
transferred to 2ml of complete DMEM without antibiotics in a 6-well plate. This was 
repeated with a second 10ul of the cell suspension, and these cells seeded in a second 6-
well plate well. Then both steps were repeated for each individual cell line. After 
incubation for 48 hours, selection with Blasticidin
S
 was initiated.    
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5.2.5  Transduction of fibroblasts using a lentiviral vector 
 
A custom lentiviral vector encoding C-terminal FLAG-tagged mtPAP, and a puromycin 
resistance gene for selection, was purchased from Genecopoeia (Cat #: LP-W1687-
Lv121, Lot #: GC10312K1105). The virus particles were provided as 200ul, with a viral 
titre of 9.4x10
9
 copies/ml. Immortalized heterozygous (C-HET) and homozygous (P1 and 
P2) PAPD1 1432A>G fibroblasts and control fibroblasts (MB-I) were seeded at 200,000 
cells in T25 flasks in standard DMEM. The following day, in a BSL-2 certified laboratory 
space, 100ul (4 x 10
10
 viral particles) of custom lentivirus encoding mtPAP-FLAG was 
added to 16ml of complete supplemented DMEM + 10ug/ml polybrene. The media was 
removed from the fibroblast seeded flasks, and replaced with 4ml/flask of virus-
containing media, then incubated overnight. The following day virus-containing media 
was removed, and replaced with complete DMEM. Cells were incubated overnight. On 
the third day, puromycin was introduced to the cultures at a final concentration of 2ug/ml. 
Transduced cells were cultured in the presence of puromycin until only resistant cells 
were present, approximately seven days. The lentiviral vector map is shown in Appendix 
B.  
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5.3  Results 
 
5.3.1  Initial attempts at transfection using pcDNA5/FRT/TO- 
  mtPAPFLAG construct 
 
 This initial transfection strategy utilized an already established system in our lab, 
the HEK293 Flp-In
TM
 T-REx
TM
 cell line and associated plasmids. This HEK293 line has 
an integrated stable FRT site in the genome used for targeted insertion of a gene of choice 
cloned into the Flp-In
TM
 vector. The cell line also has pcDNA6/TR stably integrated, for 
constitutive expression of the Tet repressor, creating an inducible system for exogenous 
gene expression. While there was value in generating HEK293 cells that could express 
tagged mtPAP, in the early stages of the project the goal was stable transfection with 
FLAG-tagged mtPAP into the mutant fibroblasts, with co-transfection using the 
pcDNA6/TR vector for Tet repressor expression. This was designed to create an 
inducible, tagged mtPAP rescue of the mutant phenotype. The pcDNA5/FRT/TO plasmid 
is typically used in our lab for the HEK293 transfections, and would be used for cloning 
of the FLAG-tagged mtPAP. The fibroblasts do not have a stable FRT site in their 
genome like the HEK293 cells, so integration into the fibroblast genomes would be a 
random in location.  
 Generation of the mtPAPFLAG amplicon was successful (Figure 1A), using 10ng 
fibroblast cDNA as a template in a PCR with the mtPAPF and mtPAPFLAGR primers 
(See appendix A). The mtPAPFLAG primer inserted a FLAG-tag at the 1731nt position 
in the C-terminus of mtPAP amplicon, replacing the terminal five residues.  
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 In parallel, the pcDNA5/FRT/TO plasmid, a tetracycline-regulated, CMV/TetO2 
promoter driven expression vector, was harvested and purified from bacterial stocks. 
Digestion with BamH1 and Not1 (Figure 5.1B, lane 3), then dephosphorylation, was 
performed to prepare the vector for ligation with the mtPAPFLAG insert. The ligation 
reaction was used to transform Bioline α-select bacteria. However only one resistant 
colony harbored the correctly assembled construct, as confirmed by BamH1 and Not1 
digestion (Figure 5.1C). Sequencing confirmed the correct orientation and fidelity of the 
mtPAPFLAG amplicon in the construct, which will be referred to as "pcDNA5-
mtPAPFLAG".   
 While the work cloning mtPAPFLAG into the vector was ongoing, heterozygous 
PAPD1 mutant fibroblasts were seeded for generating a 1-10ug/ml titration curve for 
Blasticidin
S
 (Figure 5.2). A concentration of 2ug/ml Blasticidin
S
 was chosen as the 
optimal concentration for the transfections, as this concentration exerted the desired 
killing effect while using minimal antibiotic.  
 The pcDNA5-mtPAPFLAG vector contains a promoter that is bound by the Tet 
repressor, encoded on the pcDNA6/TR vector. Both vectors must be used in co-
transfection of cells to allow for inducible expression of mtPAPFLAG with tetracycline. 
Only pcDNA6/TR encodes for resistance to Blasticidin
S
, so its presence is the only one 
selected for. To increase the chances of resistant cells harboring both constructs, rather 
 
Figure 5.1. Amplification, digestion, and confirmation of the pcDNA5-
mtPAPFLAG construct. 
A. Result of mtPAPFLAG PCR (lane 2). B. Result of BamH1+Not1 digest on pcDNA5/FRT/TO. The uncut plasmid 
(lanes 1-2) and the digested plasmid (lane 3). C. Confirmation of the insertion in the plasmid. Single digest with 
BamH1 of pcDNA5-mtPAPFLAG construct (lane 1), digest of construct with BamH1 and Not1 (lane 2). All gels are 
1% agarose and DNA visualized by UV transillumination. Size markers are the same on all gels.  
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than only pcDNA6/TR, the ratio of pcDNA5-mtPAPFLAG to pcDNA6/TR used to 
transfect the cells is 9:1. The total amount of DNA used in the transfections was 2ug.  
 Multiple attempts to transfect the immortalized fibroblasts with the pcDNA5-
mtPAPFLAG and pcDNA6/TR plasmids using Superfect were unsuccessful. While small 
numbers of cells survived the first few days of selection, these did not divide and slowly 
died off. After repeated transfections not producing Blasticidin
S
 resistant cells, it became 
apparent a more effective transfection method would be necessary.  
 Electroporation was the second method attempted for transfection of the 
immortalized fibroblasts. Using the Neon
TM
 transfection system (Invitrogen), electrical 
pulses replaced the cationic lipid-based reagents in the reaction. The same constructs and 
plasmids, pcDNA5-mtPAPFLAG and pcDNA6/TR, were used. As with the earlier 
transfections, once selection by Blasticidin
S
 began most cells died off quickly, with only 
few remaining. These surviving cells did not proliferate, and eventually died.  
  
5.3.2  Lentiviral transduction of PAPD1 mutant fibroblasts 
 
 
 
Figure 5.2. Titration of Blasticidin
S
 to generate a kill curve. 
A. Fibroblasts heterozygous for the PAPD1 1432A>G mutation were seeded 50,000 cells/well in 6-well plates. 
After 7 days treatment with BlasticidinS the cell growth was assessed by cell counting. B. Representative brightfield 
images of three concentrations of BlasticidinS after 7 days. 2ug/ml was chosen as the optimal selection 
concentration.  
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 The varying methods of transfection were unsuccessful, underscoring the 
requirement for a more robust gene delivery method. Viral vectors are routinely 
employed for difficult to transfect cell lines, and so one was designed for this experiment. 
A custom replication-incompetent lentivirus was designed and purchased from 
Genecopoeia. The custom virus encoded a FLAG-tagged wild-type version of mtPAP, 
driven by the CMV promoter and paired with a puromycin resistance gene for selection 
purposes (the lentiviral vector is referred to as LVPAPD1 in this text).  
 An excessively high multiplicity of infection was chosen, in order to ensure high 
levels of transduction. Under BSL-2 conditions, each of the fibroblast cells lines, C-Het, 
P1, P2, and C2 were exposed to virus-containing medium in the presence of polybrene 
and incubated overnight. The next day the virus-containing medium was removed, and 
replaced with fresh media. On day 3 puromycin at 2ug/ml final concentration was 
introduced to the cultures to begin selection of transductants. Previously, a 0.5-10ug/ml 
kill curve had demonstrated that 0.5ug/ml puromycin was sufficient to kill off non-
resistant fibroblast cells (data not shown). The concentration was increased to 2ug/ml on 
the recommendation of Dr. Chris Morris (Newcastle University), to select for high 
transgene expression. The non-transduced immortalized fibroblasts died off quickly, with 
 
 
 
Figure 5.3. Cellular transduction using lentiviral vectors 
Cartoon representation of the process of producing and employing a lentivirus for cellular transduction of a gene of 
interest. A. The plasmids encoding viral packaging factors as well as the gene of interest are transfected into 
HEK293 cells. B. The packaging cells produce replication-deficient viral particles over a span of time, these viral 
particles are collected and titer assessed. C. The target cell line is exposed to the lentiviral particles, which 
infect/transduce the cell with gene of interest. D. The gene of interest is stably integrated into the genome of the 
target cell line, and expresses the desired gene product.  
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a relatively high rate of transduction observed from the percentage of surviving cells 
(estimated 50% survival). The cells resistant to puromycin quickly proliferated and once 
cryogenic stocks had been stored, molecular analysis of the effects of the wild-type 
mtPAP expression was undertaken.  
  
5.3.3  Transgenic expression of wild-type PAPD1 restores poly(A)  
  length in homozygous PAPD1 1432A>G mutant fibroblasts 
 
 With the necessary amounts of transduced fibroblasts grown in culture, the cells 
were harvested and RNA and protein isolated as detailed in chapter 2. The three initial 
parameters to be analyzed were polyadenylation status, steady-state levels of 
mitochondrial mRNAs, and steady-state levels of respiratory chain proteins, particularly 
the mtDNA encoded subunits. The initial analysis was via immunoblot. To establish 
whether the transduction was successful, increased levels of mtPAP was probed and any 
recovery of depleted respiratory chain proteins was investigated. One of the homozygous 
fibroblast lines (P1) was not included in the initial analysis, as the culture was not ready 
at the time. The other three transduced lines were probed for the SDHA, COX1, COX2, 
and TOM20.  
 When mtPAP levels were probed on the membrane, an increased amount of the 
protein was present, evidence of elevated expression due to presence of the transgene. 
Upon probing for COX1 and COX2 levels, a recovery of the depletion for both subunits 
was observed. This was the first indication that the pathological phenotype had been 
rescued with exogenous expression of WT mtPAP.   
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 Following preliminary evidence that transduction of the fibroblasts with the WT 
PAPD1 transgene was successful via immunoblotting, I isolated whole cell RNA from all 
four transduced fibroblast lines to perform the fluorescent MPAT assay. The RNA14, 
MTND3 and MTCO1 transcripts were analyzed for changes in polyadenylation profiles. 
The effect of the mtPAP transgene expression was clear. As shown in Figure 5.5, there is 
a complete rescue of the short oligo(A) population of the transcripts. All four cell lines 
show a uniform population of polyadenylated transcript sizes, with increases in the 
median lengths. The range of poly(A) tail sizes has also expanded in the transduced cell 
lines, extending to longer lengths than observed with the non-transduced transcripts. 
These changes are consistent for both mutant and control fibroblasts. The rescued 
homozygous mutant fibroblasts still show small amounts of oligoadenylation, which 
matches the comparative amounts detected in the non-transduced cells. Both the RNA14 
and MTND3 transcripts conformed to this pattern.  
 The MTCO1 polyadenylation in the transduced homozygous mutant cells showed 
smeared results in the corresponding lanes on the gel (data not shown). Both the 
heterozygous and control transduced cell lines exhibited the same pattern observed for the 
other two analyzed transcripts, uniform poly(A) tails with increased median length and 
range of lengths. For reasons unclear, after multiple repeats of the MPAT assay, clear 
detection of MTCO1 poly(A) status with the transduced homozygous mutant cells was 
unobtainable. However, recovery of the COX1 and COX2 depletions on immunoblotting 
strongly suggests that the MTCO1 truncated poly(A) tail has been restored to some degree 
in the transduced homozygous mutant fibroblasts.  
 
Figure 5.4. Immunoblot evaluation of transduction of wild-type mtPAP 
Whole cell lysate (40ug) from pre- and post-LVPAPD1 transduced fibroblast lines was separated by SDS-PAGE and 
transferred to PVDF membranes. A. Antibodies against COX1and COX2 were used to assess steady-state levels of 
the proteins, with SDHA as a loading control. B. Antibodies against mtPAP were used to assess steady-state levels 
of the proteins, with TOM20 as a loading control. 
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5.3.4  Transgenic WT PAPD1 expression restores steady-state  
  levels of mt-mRNAs  
 
 
 
Figure 5.5. Wild-type PAPD1 transgene expression restores poly(A) tails on mt-
mRNAs 
Whole cell RNA was isolated from pre- and post-transduced fibroblasts and 5ug used for performing the fluorescent 
MPAT assay. RNA14(A) and MTND3 (B) polyadenylation statuses was analyzed. The positions of poly(A) and 
oligo(A) populations are labeled on the left side of the gel images. To the right of the gel images are lane plot 
profiles of signals.   
A 
B 
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 Once the polyadenylation recovery status was confirmed in the +LVPAPD1 
fibroblasts, the steady-state levels of the mt-mRNAs were analyzed by northern blot to 
establish whether changes had occurred as a consequence of transduction. The panel of 
transcripts shows a significant recovery of wild-type steady-state levels in the transduced 
cells, as shown in Figure 5.6. For MTCO1, MTCO3 and RNA14, the depletions are largely 
reversed, bringing transcript levels back up to comparable levels with the control cell line. 
In the case of MTND1, the extra-stabilization of the transcript associated with the 
homozygous mutants is reduced to closer to wild-type levels, but still moderately elevated 
compared to the transduced heterozygous mutant and control lines. MTND3, which was 
unaffected in both the heterozygous and homozygous PAPD1 mutants, shows no changes 
as a result of transgene expression. The mt-rRNAs that are not polyadenylated, are not 
included here and they do not show significant changes resulting from LVPAPD1 
treatment. 18S rRNA was probed as a loading control for the blot.  
 
 
 
Figure 5.6. Expression of wild-type PAPD1 transgene restores steady-state levels 
of mt-mRNAs 
Whole cell RNA (4ug) isolated from pre- and post-transduced fibroblast lines was separated by formamide/agarose 
gel electrophoresis and transferred to a nylon membrane. Steady-state levels of mitochondrial mRNAs were 
assessed by hybridization with [32P] radiolabeled probes corresponding to target mRNAs and rRNAs. 18S rRNA 
was used as a loading control. Blots were developed by autoradiography, and imaged by a Typhoon FLA 9500 
imager. Note: Pre-transduced blot images are the same shown in Figure 4.7.     
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5.3.5  Transgenic PAPD1 expression restores steady-state levels of 
  mtDNA-encoded OXPHOS proteins  
 
 The depletion of respiratory complex subunits stands as the most likely cause of 
the complex assembly defects and activity disruption that underlies the neuromuscular 
disorder the patients are afflicted with. Thus, it was imperative to observe whether the 
recovery of full length poly(A) tails and mt-mRNA stabilities translated to restoration of 
steady-state levels of mtDNA-encoded polypeptides. This was assessed by 
immunoblotting for respiratory chain subunits. As shown in Figure 5.7, the major 
decreases in steady-state levels for mtDNA-encoded proteins appear to be substantially 
replenished and closer to wild-type levels (lanes 2-3 vs 6-7). Four mtDNA-encoded 
respiratory subunits were probed on the immunoblots: COX1, COX2, ND1, and ATP8. 
Two nuclear-encoded complex I subunits, NDUFB8 and NDUFA9, were probed as well. 
As mentioned in Chapter 4, while not mtDNA-encoded, the NDUFB8 signal on 
immunoblots can act as an indicator of complex I assembly. In the homozygous mutant 
fibroblasts, these subunits show decreased signal. In the transduced lines, the signals are 
 
 
Figure 5.7. Expression of wild-type PAPD1 transgene reverses depletion of 
mtDNA-encoded respiratory subunits. 
Whole cell lysate (40ug) harvested from the fibroblast panel pre- and post-treatment with LVPAPD1 was 
separated by 12% SDS-PAGE and transferred to PVDF membranes. The membranes were then probed with 
antibodies against mitochondrial mtDNA and nDNA-encoded respiratory subunits. SDHA was included to serve 
as a loading control. Blot were developed using ECL+ (GE) and imaged using the Chemidoc MP imaging 
system (Bio-Rad).  
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significantly recovered. This likely indicates an amelioration of the complex I assembly 
defect due to the reversal of complex I subunit depletion. It would also be predicted that 
the complex IV assembly defects would be rescued from the reestablished levels of 
subunits. LRPPRC was probed to assess any changes pre- and post-transduction, as it is a 
putative regulator of mitochondrial polyadenylation. No changes LRPPRC steady-state 
levels were observed pre- or post-LVPAPD1 treatment.  
 When mtPAP was probed as part of the immunoblot panel, a doublet was 
observed in the transduced cells. The second mtPAP species served as confirmation of 
transgene expression. As the FLAG-tag changes the charge of the enzyme enough to alter 
the migration through the SDS polyacrylamide gel during separation, this could cause the 
doublet effect.    
 
5.4  Discussion 
 
5.4.1  Stable integration of wild-type PAPD1 transgene via   
  lentiviral vector 
 
 Primary fibroblasts are classically considered a difficult to transfect cell line, and 
indeed the initial attempts to transfect the cells were unsuccessful. Using two plasmids in 
the same transfection reaction, only one of which could be selected for, likely made the 
situation more complicated and difficult than it needed to be. The use of cationic lipid 
reagents and electroporation was unsuccessful, for reasons that are unclear. This is a 
common problem with fibroblast transfection, at least in the creation of stable 
transfectants. Transient transfection also presents a problem, potentially, via the 
heterogeneous levels of transgene expression in the cell culture population. The effects 
resulting from restored wild-type expression may not be as clear in such a system. Thus, a 
priority was put on generating stable transfectants.   
 Viral vectors presented a much more efficient method of delivering the PAPD1 
transgene. The drawback with viral vectors is largely the necessity of dedicated handling 
facilities. As my host lab did not have permission for viral production, custom designed 
and preprepared virus particles were purchased commercially. Handling of the virus was 
facilitated by access to BSL-2 certified culture hoods in Dr. Chris Morris's lab in a 
neighboring institute.  
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 The custom lentivirus carrying a wild-type PAPD1 gene, termed here 
"LVPAPD1", was employed to successfully transduce a significant percentage of the 
fibroblast populations exposed to virus-containing medium, as initially assessed by 
resistance to puromycin. Experimental evidence indicated that the transduction was 
successful, and rescued the pathological phenotype in the homozygous mutant fibroblasts.  
    
5.4.2  Transgenic expression of wild-type PAPD1 restores full  
  length poly(A) tails on mt-mRNAs 
 
 The primary defect of the N478D mtPAP mutation is a reduced ability to generate 
full-length poly(A) tails on mt-mRNAs. The aim of this complementation experiment was 
a rescue of this specific deficiency. All the downstream molecular pathologies that were 
observed logically could be a consequence of the shortened mitochondrial poly(A) tails.  
 The analysis of polyadenylation status of several mitochondrial mRNAs using the 
MPAT demonstrated that full length poly(A) tails were recovered in the transduced 
homozygous mutant fibroblasts. The majority of poly(A) tail lengths were of the average 
control length or modestly longer. Additionally, both control and patient transduced lines 
showed an increase in the range of lengths for polyadenylation. This may be due to the 
existence of an equilibrium of activities between the poly(A) polymerase and 
deadenylation factors. Rather than poly(A) tail length solely reflecting the poly(A) 
polymerase's processivity, with deadenylation acting as a degradation event 
independently at a later point, precise regulation of poly(A) tail length could be a 
balancing act of these activities. These factors could be the PNPase/hSuv3 
"degradosome" complex, PDE12, or yet undiscovered exoribonucleases. Evidence 
supporting this include mild poly(A) length increases when depleting PNPase via siRNA 
(Slomovic and Schuster, 2007), or overexpression of PDE12 causing shortening of 
poly(A) tails in mitochondria (Rorbach et al., 2011). The increase in average poly(A) 
length and range of poly(A) lengths in the transduced fibroblasts may be a result of 
increased steady-state levels of mtPAP, shifting the ratio of adenylation to deadenylation 
events towards polyadenylation.  
 Both RNA14 and MTND3 exhibited similar oligo(A) patterns and recovery of full 
length poly(A) tails in transduced cells. MTCO1 was analyzed via MPAT, however the 
transduced homozygous mutant cells demonstrated aberrant signal on the 
polyacrylamide/urea gel. Rather than discrete poly(A) tails lengths produced, there was 
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smearing of signal. This result was obtained on multiple independent repeats. Analysis of 
the gene-specific PCR products from the homozygous mutant cell lines by agarose gel 
electrophoresis, prior to the fluorescent-labeling PCR, showed no discernible size 
difference between heterozygous mutant and control cell line's PCR products (Appendix 
C). In the non-transduced homozygous mutant cell lines, the size differences of the PCR 
products due to poly(A) truncation are clearly observable. This indicates the full length 
poly(A) tail has been recovered for MTCO1 transcripts in the homozygous mutant cell 
lines. The reason MTCO1 is the only one to show these results is unclear, but may be a 
technical artifact of the MPAT assay. The recovery of COX1 and protein supports re-
establishment of the wild-type poly(A) tail length on the MTCO1 mt-mRNA.  
 
 
5.4.3  Transgenic expression of wild-type PAPD1 reverses altered  
  stability of mt-mRNAs and depletions of OXPHOS proteins 
 
 Analysis of the heterozygous mutant fibroblasts had provided some insight into 
the nature of the mutation. As the heterozygous cells demonstrated an essentially wild-
type phenotype, it could be inferred that the N478D substitution was not a dominant loss 
of function mutation. At a minimum, expression of wild-type mtPAP equal to that of the 
heterozygous mutant would be predicted to bring the homozygous mutant phenotype 
closer to normal functioning.  
 Once the rescue of the oligo(A) tails was confirmed via the MPAT assay, it was 
necessary to investigate whether there was also correction of the downstream defects. 
This was accomplished by northern blotting and immunoblotting. Steady-state levels of 
mt-mRNAs and respiratory chain subunits were compared pre- and post-LVPAPD1 
treatment. As predicted, both mt-mRNA and polypeptides demonstrated considerable 
recovery towards control levels of gene expression products. The reasons for such 
variable changes in mt-mRNA stabilities in homozygous mutant cells is still unclear, but 
the effect is reversed upon expression of transgenic wild-type mtPAP. The levels of 
MTND1 are still mildly elevated compared to control and heterozygote levels, however 
this may be due to the heterogeneous mtPAP population present in the transduced cells. 
The N478D mtPAP may still be generating oligo(A) tails, that are not further adenylated 
by the transgenic wild-type mtPAP. It may be these persisting transcripts with oligo(A) 
tails are responsible for the increased transcript levels observed. This gain of stability may 
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be more difficult to reverse than recovery of decreased steady-state levels. Despite the 
persistence of extra-stable MTND1 transcripts, the depletion of protein levels observed at 
steady-state is rescued. The immunoblots of the OXPHOS subunits all show decreased 
levels at steady-state in the homozygous mutant fibroblasts, and in the transduced cells 
this effect is abolished. The causative pathogenicity of the N478D mutation was 
convincingly confirmed by the analysis of poly(A) status, and mt-mRNA/mtDNA-
encoded protein steady-state levels. By rescuing the fundamental defect of 
polyadenylation, the broader mitochondrial dysfunction was ameliorated.   
 There are many characteristics of the N478D mtPAP still unknown. These include 
whether N478D mtPAP can homodimerize, or heterodimerize with wild-type monomers. 
In the heterozygous, and rescued transduced fibroblasts, either heterodimers possess 
enough poly(A) activity to generate enough full length poly(A) tails, or the amount of 
wild-type homodimers is sufficient for functional polyadenylation. In addition, it is 
unknown if the N478D mtPAP generates the oligo(A) tails on mt-mRNA transcripts, or if 
another polymerase is responsible. In order to answer some of these questions, a more 
thorough investigation of the wild-type and N478D mtPAP enzymes was carried out 
using recombinant versions of the proteins, as detailed in the next chapter.    
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Chapter 6 
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In vitro analysis of recombinant wild-type and N478D mtPAP 
polyadenylation activity 
 
6.1  Introduction 
 
 The data presented thus far have shown that the poly(A) tail generated by mtPAP 
by has an important role in mitochondrial gene expression dynamics. However, these 
biochemical characterizations of the PAPD1 1432A>G mutant and control fibroblasts 
have not offered insights as to the exact mechanism by which the N478D mutation 
disrupts polyadenylation activity. Furthermore, there are many aspects of the wild-type 
polymerase that are still ill-defined. As stated earlier, and shown here in Figure 6.1, the 
N478D mutation is located in a region of the enzyme that was not resolved in the 
published crystal structure reported 
in Bai et al. 2011. As a result, there 
is not a defined domain assigned to 
the region. The nature of this 
region's function is obscured by this 
lack of structural data. This makes it 
hard to predict what the loss of 
functionality caused by the mutation 
may be. The motif falls within a 
section of the fingers domain. As 
the N-P-F-E polypeptide motif in 
particular is highly conserved across 
species, and is within a conserved 
region of approximately 40 amino 
acids, this may be evidence of its 
importance to enzyme integrity. 
There is not an obvious involvement 
in catalytic activity, RNA binding, 
dimerization, or protein-protein interactions. Particularly catalytic activity, as the 
mutation is far removed from the active site of the enzyme.  
 This lack of insight from the fibroblast studies necessitated investigating the wild-
type and N478D mtPAP enzymes in an isolated fashion. This was best accomplished by 
 
 
Figure 6.1. The location of the mtPAP N478D 
mutation 
Structural model of the recombinant mtPAP monomer, 
indicating the location of the N478D mutation. Color is by 
secondary structure: alpha-helix (green), beta-sheets (blue), 
unstructured regions (magenta). The section of the peptide 
harboring the N478D mutation is highlighted by red residues at 
the beginning and end of the region (boxed). The N-terminus 
end of the recombinant protein is indicated by an asterisk(*). 
The structure is available from the Protein Data Bank, PDB: 
3QP1, reported by Bai et al., 2011. This image was generated 
using the Chimera 1.8.0 software, available from UCSF.  
* 
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generating recombinant proteins and constructing an in vitro experimental system. An in-
depth report on the structural and activity characteristics of mtPAP was provided in Bai et 
al. 2011. This was the first report of the crystal structure of mtPAP, although the first 
report of mtPAP in vitro activity came from Nagaike et al. 2004. The initial strategy for 
generating recombinant enzyme was generating GST-tagged proteins, but this approach 
lacked high protein yields. Subsequently, a formal collaboration between my host lab and 
Professor Liang Tong's lab at Columbia University was established. This provided me 
with their His-tagged recombinant mtPAP construct, from which I generated constructs to 
express the mutant mtPAP protein. Professor Tong's group then assisted in generating and 
purifying the necessary recombinant proteins.  
 There are conflicting reports and conclusions regarding in vitro studies of mtPAP. 
Several groups have reported that the enzyme is independently capable of generating 
poly(A) tails (Nagaike, 2005; Bai et al., 2011), while another has reported the necessity of 
LRPPRC being present for optimal activity (Chujo et al., 2012). Resolving this conflict 
was one of the priority aims of this in vitro work. There are multiple other questions these 
investigations aim to address:  
Which factors, if any, does mtPAP need to polyadenylate RNA?  
What is the exact contribution of LRPPRC on poly(A) activity?  
Does the N478D mutation compromise catalytic activity itself, or disrupt critical 
interactions? What is the effect of LRPPRC on mutant poly(A) activity?  
Is mtPAP active only on specific RNA substrates, or is its specificity more broad?  
Is SLIRP necessary for poly(A) activity, with or without LRPPRC?  
Does the mutant mtPAP generate the oligo(A) tails observed in vivo? 
 Do oligoadenylated RNAs present as a more optimal substrate for mtPAP? 
 These are the questions that a well designed in vitro system would be equipped to 
answer. Towards that end, in addition to the collaboration with Liang Tong's lab, we also 
established a collaboration with Professor Nils-Goran Larsson's lab (Dr. Henrik Spahr), to 
acquire recombinant LRPPRC, SLIRP, and LRPPRC/SLIRP complexed together. This 
allowed for an array of experiments utilizing mtPAP, LRPPRC, SLIRP, and varying RNA 
substrates to be examined individually and in concert for their impact on polyadenylation 
activity.  
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6.2  Materials and methods 
 
6.2.1  Generation of the mtPAPΔN-GST fusion construct 
 
A PCR product coding for the first 30 amino acids of the N-terminus of mtPAP removed 
was generated using the primers mtPAP6PF and mtPAPR2 (2.2.4.4). The pcDNA5-
mtPAPFLAG construct was used as a template, although mtPAPΔN was designed to 
regenerate the normal C-terminus with its stop codon, rather than a FLAG-tag. Deletion 
of the first 30 amino acids removed the predicted mitochondrial targeting sequence, 
which would be cleaved off upon import into mitochondria. This generated an amplicon 
that would encode an N-terminal truncated mtPAP with BamH1 and Not1 restriction sites 
at the 5' and 3' ends, respectively. The PCR reaction was then separated through a 1% low 
melting temperature agarose gel, and the DNA band corresponding to the correct size was 
excised and purified. The purified mtPAP6P PCR product was then digested with BamH1 
and Not1, followed by phenol/chloroform extraction and EtOH precipitation. The 
expression vector pGEX-6P-1 was digested with BamH1 and Not1, dephosphorylated, 
and the linear products phenol/chloroform extracted and EtOH precipitated. The PCR 
fragment was then cloned into the BamH1 and Not1 sites of pGEX-6P-1 expression 
vector. The pGEX-mtPAPΔN construct was used to transform Bioline α-select bronze 
bacterial cells (Novagen). Transformed colonies were selected with ampicillin (100ug/ml) 
on LB-Agar plates. Colonies confirmed by PCR analysis harboring the pGEX-mtPAPΔN 
construct were expanded into 5ml cultures and incubated at 37⁰C overnight shaking. The 
construct was then purified from cultures with GeneJet plasmid prep kit (Fermentas), 
according to manufacturers protocol, and sequenced (as detailed earlier) to confirm 
accuracy of the construct. See 2.2.4.4 for primers, PCR profiles, and reaction mixes. 
Bacterial propagation of other constructs was carried out in the same manner described 
here, with varying antibiotics for selection based on the vectors.  
 
6.2.2  Generation of 1432A>G mutant pET28a-mtPAP by   
  site-directed mutagenesis 
 
The pET28a-mtPAP construct was a generous gift from Liang Tong's lab. For generating 
the 1432A>G substitution within the construct, the Quikchange
®
 II Site-Directed 
Mutagenesis Kit (Stratagene) was used, according to manufacturer's instructions. The 
126 
 
pET28a-mtPAP construct was used as the template for the mutagenesis reaction. The 
primers Mut-mtPAPF and Mut-mtPAPR (2.2.4.4) were used for generating the point 
mutation. The mutant strand synthesis reaction was assembled as below: 
 
Component Final Concentration in PCR Reaction 
10X Reaction Buffer  1X 
dNTP Mix 1ul 
mtPAPmutF (10uM) 125ng 
mtPAPmutR (10uM) 125ng 
pET28a-mtPAP DNA 50ng Total 
PfuTurbo Polymerase (2.5 U/ul) 2.5U 
ddH2O Made up to 50ul 
 
The PCR profile for the mutagenesis reaction: 
 
Step Reaction Profile Reaction Step 
1 95⁰C - 30 seconds Initial Denaturation 
2 95⁰C -  30 seconds Denaturing 
3 55⁰C - 1 minute Annealing 
4 68⁰C - 6 minutes Extension 
5 Back to Step 2, 12 cycles # of cycles 
7 4⁰C - Indefinitely Hold 
 
Once thermal cycling was complete, 1ul (10U) of Drp I was added directly, the reaction 
mixed, then incubated at 37⁰C for 1 hour. The completed reaction was then used for 
transforming XL1-Blue supercompetent bacterial cells. The cells were thawed on ice, as a 
50ul aliquot, and then had 1ul of the Drp I-treated mutagenesis reaction added. This was 
incubated on ice for 30 minutes, followed by a heat pulse at 42⁰C for 45 seconds, then 
moved back to ice. 0.5ml of SOC media was added to the cell mixture, moved to 37⁰C, 
shaking, for 1 hour. From there, the cells were spread on kanamycin and chloramphenicol 
agar plates and incubated overnight at 37⁰C. Resistant colonies were screened for correct 
construct transformation.     
 
6.2.3  Recombinant expression of mtPAPΔN-GST  
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Chemically competent Escherichia coli strains Rosetta (DE3) (Novagen) were 
transformed according to manufacturer’s protocol with pGEX-mtPAPΔN construct. 
Tuner strain (Novagen) was also transformed by adding 10ng construct DNA to 50ul 
aliquot of bacteria, incubating on ice 30min, heat shocking at 42⁰C for 2 min, then 
incubating on ice 2 min. Selection was performed by 100ug/ml ampicillin (Rosetta and 
Tuner) and 34ug/ml chloramphenicol (Rosetta) on antibiotic supplemented LB-agar 
plates. Resistant colonies were expanded to 5ml cultures supplemented with 100ug/ml 
ampicillin (Rosetta and Tuner) and 34ug/ml chloramphenicol (Rosetta). Once cultures 
reached an OD600 of 0.5 they were induced with 1mM isopropyl β-D-
thiogalactopyranoside (IPTG) either overnight at 16⁰C or for 3 hrs at 37⁰C. Various 
induction conditions included an initial cold shock of 5min on ice prior to the addition of 
IPTG for Rosetta strain, as well as titrating induction with 0.05mM, 0.1mM, and 0.2mM 
IPTG for the Tuner strain. Samples were taken from the uninduced and induced cultures, 
and lysed. The remaining culture volume was split into soluble and insoluble fractions via 
pelleting bacterial cells at 5000g for 5min at 4⁰C, then re-suspending in CelLytic B 
(Sigma). Mixture was then centrifuged at 15,000g for 8min at RT. The supernatant was 
collected, and this constituted the "soluble" fraction, and the remaining pellet was re-
suspended in PBS, which constituted the "insoluble" fraction. Samples of bacterial cell 
lysate were prepared and separated via 12% SDS-PAGE as detailed for western blotting, 
and then visualized by Coomassie blue staining. Confirmation of recombinant mtPAPΔN-
GST fusion protein expression was shown via immunoblotting the bacterial lysate 
samples using anti-mtPAP antibodies, as detailed in western blot methods. For removal of 
the GST-tag, the soluble fraction of bacterial lysate was transferred to a gravity flow 
chromatography column (Bio-Rad) containing 0.6ml glutathione-Sepharose beads (GE 
Healthcare), which were pre-washed with dH2O and then PBS. The lysate and beads were 
incubated overnight in the column at 4⁰C on a rocker. The next day the beads were 
washed with 5 column volumes of PBS, with 1mM PMSF and protease inhibitors 
(Roche). Then washed with 5 column volumes of PBS alone. Elution of the tag-free 
protein was accomplished with adding 48U PreScission Protease (GE Healthcare) to 
0.75ml PBS, 1mM DTT, 1mM EDTA, and incubated overnight at 4⁰C on a rocker. The 
cleaved protein was collected by gravity flow the next day in a chilled 1.5ml tube.  
 
6.2.4  Recombinant expression and purification of His-mtPAP 
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Chemically competent Escherichia coli Rosetta DE3 strain (Novagen) were transformed 
according to manufacturer’s protocol with pET28a-PAPD1 construct. Selection was 
performed on 50ug/ml kanamycin and 37ug/ml chloramphenicol supplemented LB-agar 
plates. Resistant colonies were expanded to 1L cultures supplemented with 50ug/ml 
kanamycin and 34ug/ml chloramphenicol. Once cultures reached an OD600 of 0.5 
recombinant protein production was induced with 1mM isopropyl β-D-
thiogalactopyranoside (IPTG) overnight at 20⁰C. After the overnight incubation the 
cultures were pelleted by centrifugation in a Sorvall RC5 centrifuge (GSA rotor), set at 
5000rpm, at 4⁰C, for 15 minutes. These pellets were either frozen at -80⁰C for use within 
two weeks, or directly processed. The pellet was resuspended in 10ml 50mM Tris pH 8.5, 
0.3M NaCl, 1mM PMSF and 1 tab protease inhibitors (Roche) and kept on ice. The 
bacterial cells in suspension were then disrupted on ice using a Sonopuls ultrasonic 
homogenizer (Bandelin), set at 4 minutes for 5 cycles, at 50% power. The insoluble 
fraction of the homogenized suspension was pelleted by centrifugation in the Sorvall RC5 
centrifuge (SS-34 rotor), set at 15,900rpm, at 4⁰C, for 30 minutes. The soluble fraction 
was collected, then syringe filtered using a 0.45um filter (Anachem). During 
centrifugation, a gravity flow chromatography column with 0.5ml of HIS-Select
®
 Ni-
NTA affinity gel (Sigma) was prepared by washing the resin with 2 column volumes of 
dH2O, then 3 column volumes of 50mM Tris pH 8.5, 0.3M NaCl. The filtered soluble 
fractions were added to the column, mixed with the nickel resin, and incubated at 4⁰C for 
1 hour, rotating. The column was then emptied by gravity flow, and washed with 5 
column volumes of 50mM Tris pH 8.5, 0.3M NaCl, 20mM imidazole. Elution of his-
tagged mtPAP was performed with 2ml 50mM Tris pH 8.5, 0.3M NaCl, 250mM 
imidazole. The elution was injected onto a HiLoad 16/60 Superdex 200 prep grade size 
exclusion chromatography column (GE Healthcare), connected to an AKTA platform 
(GE Healthcare). The column buffer was 50mM Tris pH 8.5, 0.3M NaCl, flow rate was 
0.1ml/minute, with a column pressure of 0.5 MPa. Fractions were monitored by UV 
absorbance and collected every 2ml. Eluted fractions corresponding to UV absorbance 
peaks were analyzed by 12% SDS-PAGE and staining with Coomassie brilliant blue. The 
fractions harboring correct sized protein were pooled, and concentrated using 30,000 
MWCO Amicon Ultra centrifugal filters (Millipore). Glycerol was added to a final 
concentration of 5%, and the protein aliquoted, flash frozen, and stored at -80⁰C.   
 
129 
 
For recombinant proteins sent from collaborators (wild-type and N478D His-mtPAP, 
LRPPRC, SLIRP, LRPPRC/SLIRP complex), the primary stocks were stored at -80⁰C 
upon arrival. When aliquoting, the frozen stocks were thawed by hand, and quickly 
aliquoted in 0.5ml tubes pre-chilled on ice, then immediately flash frozen. The flash 
frozen aliquots were stored at -80⁰C for future use in polyadenylation assays. 
 
6.2.5   In vitro transcription and radiolabeling of RNA  
 
Templates for in vitro transcription were prepared by PCR amplification. Amplicons 
corresponding to the 3' 277nt of MTND3 and 3' 248nt of MTATP6, with and without 
oligo(A) tails were generated using the primers ND3PAP-F, ND3PAP-R, A6PAP-F, 
A6PAP-R, ATP6RevA8, and ND3RevA8 (c.f. 2.2.4.4). PCR amplicons were purified 
using StrataPrep
®
 PCR purification columns (Agilent Technologies). The template DNA 
was then used in transcription reactions using the Ampliscribe Sp6 transcription kit 
(Epicentre Biosciences). The reaction was assembled as follows: 
Component Volume (ul) 
Template DNA 250ng 
10x Sp6 Reaction Buffer 2 
100mM ATP 1.5 
100mM GTP 1.5 
100mM CTP 1.5 
100mM UTP 1.5 
100mM DTT 2 
SUPERase-In  0.5 
Ampliscribe Sp6 Enzyme Solution 2 
DEPC-treated H2O Up to 20 
 
For radiolabeling RNA transcripts, 5ul of [α-32P]-UTP at 3000 Ci/mmol (Perkins-Elmer) 
was added to the reaction, with corresponding decreases in H2O volume. The 
transcription reaction was incubated for 2 hours at 37⁰C, then had 1ul DNase I (1U) 
added, and continued incubating for 15min. RNA was purified by phenol/chloroform 
extraction and ethanol precipitation, then resuspended in DEPC-treated H2O. For non-
radiolabeled RNA, concentration was determined by UV spectrophotometry. For 
radiolabled transcripts, concentration was measure by scintillation.  
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For higher resolution analysis of in vitro polyadenylation, custom ordered RNA 40nt and 
48nt transcripts from Dharmacon were used as polyadenylation substrates. These 
transcripts corresponded to the 3' 40 nucleotides of MTATP6, with or without an 8nt 
oligo(A) tail.  
 
6.2.6  Polyadenylation Assay  
 
A 10x poly(A) reaction buffer was made up, RNase-free, consisting of 500mM Tris pH 8, 
400mM KCl, 5mM MgCl2, 1mM MnCl2. A typical poly(A) activity reaction was 
assembled as follows: 
 
Component Volume 
10x poly(A) buffer 1ul 
100mM DTT 0.15ul (1.5x concentration) 
100mM ATP 1.5ul (1.5x concentration 
SUPERase-In
TM
 (20U/ul) 0.5ul 
0.5M MgCl2 0.3ul (1.5x concentration) 
RNA 50ng 
DEPC-treated H2O Up to 10ul 
LRPPRC/SLIRP, LRPPRC, or SLIRP (diluted in 
1x poly(A) reaction buffer) 
0.5uM final 
His-mtPAP enzyme (diluted in 1x poly(A) 
reaction buffer) 
0.55uM final 
 
Reactions were assembled as master mixes without mtPAP, starting with the DEPC H2O, 
then adding 10x poly(A) buffer, DTT, ATP, SUPERase-In
TM
, and MgCl2. Recombinant 
wild-type or N478D mtPAP, LRPPRC, SLIRP, or LRPPRC/SLIRP complex were the 
final reaction components, added after the master mixes were assembled and aliquoted. 
The proteins were removed from -80⁰C, and thawed by hand, then diluted in 1x poly(A) 
buffer. They were then immediately added to the in vitro polyadenylation reactions, 
which were placed at 37⁰C for variable time lengths. Any remaining volume of the non-
diluted protein stock was flash frozen, and returned to -80⁰C. Once the polyadenylation 
reaction time was complete, the reactions were quenched by adding 25ul 90% 
formamide/1x TBE/xylene cyanol buffer. The terminated reactions were either stored at -
20⁰C, or directly analyzed. To observe the polyadenylation results, the terminated 
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reactions were either loaded on low-resolution (6%) or high-resolution (15%) 
polyacrylamide/8M urea gels. Low-resolution gels were used for analyzing the 248/277nt 
RNA transcripts, and high-resolution gels were used for analyzing the 40nt RNA 
transcripts. The RNA was electrophoresed at 100V in 1x TBE buffer, for 2-4 hours at 
room temperature. Once electrophoresis was complete, the gels were stained with 1x 
SYBR Gold (Invitrogen) in 1x TBE buffer for 15-40min. The gels were scanned using a 
Typhoon FLA 9500 imager (GE Healthcare), with settings for "SYBR Gold": Long Pass 
Blue filter, 473nm laser, 450V PMT. For analysis of poly(A) extensions, approximate 
lengths were calculated using the log of the molecular weight of the ssRNA standards, 
along with the standard's migration distance through the gel. These values were graphed 
using GraphPad Prism and a best fit line was determined for the ssRNA standards. The 
slope and y-intercept of the line was used to determine the sizes of the poly(A) 
extensions, then nucleotide lengths were calculated from the size determinations. 
 
6.2.7  Electrophoretic Mobility Shift Assay (EMSA) 
 
The EMSA binding reactions were performed in a similar manner to the polyadenylation 
assays, but lacking ATP and the addition of 10% glycerol. The binding reactions were 
assembled as follows, typically as a master mix: 
Component Volume 
10x poly(A) buffer 1ul 
100mM DTT 0.15ul (1.5x concentration) 
SUPERase-In (20U/ul) 0.5ul 
0.5M MgCl2 0.3ul (1.5x concentration) 
RNA 50ng 
Glycerol 0.75ul (5% final) 
DEPC-treated H2O Up to 10ul 
Protein (diluted in 1x poly(A) reaction buffer) 
Varying amounts in 5ul, for a 
total reaction volume of 15ul 
 
Once proteins were added to the reaction, samples were incubated at 37⁰C for 20min. The 
whole samples were then loaded onto 6% polyacrylamide/0.5x TBE gels. Running buffer 
for the gel electrophoresis was pre-chilled 0.5x TBE buffer. The bound and unbound 
RNA/protein complexes were separated by electrophoresis at 100V, at 4⁰C, for 60-80 
minutes. Once separation was complete, the gels were stained with 1x SYBR gold in 0.5x 
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TBE buffer for 20 minutes. Visualization of the RNA/protein complexes was performed 
with a Typhoon FLA 9500, using the "SYBR gold" setting: long pass blue filter, 473nm 
laser, 450V PMT.  
 
6.2.8  Far-UV Circular Dichroism Spectroscopy  
 
This analysis was performed in Professor Alastair Hawkins' lab. Briefly, the wild-type 
His-tagged mtPAP protein was diluted to 0.22mg/ml (3.75uM), and the recombinant His-
tagged N478D protein diluted to 0.21mg/ml (3.58uM) in a buffer consisting of 50mM 
Tris HCl pH 8.5, 0.3M NaCl, and 5% (v/v) glycerol. The instrument used was a Jasco J-
810, with a 0.01cm pathlength. The wavelength scanned was 260nm to 195nm. 5 
cumulative scans were carried out each sample and this was repeated with buffer.  The 
buffer baseline was subtracted from the experimental trace, the data adjusted for 
concentration, and presented as molecular CD units.  
 
6.2.9  Analysis of mtPAP dimerization by size-exclusion   
  chromatography 
 
Calibration standards (GE Healthcare) prepared according to manufacturer's instructions 
and injected onto a Superdex 200 HR 10/30 analytical grade size exclusion 
chromatography column (GE Healthcare), connected to an AKTA platform (GE 
Healthcare). The column was equilibrated overnight with buffer consisting of 50mM Tris 
pH 8.5, 0.3M NaCl, flow rate was 0.1ml/minute, with a column pressure of 0.5 MPa. The 
elution of proteins was monitored by UV absorbance. After elution of the calibration 
standards, wild-type and N478D recombinant mtPAP proteins were diluted to 0.45mg/ml 
in 200ul of the equilibration buffer, and 100ul of each injected onto the column 
separately. The elution fractions of the mtPAP proteins was compared to the elution 
fractions of the calibration standards to ascertain dimerization status.  
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6.3  Results  
 
6.3.1  Generation of wild-type and 1432A>G pGEX-mtPAPΔN  
  construct 
 
 For developing a recombinant mtPAP protein with a fusion tag, initially the 
pGEX-6P-1 vector was used for expression, as the system is well established in our lab. 
The pGEX-6P-1 plasmid is a chemically-inducible, tac promoter driven vector for 
expression of GST-tagged recombinant proteins in E. coli. The protein product produced 
from this vector is fused at the N-terminus to a glutathione S-transferase (GST) tag. This 
promotes solubility, and also serves as a means of purification. Initially, the solubility of 
recombinant mtPAP enzyme was unknown, thus a pro-solubility tag seemed optimal. The 
GST tag binds to glutathione-Sepharose beads, and can be enzymatically cleaved by a 
commercial protease (PreScission Protease), allowing for elution of GST-free 
recombinant protein. The mtPAP amplicon generated for recombinant expression had the 
sequence encoding the first 30 amino acids removed. This region is predicted to be the 
mitochondrial targeting sequence. These sequences are generally hydrophobic, and 
therefore can have an impact on solubility. The targeting sequence is also cleaved off 
when the protein is transported into mitochondria, and the recombinant mtPAP 
 
 
Figure 6.2. Amplification, digestion, and confirmation of the pGEX-mtPAPΔN 
construct 
A. PCR control (lane 1) and mtPAPΔN PCR reaction (lane 2). B. Confirmation of correct construct by excision of the 
insert with BamH1 and Not1 digests. Plasmids were harvested from multiple colonies, with several showing correct 
size inserts (lanes 2, 4-5). The plasmid from lane 4 was used for further recombinant work. 
134 
 
(designated mtPAPΔN) was designed to reflect this mature form. The primers mtPAP6PF 
and mtPAPR2 (c.f. 2.2.4.4) were used in the PCR reaction, and the DNA template was the 
pcDNA5-mtPAPFLAG construct. The region of the gene being cloned for recombinant 
expression was internal to the coding region in the pcDNA5-mtPAPFLAG construct. The 
mtPAPR2 primer was designed to replace the FLAG tag with the five C-terminal peptides 
and stop codon of the protein coding sequence. This PCR reaction was successful, 
generating a product of 1.6 kb (Figure 6.2A). The amplicon was termed mtPAP6p. The 
pGEX-6P-1 vector was BamH1 and Not1 digested, then dephosphorylated to prepare for 
ligation with the mtPAPΔN amplicon. The ligation reaction products were successfully 
transformed into Bioline α-select bacteria, generating many ampicillin-resistant colonies. 
Several were picked for plasmid harvesting, and the resultant plasmids subjected to 
BamH1/Not1 double digestion to confirm the mtPAPΔN insert. As shown in Figure 6.1B, 
multiple colonies harbored the correct pGEX-mtPAPΔN construct. Specifically, colony 
64, as shown in Figure 6.2B, was used for isolating plasmid to transform Rosetta (DE3) 
cells, after it was sequenced to confirm lack of mutations introduced by PCR and 
accuracy of the construct.  
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 For generating the 1432A>G point mutation within the pGEX-mtPAPΔN 
construct, the Quikchange
®
 II Site-Directed Mutagenesis kit was employed. The 
mutagenesis reaction was used to transform bacterial cells for propagation of the mutant 
plasmid. The bacteria were analyzed by restriction digest to confirm presence of the 
mutated construct, then sequenced to verify the correct placement of the point mutation. 
These analyses are shown in Figure 6.3. The 1432A>G mutation creates a BamH1 
restriction digest site within the PAPD1 gene. As a BamH1 restriction site was used for 
cloning the PAPD1 gene into the pGEX-6P-1 vector, digestion with BamH1 creates three 
fragments visible on agarose gel electrophoresis: the vector backbone, the excised 
mtPAP6p insert, and a fragment of the insert corresponding to the length of nucleotides 
between the 5' BamH1 restriction site used for cloning and the BamH1 site generated as a 
result of the point mutation. Figure 6.3A shows this characteristic three fragment pattern 
from BamH1 restriction digestion of the mutant plasmid.  
 
 
 
 
Figure 6.3. Confirmation of the 1432A>G mutation in the pGEX-mtPAPΔN 
construct 
A. The presence of the 1432A>G mutation in pGEX-mtPAPΔN was confirmed using restriction digest analysis, as 
the mutation creates a BamH1 site. The size change and resulting smaller fragment excision are visible via 
separation by 1% agarose gel electrophoresis. B. Sequencing was undertaken to confirm the mutation's presence, as 
well as the fidelity of the insert and insertion into the vector.  
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6.3.2  Expression of wild-type and N478D recombinant 
mtPAPΔN-GST 
 
 With the integrity of the wild-type and 1432A>G pGEX-mtPAPΔN constructs 
verified, the next step was to express the fusion proteins in E. coli cells. Expression of the 
wild-type fusion protein was undertaken first, with the goal of optimizing the process 
before expression and purification of the mutant protein commenced. The first bacterial 
strain used for expressing mtPAPΔN-GST was Rosetta (DE3) cells. The bacterial cells 
were induced under two different conditions to test which produced more soluble protein. 
Cultures were either incubated at 37⁰C for 3 hours, or at 16⁰C overnight. The uninduced, 
induced, soluble, and insoluble fractions were then analyzed by 12% SDS-PAGE and 
Coomassie staining. As shown in Figure 6.4A, it was immediately apparent that the vast 
majority of protein being produced was insoluble, regardless of the incubation conditions. 
There appeared to be small amounts of the fusion protein present in the soluble fraction of 
both conditions, so arbitrarily the 37⁰C incubation fractions were analyzed further. These 
samples were used for immunoblotting with the anti-mtPAP antibody (Figure 6.4B), in 
order to confirm the identity of the protein size assumed to be mtPAPΔN-GST on the 
comassie stained gel. The product visualized on the immunoblot appeared at the weight 
 
 
Figure 6.4. Expression of recombinant mtPAPΔN-GST fusion protein 
A. Coomassie stain showing two incubation conditions of Rosetta cells, with separate fractions. The expected size of 
mtPAP is approximately 92 kDa. B. Fractions from 3 hours at 37⁰C were separated with SDS-PAGE, then 
immunoblotted using an antibody against mtPAP. The soluble fraction showed mtPAP at an increased size, as  
expected with the GST fusion product. Fibroblast whole cell lysate (20ug) was loaded to act as a size comparison for 
mtPAP and mtPAPΔN-GST.  
137 
 
expected for the mtPAPΔN protein with the GST tag, an increase in size of approximately 
26 kDa, from 60kDa to 86kDa. 
 In an attempt to improve upon the expression profiles observed in the Rosetta 
cells, the Tuner strain of bacteria was transformed with the pGEX-mtPAPΔN construct. 
Tuner cells can be induced in a concentration-dependent manner with IPTG. Six cultures 
were generated from a transformed colony to be induced with three separate 
concentrations of IPTG and incubated either overnight at 4⁰C or 3 hours at 37⁰C, as 
outlined in Figure 6.5. None of these conditions in the Tuner strain produced more 
soluble fusion protein than the original conditions described earlier (data not shown). As 
use of the Rosetta (DE3) cells was well established, further work with the Tuner cells was 
suspended and Rosetta cells were returned to as the expression vehicle of choice. Based 
on the reports from Naigaike et al. and Bai et al. there was not an expectation of needing 
large amounts of recombinant protein for in vitro studies. Thus, the amount of soluble 
mtPAPΔN-GST expressed in the Rosetta cells seemed sufficient to attempt scaling up the 
culture size, as the small amounts of protein recoverable would be enough for 
experimental needs.  
 The expression of N478D mtPAPΔN-GST was the next priority. The mutation is 
not predicted to massively alter the conformation of the enzyme, so major changes in 
solubility of the mutant recombinant fusion protein were not expected. The Rosetta (DE3) 
cells were transformed with the mutated pGEX-mtPAPΔN plasmid, and induced in the 
same manner as the wild-type expression. As shown in Figure 6.6, the expression and 
solubility profile of the mutant recombinant protein is essentially identical to the wild-
Figure 6.5. The Incubation Conditions and IPTG Concentrations used for Tuner 
Strain mtPAPΔN-GST Expression 
Schematic of the assorted conditions tested for mtPAPΔN-GST expression using the Tuner strain of bacteria.  
Tuner Bacterial 
Cells 
16C 
Overnight 
0.05mM 
IPTG 
0.1mM 
IPTG 
0.2mM 
IPTG 
37C for 3 
hrs 
0.05mM 
IPTG 
0.1mM 
IPTG 
0.2mM 
IPTG 
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type. Once again there is a very small percentage of the total expressed protein present in 
the soluble fractions. As with the wild-type, this small percentage would potentially still 
be sufficient with larger cultures prepared, considering the small amounts of enzyme used 
in in vitro assays reported in previous research articles.   
   
 
 6.3.3  Analysis of mtPAPΔN behavior in solution 
 
 Large 500ml cultures were prepared for both wild-type and N478D mtPAPΔN 
expression. The final overnight incubation is with the Prescission Protease at 4⁰C, after 
which the cleaved recombinant protein is eluted. The proteins were eluted in PBS, with 
0.5mM ATP and 2mM MgCl2. In order to assess aggregation or precipitation of the 
cleaved protein, I examined the protein in solution at three separate storage temperatures, 
with or without 50% glycerol added. The purpose of which was to determine optimal 
storage conditions for the cleaved enzyme. The aggregation of the protein was assessed 
using dynamic light scattering (Figure 6.7). Ideally, the particle of interest will be a size 
between 10nm and 100nm, with all 5 traces virtually superimposable. The condition that 
led to the optimal particle size readings was primarily lack of glycerol added to the 
solution. Although it is possible that 50% glycerol was too high a concentration. All three 
temperatures of storage produced similar readings, although -20⁰C storage appeared to be 
the most favorable condition, as can be seen by the consistent DLS readings and size of 
the particle (approximately 20nm).    
 
 
Figure 6.6. Expression and solubility of N478D mtPAPΔN-GST 
Comassie stained gel showing two colonies of Rosetta cells expressing N478D mtPAPΔN-GST. The expected 
size of the mutant mtPAP is approximately 92 kDa, unchanged from the wild-type. The majority of the expressed 
protein was still in the non-soluble fractions.  
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  The in vitro polyadenylation assay was based on the method detailed in Bai et al. 
The buffer composition from their procedure was used, as was the reaction temperature 
and gel electrophoresis conditions. The RNA substrate, however, differed. Rather than 
using pre-cleaved mRNA from the pG3SVL-A plasmid, my experiments used RNA 
transcripts corresponding to regions of mitochondrial mRNAs. I generated [
32
P] 
radiolabeled transcripts corresponding to the final 248nt of the MTATP6 transcript, and 
the final 277nt of the MTND3 transcript. Approximately 50-200ng of the wild-type and 
N478D mtPAPΔN proteins were incubated at 30⁰C for 30min with radiolabeled 
transcripts (approximately 1000cpm) in 1x reaction buffer with ATP, DTT, and RNase 
inhibitor. 
 Over the course of several polyadenylation assays, each analyzed by separation on 
a 6% polyacrylamide/8M urea gel and developed by autoradiography, the results failed to 
show poly(A) extensions on the radiolabeled transcripts. This was true for both the wild-
type and mutant mtPAPΔN. The concentration of recombinant protein in the reactions 
was difficult to increase due to the minute amounts of soluble protein being generated.  
 
 
Figure 6.7. Analysis of mtPAPΔN in solution by dynamic light scattering. 
Purified mtPAPΔN was stored at three separate temperatures, with or without 50% glycerol added to the buffer, for 24 
hours. The next day samples of 20ul were taken from the stored aliquots and analyzed by DLS. Monodispersed protein 
is represented by a uniform peak between 10 and 100nm. Larger peaks may indicate aggregation of protein. Each 
graph represents a series of five measurements.  No glycerol and storage at -20⁰C gave the best results.  
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 After the failed polyadenylation assays were analyzed, the decision was made to 
contact the authors of Bai et al. and request the plasmid reported in the paper for use in 
this work's recombinant mtPAP expression. This would benefit from following a protocol 
optimized for generating soluble mtPAP, and allow the project to move forward with a 
validated expression construct. 
 
6.3.4  His-mtPAP expression and generation of the 1432A>G  
  substitution in the pET28a-PAPD1 construct 
  
 The construct, designed and assembled in Liang Tong's lab at Columbia 
University, is a 44-538 residue fragment of mtPAP cloned into the pET28a(+) vector 
using the NotI and NdeI 
restriction sites. This generates 
an N-terminal 6xHis-tagged 
version of mtPAP, allowing for 
affinity purification using 
nickel-charged resin. The 
cloning, propagation, expression 
and purification of the plasmid 
and its product is detailed in Bai 
et al. These methods were 
largely adopted here. I 
transformed α-select cells for 
propagating the plasmid, and 
Rosetta (DE3) cells for 
expressing the recombinant 
protein. The initial expression 
results were encouraging. An 
initial half liter of transformed 
Rosetta culture was lysed, using new buffer for resuspension of the pelleted cells and 
subsequent sonication, based on Bai et al's methods (50mM Tris pH 8.5, 0.3M NaCl, 1 
tab protease inhibitors, 1mM PMSF, 1ul Benzonase). The sonicated suspension was 
separated into soluble and non-soluble fractions by centrifugation, then the soluble 
supernatant was placed into a gravity flow chromatography column loaded with Ni-NTA 
 
 
Figure 6.8. Initial expression and affinity 
purification of 6xHis-tagged mtPAP 
His-mtPAP was expressed in Rosetta (DE3) cells overnight with 
1mM IPTG at 20⁰C. The recombinant enzyme was then purified 
from lysed bacteria using nickel affinity chromatography. The gel 
lanes are induced bacterial lysate soluble fraction (lane 1), an initial 
1ml of elution buffer passed through the column (lane 2), and a 
second 1ml of elution buffer passed through the column (lane 3). 
These samples were separated by 12% SDS-PAGE and the gel 
stained with Coomassie Brilliant Blue, dried, and imaged.   
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resin. Once the supernatant had flowed through, and the resin was washed with buffer, the 
bound His-mtPAP was eluted using a high concentration of imidazole (0.25M). The 
results of the elution are shown in Figure 6.8. The expected recombinant product was 
observed, migrating at approximately the mature 60kDa size, a decrease from the 66kDa 
full-length enzyme. The yield of soluble protein bound to the nickel resin was 
significantly greater than observed with the mtPAPΔN-GST recombinant protein. As 
shown in Figure 6.8 (lanes 2-3 compared to lane 1), the amount of soluble His-mtPAP is 
not dramatically higher than other soluble proteins present in the bacterial supernatant. 
Most of the expressed protein is likely still in the non-soluble fraction. The yield that is 
available in the soluble form, however, was enough of an increase over mtPAPΔN-GST 
expression levels to justify further use of the His-mtPAP system.  
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 As a result of using imidazole to elute the His-tagged protein from the nickel 
resin, removal of the imidazole (present at 250mM in the elution buffer) is necessary. 
This can be accomplished in a variety of ways. Dialysis with buffer that does not contain 
imidazole is one solution, another is size-exclusion chromatography, which has the added 
benefit of further purifying the extract from the nickel resin. Size-exclusion 
chromatography was chosen as the second purification step as it was the method of choice 
in Bai et al. A HiLoad 16/60 Superdex 200 prep grade size exclusion chromatography 
column was used for the gel filtration. The purity of the fractions eluted from the 
chromatography column were a marked improvement from the affinity purification step, 
as shown in Figure 6.9A (lane 6). The chromatogram from the AKTA showed a 
characteristic two peak profile during the column run (Figure 6.9B). Only the second 
peak corresponded to the His-mtPAP protein. Figure 6.9A (lane 5) shows, to a better 
 
 
 
Figure 6.9. Purification of His-mtPAP via size exclusion chromatography 
A. His-mtPAP recombinant protein was purified using nickel affinity chromatography, followed by size-
exclusion chromatography. Samples taken from each step of purification were separated by 12% SDS-PAGE, 
and the gel stained with Coomassie Brilliant Blue. B. Chromatogram produced by the AKTA platform used for 
performing the size-exclusion chromatography. The characteristic dual peaks are present, represented by the dark 
blue line.   
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extent, the increase in yield of soluble recombinant protein that the pET-PAPD1 construct 
provided. This was coupled with information gained from consulting members of 
Professor Tong's lab, specifically Dr. Jeong Ho Chang, specifically regarding expression 
of His-mtPAP. Their recommendation was performing much larger bacterial preparations 
and purifications in order to generate enough protein to pool into stocks with high His-
mtPAP concentrations. With the expression data from our lab for His-mtPAP, as well as 
recommendations for larger purifications, I then moved on to generating a mutant version 
of His-mtPAP.  
 The process for producing the 1432A>G substitution in the pET28a-PAPD1 
construct followed in exactly the same manner as mutating the pGEX-mtPAPΔN 
construct. The Quikchange II Site-Directed Mutagenesis kit was again employed, with the 
same set of primers used to create the mutation. Figure 6.10A shows confirmation of the 
1432A>G substitution in the plasmid, which will alter the asparagine residue to an 
aspartate. The mutated plasmid was then used to transform α-select and Rosetta (DE3) 
bacterial strains, for plasmid propagation and protein expression, respectively. As 
illustrated in Figure 6.10B, the N478D His-mtPAP appeared to express at a similar level 
to the wild-type His-mtPAP protein. At this point, with both wild-type and mutant protein 
generated, the next priority was assessing their in vitro polyadenylation activity.  
 
A 
 
 
 
Figure 6.10. Production of the N478D His-mtPAP 
A. Electropherogram of mutant pET28a-PAPD sequencing, to confirm the presence of the 1432A>G point 
mutation. B. Coomassie stained gel of mutant His-mtPAP purification by nickel affinity chromatography.  
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6.3.5  Initial His-mtPAP poly(A) assay results 
 
 The initial attempts at observing in vitro polyadenylation activity using the His-
mtPAP enzyme were based partly on the methodology from Bai et al. RNA transcripts 
corresponding to the 3' 248nt of the MTATP6 mt-mRNA were radiolabeled, incubated 
with His-mtPAP, separated on a 6% polyacrylamide/8M urea gel, then visualized with 
autoradiography. Changes in substrate length due to polyadenylation were actually 
visible, and corresponded to increases in protein concentration in the assay reactions. As 
shown in Figure 6.11, the signal for the naked 3' end ATP6 substrate RNA diminishes as 
the concentration of wild-type His-mtPAP increases (lanes 4-5). There also appears to be 
an increase in signal above the substrate, which may be polyadenylated RNA. E. coli 
poly(A) polymerase (PAP) was included as a positive control for the assay (lane 6), and 
all substrate appears shifted to larger species. While the results were encouraging, 
particularly compared to the assays using mtPAPΔN-GST, the resolution and 
interpretation of the results were not particularly clear. This was the first evidence 
however, in our lab, that mtPAP was capable of adenylation without other factors needing 
to be present.  
 
 
 
 
 
Figure 6.11. Early stage in vitro polyadenylation reactions. 
Wild-type (lanes 4-5) and N478D His-mtPAP (lanes 1-3) produced in our laboratory used in polyadenylation 
reactions. E. coli PAP included as positive control (lane 6). RNA substrate was radiolabeled with [α-32P] UTP. The 
poly(A) reactions were separated by polyacrylamide/urea gel electrophoresis, then the gel dried and visualized by 
autoradiography.  
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 The wild-type and N478D mutation His-mtPAP enzymes poly(A) activity were 
compared, to assess potential differences in polyadenylation. Figure 6.11 shows several 
amounts of wild-type (lanes 4 – 5) and N478D (lanes 1 – 3) His-mtPAP poly(A) activity 
compared. It is suggestive that there is more activity in the wild-type reactions than in the 
mutant reactions. Whether the mutant His-mtPAP is generating the oligo(A) tails 
observed in vivo is unclear from this gel. The most clear change is the decrease in RNA 
substrate signal that likely amount to size changes resulting from polyadenylation. The 
actual signals from polyadenylated transcripts are less clear, and more difficult to 
interpret. Despite these hurdles, this assay suggested the N478D mutation may directly 
affect poly(A) activity of the enzyme. The results also provide potential evidence that the 
mutant does retain some amount of enzymatic activity, albeit significantly less than the 
wild-type. This is shown by decrease in the non-adenylated substrate signal compared to 
the no enzyme lanes.   
 While these poly(A) assay gels provided some preliminary insight as to the 
polyadenylation capabilities of the recombinant protein, and to differences between the 
wild-type and mutant enzymes, the aesthetic quality and clarity of the results were poor. 
There were multiple issues with the recombinant protein stocks as well. The 
concentration of the protein eluting from the nickel affinity gel was high, but the 
background proteins carried over was unsatisfactory, and the high amount of imidazole 
present was problematic. Both of these issues were solved by implementing gel filtration 
kDa 
 
 
Figure 6.12. Coomassie staining of wild-type and N478D His-mtPAP from the 
Tong lab. 
Wild-type (lane 1) and N478D His-mtPAP (lane 2) stocks (1ul) were separated by 12% SDS-PAGE and stained with 
Coomassie Brilliant Blue. The stocks were estimated at 6mg/ml and 9mg/ml for the wild-type and mutant protein, 
respectively.   
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as a second purification step. However, further problems were encountered when it came 
to concentrating the fractions eluting off the gel filtration column. Both wild-type and 
mutant His-mtPAP appeared very prone to sticking to the membranes of concentrator 
columns. This was a major issue, as higher concentrations are required in order to dilute 
out the storage buffer for use in the polyadenylation assays. This in turn made 
measurements for use in activity assays difficult, affecting replication and interpretation 
of results. These problems were largely technical in nature, and with time, would likely 
have been able to be resolved. Professor Liang Tong and a postdoctoral researcher in his 
lab, Dr. Jeong Ho Chang had already provided consultation about the recombinant 
expression of the His-mtPAP protein, as we were using their pET28a-PAPD1 expression 
construct. Rather than allow the momentum of the research to be slowed by the 
potentially extensive troubleshooting of the purification/concentrating, the decision was 
made to establish a formal collaboration with Professor Tong's lab. Dr. Chang at 
Columbia University was sent the mutant plasmid, and they provided high concentration 
stocks of the wild-type and mutant His-mtPAP protein. This allowed the experiments on 
in vitro activity to continue, while the difficulties with the purification of the recombinant 
enzymes in our lab could be resolved. Figure 6.12 shows the comparison of the protein 
concentrations of the enzyme stocks. The wild-type protein stock was 6mg/ml, and the 
N478D mutant was 9mg/ml. The following experiments in this chapter were performed 
using the recombinant wild-type and N478D His-mtPAP that was sent to our lab from 
Professor Tong.  
 
 
6.3.6  Analysis of secondary structure for wild-type and N478D  
  His-mtPAP 
 
 In order to assess possible structural impacts from the N478D mutation, both 
wild-type and mutant recombinant His-mtPAP protein were examined using far-UV 
circular dichroism spectroscopy. This method is able to estimate secondary structure of 
proteins. By comparing the wild-type spectroscopic signature to that of the mutant, 
inferences as to changes in the secondary structure as a result of the mutation can be 
made. Figure 6.13 shows the spectra of the two enzymes. The signatures are virtually 
superimposable. The spectra are also consistent with that of well-folded proteins. The 
intensity of the signal from the mutant protein is greater than that for the wild type 
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protein, and this would typically imply greater secondary structure. However it is unlikely 
that a mutation would increase rather than decrease secondary structure. The difference in 
intensity likely stems from minor imprecision in measurement of protein concentrations, 
as the Nanodrop spectrophotometer has limited sensitivity. The spectroscopic data 
suggest that the N478D mutation does not cause major disruption to the enzyme structure.  
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Figure 6.13. Analysis of wild-type and N478D recombinant His-mtPAP by far-UV 
circular dichroism spectroscopy. 
Wild-type (blue line) and N478D (green line) His-mtPAP were analyzed in a solution of 50mM Tris HCl pH 8.5, 
0.3M NaCl, 5% (v/v) glycerol buffer. Both spectra results are consistent with well-folded proteins, and virtually 
overlap. The measurements were carried out with a Jasco J-810 instrument, with a cuvette pathlength of 0.01cm.  
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6.3.7  Analysis of wild-type and N478D His-mtPAP dimerization 
 
 One potential effect of the 
mutation was disruption of 
dimerization. According to Bai et al. 
2011, dimerization is necessary for 
enzymatic activity. As the mutant had 
shown reduced activity in the 
preliminary assays, its potential 
monomer status had to be investigated. 
To accomplish this, both the wild-type 
and N478D recombinant His-mtPAP 
were injected on to an analytical grade 
size exclusion chromatography 
column, used for high resolution 
separation of proteins. The elution 
fractions of the His-mtPAP proteins 
were compared to calibration standards 
of known and varying size. As showin 
in Figure 6.14, the peaks for wild-type 
and N478D His-mtPAP were both located very close to the elution peak of aldolase, a 
158kDa protein. As neither protein was eluted after conalbumin, a 75KDa protein, it did 
appeared that neither wild-type nor N478D His-mtPAP enzyme adopts a monomeric form 
in solution. This effectively ruled out the mutation causing a disruption of the dimeric 
state previously reported to be the only active form of mtPAP.  
 
 
6.3.8  Optimization of the fluorescent poly(A) activity assay 
 
 With high-concentration stocks of the recombinant His-mtPAP enzymes, I was 
able to convert the poly(A) activity assay to a fluorescent, rather than radiolabeled, 
platform. The major change from previous experiments was not radiolabeling the RNA 
substrates used in the poly(A) reactions, but staining the gels on which the products had 
been separated with SYBR gold, a fluorescent nucleic acid-binding dye. The dye can be 
 
Figure 6.14. Analysis of wild-type and 
N478D His-mtPAP multimerization. 
Wild-type and N478D His-mtPAP (4.5ug) were assessed by 
analytical grade size exclusion chromatography. Elution 
fractions for ferritin (440KDa), aldolase (158kDa) and 
conalbumin (45kDa) are indicated.  
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visualized by scanning the gel itself with the 473nm laser on a Typhoon imager. This 
approach provided much cleaner data, with a quicker turnaround time, as no long 
exposure times associated with autoradiography were necessary.  
 The initial experiments utilizing this fluorescent approach, and employing the 
Tong lab-produced recombinant His-mtPAP examined the amount of poly(A) activity 
relative to the protein levels in the reactions. The oligoadenylated MTND3 RNA substrate 
was used in the initial assays. An RNA concentration of 0.25uM was employed for these 
assays, as it was easily visualized using SYBR Gold. As Figure 6.15A demonstrates, the 
degree of size change as a result of polyadenylation increases with the amount of His-
mtPAP input into the reaction. The other condition tested in the experiment was whether 
the activity changes as a result of a single round of freeze-thawing, provided the thawed 
 
 
 
 
Figure 6.15. Optimizing conditions for the fluorescent poly(A) activity assay. 
A. Varying amount of one or two freeze-thaw cycled wild-type His-mtPAP (0.55uM) were incubated with RNA 
substrate (0.25uM) for 1hr at 37⁰C. Reactions were quenched with 90% formamide/1x TBE, separated through a 6% 
polyacrylamide/8.3M urea gel, then stained with SYBR gold. Stained products were visualized by scanning with a 
Typhoon FLA 9500 instrument. B. The effect of different incubation temperatures for the poly(A) assay was 
investigated, then analyzed in the same manner as A. The RNA substrate in A and B was a 278nt oligo(A) 3' fragment 
of MTND3. 
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protein is quickly flash frozen once the necessary amount is removed. This provided an 
approximate understanding of whether stocks of protein could be used again in assays if 
thawed once before. Figure 6.15A demonstrates that the polyadenylation activity from a 
single thawing cycle versus two does not appear to differ significantly.  
 Another assay condition investigated was the optimal incubation temperature of 
the polyadenylation reaction. Other reports detailing in vitro polyadenylation reactions 
have incubated reactions at 30⁰C. The poly(A) assay was carried out at this temperature, 
as well as 37⁰C to observe any differences in enzymatic activity. In parallel, I tested 
whether heating the reactions to 55⁰C after the addition of formamide prior to loading on 
to the gels aided in electrophoresis results. It was imperative that the lengths of the 
poly(A) tails being generated in the in vitro reactions were able to be measured. Towards 
this end, a ssRNA ladder was included in the gels analyzing the poly(A) results.  
 Figure 6.15B illustrates the results of the conditions tested on polyadenylation 
activity, as well as the inclusion of the ssRNA size markers. An obvious aspect of the 
reactions is the length of poly(A) tail being generated. While the majority of the lengths 
appear to be within the physiological 40-60nt range, there is a significant amount of 
product even extending up to approximately 1000nt. Poly(A) tails extended to such a 
degree have not been observed in mitochondria. Incubating the polyadenylation reactions 
at 30⁰C versus 37⁰C seemed to affect the distribution of larger poly(A) length, tighter at 
30⁰C, more disperse at 37⁰C. There did appear to be less remaining non-adenylated RNA 
substrate at 37⁰C, compared to 30⁰C, although the difference is not great. For this reason, 
37⁰C continued to be the incubation temperature utilized in these in vitro assays.  
 Heating the reactions in formamide prior to loading had a negative effect on 
poly(A) length on gel separation. Whether this is due to degradation of the RNA or is a 
gel migration issue, is unclear. The reactions were no longer heated prior to loading on 
gels for future assay analysis.  
 
6.3.9  Wild-type and mutant His-mtPAP nucleotide affinities 
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 A potential explanation for the reduced polyadenylation observed with the N478D 
mutant mtPAP could be alterations to its affinity for ATP. Thus, I sought to examine the 
polyadenylation activities of the wild-type and mutant enzymes in the presence of several 
concentrations of ATP. Discussions with structural biologist and crystallographer 
Professor Rick Lewis (Newcastle University) yielded the hypothesis that the N478D 
mutation could potentially have shifted the affinity of the active site from ATP towards 
GTP as a substrate. So in addition to poly(A) reactions with a titration of ATP, I 
performed the same reactions in the presence of different concentrations of GTP. The 
results are shown in Figure 6.16. The wild-type enzyme exhibited an affinity for ATP, 
with major activity between 0.1mM and 1mM ATP concentrations. It is difficult to 
determine if there is any activity for the N478D His-mtPAP in the presence of ATP, or if 
the extensions are too short to be resolved clearly on the gel. On the 6% polyacrylamide 
A 
 
B 
 
 
 
 
Figure 6.16. Nucleotide affinities for wild-type and N478D His-mtPAP 
A Wild-type His-mtPAP (0.55uM) activity with titrations of ATP and GTP. B N478D His-mtPAP (0.55uM) activity in 
the presence of ATP and GTP titrations. A gel artifact is present at 500nt. The RNA substrate in A and B were different 
preparations of the 277nt 3' fragment of MTND3 (0.25uM). Reactions were quenched with 90% formamide/1x TBE, 
separated through a 6%  polyacrylamide/8.3M urea gel, then stained with SYBR gold. Stained products were visualized 
by scanning with a Typhoon FLA 9500 instrument. 
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gels, the resolution within the physiological poly(A) length range is poor. Only the larger 
sizes are able to be clearly measured in these gels. Neither protein can utilize GTP to any 
significant degree. Again, assessment of polyadenylation in the physiological length 
range is difficult here. Certainly, the hypothesis of the N478D mutation conferring GTP 
nucleotide preference is refuted by these results, at least to the extent that GTP would 
confer any activity comparable to ATP.  
 
 
6.3.10 Comparison of oligoadenylated vs non-oligoadenylated  
  transcripts as substrates for poly(A) extensions 
  
 The presence of oligo(A) tails on mt-mRNAs in systems where mtPAP is knocked 
down (Slomovic and Schuster, 2007), as well as LRPPRC knock-outs (Ruzzenente et al., 
2012), raises the possibility that oligoadenylation is a step that precedes polyadenylation. 
It is possible that the oligoadenylated 3' termini present a more optimal substrate for 
mtPAP, rather than a naked 3' end. In order to test this possibility, both oligoadenylated 
(with 8 adenines) and naked 3' end transcripts (prepared as detailed in 6.2.5) were 
incubated with wild-type His-mtPAP enzyme. The results are shown in Figure 6.17. 
Wild-type His-mtPAP does not appear to utilize the +/− oligo(A) substrates differently. 
The characteristic two populations of polyadenylated transcripts are present, the 
physiological poly(A) lengths and the super-adenylated lengths. In the case of the ATP6-
A8 RNA, more of the starting substrate is extended by adenylation, however this may be 
 
 
Figure 6.17. Polyadenylation of oligoadenylated and naked 3' end transcripts 
Wild-type His-mtPAP (0.55uM) was incubated with oligo(A8) and naked 3' end ATP6 RNA 248nt transcripts (0.25uM) 
in the presence of increasing concentrations of ATP. RNA loading between oligoadenylated and non-oligoadenylated 
RNA is unequal (lane 1 vs 4) but consistent within each transcript panel (1-3 or 4-6). Reactions were incubated at 37⁰C 
for 1 hour, then quenched with 90% formamide/1x TBE, separated through a 6% polyacrylamide/8.3M urea gel, then 
stained with SYBR gold. Stained products were visualized by scanning with a Typhoon FLA 9500 instrument.  
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due to the relative amounts of RNA in the reactions. The signal from each substrate alone 
are not equal, indicating a difference in the amount of transcript used in each reaction. 
However, the amount added was but consistent within each transcript panel. Thus, the 
complete shift of substrate transcript into the adenylated form in the ATP6-A8 reactions 
may be due to less RNA being present to be adenylated.  
   
6.3.11 Polyadenylation in the presence of LRPPRC and   
  LRPPRC/SLIRP complex 
 
 Chujo et al. claimed that LRPPRC was a requirement for optimal mtPAP 
polyadenylation (Chujo et al., 2012). Their data reported showed no mtPAP activity in 
the absence of LRPPRC. At this point, however, multiple experiments in my study had 
shown polyadenylation activity from His-mtPAP alone, without putative associated 
factors. In addition, various other reports of in vitro mtPAP activity exist (Nagaike, 2005; 
Bai et al., 2011). Still, these results did not rule out some sort of effect as a product of 
LRPPRC interaction. To investigate this possibility, our lab established the second major 
collaboration for this study, with Professor Nils-Goran Larsson and Dr. Henrik Spahr. In 
their lab they have generated recombinant LRPPRC, as well as co-expressed recombinant 
 
 
Figure 6.18. The effect of LRPPRC and LRPPRC/SLIRP complex on 
polyadenylation 
A. Wild-type His-mtPAP (0.55uM) was incubated either alone, or with 5nM, 50nM, or 500nM of LRPPRC or 
LRPPRC/SLIRP complex. The RNA substrate (0.25uM) was the 3' 248nt ATP6 transcript. B. Same reaction conditions 
as in A, but the RNA substrate was oligoadenylated. Reactions were incubated for 1 hour at 37⁰C. Reactions were then 
quenched with 90% formamide/1x TBE, separated through a 6% polyacrylamide/8.3M urea gel, and stained with SYBR 
gold. Stained products were visualized by scanning with a Typhoon FLA 9500 instrument. 
A 
B 
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LRPPRC complexed with SLIRP. As anecdotal reports of the difficulty of expressing 
recombinant LRPPRC, and indeed any other PPR protein, (Professor Lightowlers, 
personal communication) persist, the decision was made to collaborate with a group that 
had navigated the process successfully. Their lab sent high concentration stocks of the 
recombinant proteins, and I proceeded to carry out experiments designed to dissect the 
relationship of LRPPRC, SLIRP, and mtPAP in our in vitro system.   
 The first experiments carried out were examining the effect of LRPPRC and the 
LRPPRC/SLIRP complex on polyadenylation of oligo(A) and non-oligo(A) transcripts in 
the presence of the wild-type His-mtPAP. The results, shown in Figure 6.18, were 
contrary to the claims of Chujo et al. As the amount of LRPPRC increased in reactions 
with His-mtPAP, the amount of super-adenylated transcript appeared to decrease. The 
same pattern was exhibited with the LRPPRC/SLIRP complex. There did not appear to be 
an obvious increase in poly(A) activity. The physiological range of lengths did not seem 
to differ significantly, or consistently, with either LRPPRC or LRPPRC/SLIRP. Again, 
the resolution on the 6% polyacrylamide gels is not optimal for analysis of those poly(A) 
lengths. The LRPPRC/SLIRP complex had a greater inhibitory effect on super-adenylated 
extensions with non-oligo(A) RNA as the substrate.  
 To examine whether the inhibitory effect observed on these gels was a result of 
LRPPRC or LRPPRC/SLIRP directly, or a product of increased general protein 
concentration in the reactions, BSA was titrated into poly(A) reactions with wild-type 
 
 
 
Figure 6.19. The effect of BSA on in vitro polyadenylation activity.  
Poly(A) reactions consisting of wild-type His-mtPAP (0.55uM) were incubated in the presence of increasing amounts 
of BSA to control for protein-concentration specific effects on poly(A) activity. BSA was titrated from 0.05-1.1uM. 
Reactions were incubated for 1 hour at 37⁰C. Reactions were then quenched with 90% formamide/1x TBE, separated 
through a 6% polyacrylamide/8.3M urea gel, and stained with SYBR gold. Stained products were visualized by 
scanning with a Typhoon FLA 9500 instrument.   
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His-mtPAP. As shown in Figure 6.19, there are similarities between the LRPPRC, 
LRPPRC/SLIRP, and BSA effects. There is mild inhibition of the super-adenylated 
extensions, starting at equimolar (0.55uM) concentrations of BSA to His-mtPAP. 
However, the inhibition of super-adenylated lengths is not exactly identical to those seen 
with LRPPRC or LRPPRC/SLIRP. This leaves open the possibility that the inhibitory 
effects on super-adenylation by LRPPRC and LRPPRC/SLIRP are comprised of a mix of 
direct interaction and inhibition of enzymatic activity from higher protein concentrations 
in the reactions.   
 
6.3.12 Analysis of N478D mutant activity by high-resolution 
poly(A) assay 
 
 As the results from the in vitro poly(A) assay (using 248/277nt RNA transcripts 
and separating the products by 6% polyacylamide/8M urea gel electrophoresis) were 
examined, it became increasingly clear that the ability to measure polyadenylation 
products within the physiological range of lengths was critical to interpreting the data. 
This ability was not properly developed in the assay. While differences between the wild-
type and mutant His-mtPAP enzymes, and with/without LRPPRC or LRPPRC/SLIRP 
were apparent in the "super-adenylated" populations of transcripts, the relevance of those 
extension lengths in vivo was not clear. It was essential the physiological range of 
poly(A) lengths be examined in greater detail, and the in vitro poly(A) assay needed to be 
modified to address this crucial point.  
 To produce a higher resolution analysis of recombinant polyadenylation activity, 
several changes were made to the assay. New RNA substrates were employed, these were 
commercially generated 40 and 48 nucleotide RNA oligomers from Dharmacon, 
corresponding to the terminal 3' 40 nucleotides of the MTATP6 transcript, with or without 
an eight adenine oligo(A) tail. Usage of these RNA oligomers overcame a consistent 
problem from using in vitro transcribed RNA substrates, namely, the high levels of 
nucleotides necessary for the transcription reactions often carried over to the purified 
RNA. This caused quantitation difficulties, as the primary method of quantifying the 
RNA was via Nanodrop UV absorbance analysis. The extraneous nucleotides distorted 
the readings and often caused overestimation of RNA concentrations. This made for 
inconsistent inputs of RNA into poly(A) reactions, which complicated interpretation of 
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results at times. This problem was solved with the new oligomers, and more precise 
measurement of the RNA quantities input to poly(A) reactions was obtained.  
 The second change to the in vitro assay was increasing the polyacrylamide 
percentage in the gels used for separating the reaction products. The gels were increased 
from 6% polyacrylamide to 15% polyacrylamide. This allowed for a greater degree of 
separation for the smaller RNA molecules, and would hopefully impart the level of 
resolution necessary to examine poly(A) tails in the physiological range of lengths.  
 For the first experiment with the high-resolution approach, wild-type and mutant 
His-mtPAP activity on oligo(A) and non-oligo(A) RNA was analyzed. As Figure 6.20 
details, the poly(A) extension generated by the wild-type His-mtPAP is approximately 
30-40nt long. This measurement is much more accurately confirmed with this high-
resolution gel approach. The extensions generated by the mutant enzyme are able to be 
visualized with much greater detail, and surprisingly, appear to match the oligo(A) tails 
observed with the MPAT in the homozygous 1432A>G PAPD1 fibroblasts. These short 
adenine tails are approximately 5-10nt long. When the oligoadenylated 40-mer (RNA14-
A8) is utilized as the substrate, no subsequent increase in adenylate tail length results. 
Equimolar amounts of BSA to His-mtPAP were incubated with the RNA substrates 
 
 
Figure 6.20. High-resolution poly(A) analysis of wild-type and mutant 
polyadenylation of oligo(A) and non-oligo(A) RNA substrates. 
Wild-type (0.55uM, lanes 2, 6) or N478D His-mtPAP (0.5uM, lanes 3,7) was incubated with oligo(A) and non-oligo(A) 
40nt RNA substrates (0.25uM) corresponding to 3' end of MTATP6. BSA (0.55uM, lanes 4,8) was included as a control 
for protein concentration. Incubations were for 1 hour at 37⁰C. Reactions were then quenched with 90% formamide/1x 
TBE, separated through a 15% polyacrylamide/8.3M urea gel, and stained with SYBR gold. Stained products were 
visualized by scanning with a Typhoon FLA 9500 instrument. Gel lanes were analyzed by densitometry using Image J. 
Distance of RNA migration through the gel was used for calculating mean lengths of the poly(A) extensions. 
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(without His-mtPAP present) to control for non-enzymatic protein effects on RNA 
integrity and migration. Confident in the technique, the subsequent series of experiments 
continued usage of the modified procedure for poly(A) analysis.  
 
6.3.13 High-resolution analysis of the effect of LRPPRC and  
  LRPPRC/SLIRP complex on polyadenylation 
 
 Low-resolution analysis of the in vitro polyadenylation products had not shown 
dramatic differences between LRPPRC and the LRPPRC/SLIRP complex in terms of 
their pro- or anti-poly(A) 
effects. To determine whether 
the effects were too subtle to 
be detected by the more 
cumbersome "low resolution" 
poly(A) assay, and to more 
thoroughly investigate 
poly(A) lengths within the 
likely more relevant 
physiological length range, 
the "high resolution" analysis 
was employed. Similar to the 
previous poly(A) reactions, 
wild-type His-mtPAP was 
incubated with equimolar 
amounts of LRPPRC, 
LRPPRC/SLIRP, and BSA. 
The RNA substrate was the 
non-oligo(A) 40-mer. A 
reaction with an increased amount of LRPPRC (1.25uM) was included, as this was the 
concentration shown in Chujo et al. to impart the highest poly(A) extension increase in 
their assays.    
 As shown in Figure 6.21, with more precise insight into the physiological range of 
poly(A) lengths, effects on polyadenylation were seen with LRPPRC and 
LRPPRC/SLIRP present. An increase in poly(A) extension lengths was observed in the 
 
 
Figure 6.21. High-resolution analysis of LRPPRC 
and LRPPRC/SLIRP complex effects on 
polyadenylation. 
Wild-type His-mtPAP (0.55uM) was incubated with 40nt RNA substrate 
(0.25uM), either alone (lane 2) or with 0.5uM LRPPRC (lane 3), 0.5uM 
LRPPRC/SLIRP complex (lane 4), 0.5uM BSA (lane 5), or 1.25uM 
LRPPRC (lane 6). Incubations took place for 1 hour at 37⁰C. Reactions 
were then quenched with 90% formamide/1x TBE, separated through a 
15% polyacrylamide/8.3M urea gel, and stained with SYBR gold. 
Stained products were visualized by scanning with a Typhoon FLA 9500 
instrument. Gel lanes were analyzed by densitometry using Image J. 
Distance of RNA migration through the gel was used for calculating 
mean lengths of the poly(A) extensions. 
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presence of LRPPRC, with the effect magnified in the presence of LRPPRC/SLIRP. The 
BSA control reaction showed no difference from the reaction with His-mtPAP alone, 
indicating the extension increases are solely the result of LRPPRC and LRPPRC/SLIRP 
activity or interactions. More than doubling the amount of LRPPRC incubated with His-
mtPAP did not produce further increases in poly(A) length, suggesting the effect on 
poly(A) extension is saturated at 0.5uM. The range of lengths remained the same with 
both 0.5uM and 1.25uM concentrations, which were both shorter than 0.5uM 
LRPPRC/SLIRP. The presence of SLIRP complexed to LRPPRC appears to produce a 
synergistic effect on stimulating poly(A) activity.   
 
 
6.3.14 High-resolution analysis of the effect of LRPPRC and  
  LRPPRC/SLIRP complex on wild-type versus N478D His- 
  mtPAP activity   
  
 Continuing the analysis of the effects of LRPPRC/SLIRP on in vitro 
polyadenylation, the reactions examining mutant His-mtPAP activity were performed 
again, now with the high resolution assay. The purpose of this experiment was to 
investigate the effect the LRPPRC/SLIRP complex may have on mutant poly(A) activity, 
specifically within the physiological range of poly(A) lengths, as this was poorly resolved 
on previous assays. LRPPRC/SLIRP was used, rather than LRPPRC alone, because the 
complex appeared to be the optimal vehicle for extending polyadenylation length, 
compared to the less potent effect from LRPPRC alone. Further, there is significant 
evidence that LRPPRC and SLIRP are complexed in vivo, use of the complex in the 
recombinant reactions was presumed to impart more physiologically relevant data.  
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 Figure 6.22 shows the results of these reactions. The poly(A) extensions generated 
by the wild-type His-mtPAP enzyme with and without LRPPRC/SLIRP replicate the 
results from Figure 6.21. For the mutant His-mtPAP alone, the oligo(A) extension is 
observed, again matching the lengths seen on the MPAT analysis of mutant fibroblasts. 
Interestingly, the addition of the LRPPRC/SLIRP complex to the mutant polymerase 
reaction still facilitates an increase in poly(A) length over mutant polymerase alone.  
 
 
6.3.15 Doubling reaction time does not significantly increase the  
  LRPPRC/SLIRP pro-polyadenylation effect 
 
 
 
Figure 6.22. The effect of LRPPRC/SLIRP complex on N478D His-mtPAP activity 
Wild-type (0.55uM, lanes 2,3) or N478D (0.55uM, lanes 4, 5) His-mtPAP was incubated with (lanes 3, 5) and 
without (lanes 2, 4) LRPPRC/SLIRP complex (0.48uM). RNA substrate was included at 0.25uM. Incubations took 
place for 1 hour at 37⁰C. Reactions were then quenched with 90% formamide/1x TBE, separated through a 15% 
polyacrylamide/8.3M urea gel, and stained with SYBR gold. Stained products were visualized by scanning with a 
Typhoon FLA 9500 instrument. Gel lanes were analyzed by densitometry using Image J. Distance of RNA migration 
through the gel was used for calculating mean lengths of the poly(A) extensions.  
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 The standard incubation time for the polyadenylation reactions was one hour at 
37⁰C. To assess whether wild-type mtPAP on its own could generate poly(A) tails of 
similar lengths observed in the presence of LRPPRC/SLIRP with extended reaction time, 
the poly(A) assay was performed over a 2 hour period. Reactions were performed with 
wild-type and mutant His-mtPAP alone, and in the presence of LRPPRC/SLIRP. As 
illustrated in Figure 6.23, doubling the incubation times of the polyadenylation reactions 
produced only small gains in poly(A) extension lengths, indicating that the standard 
reaction times of one hour were already near maximal extension. These reactions also 
provide further replication of the pro-poly(A) extension effect exhibited by 
LRPPRC/SLIRP in the presence of both both wild-type and N478D polymerases.   
 
 
 
 
 
Figure 6.23. Doubling reaction time from 1 hour to 2 hours imparts small gains in 
poly(A) extension. 
A. Wild-type (0.55uM) or B. N478D (0.55uM) were incubated with (lanes 5,6) and without (lanes 2,3) 
LRPPRC/SLIRP complex (0.48uM) present. The incubation times were in sets of 0min, 60min, and 120min. The 
RNA substrate was 40nt MTATP6 3' end fragment (0.25uM). Reactions were quenched with 90% formamide/1x 
TBE, separated through a 15% polyacrylamide/8.3M urea gel, and stained with SYBR gold. Stained products were 
visualized by scanning with a Typhoon FLA 9500 instrument.  
A 
B 
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6.3.16 LRPPRC/SLIRP-mediated pro-poly(A) activity is not 
specific to mt-mRNA 3' termini 
 
 In an effort to elucidate determinants of the poly(A) length increase exerted by 
LRPPRC/SLIRP, the in vitro poly(A) assay was performed using an RNA substrate that 
was a 40nt upstream segment of the MTND3 transcript. This as opposed to the standard 
RNA substrate in the assay corresponding to the terminal 40nt of MTATP6. The aim of 
the experiment was to test if the pro-poly(A) effect is specific for polyadenylation of 3' 
sequences of mt-mRNAs. Or alternatively, if the effect is general for exposed RNA 3' 
ends.  
 In Figure 6.24, polyadenylation of the ND3 40-mer is extended with the addition 
of LRPPRC/SLIRP to the reaction, and thus the effect is not specific to 3' ends of mt-
mRNAs acting as the polymerase substrate. In addition, this represents the first result 
within this study demonstrating that His-mtPAP can polyadenylate non-mitochondrial 
mRNA 3' ends. Other reports have shown similar capability for recombinant mtPAP 
(Nagaike et al., 2008; Bai et al., 2011; Chujo et al., 2012), however up to this point this 
ability had not been confirmed with experiments as part of this study.    
 
 
Figure 6.24. Pro-poly(A) activity exerted by LRPPRC/SLIRP is sequence 
independent. 
Wild-type His-mtPAP (0.55uM) was incubated with (lanes 5,6) and without (lanes 2,3) LRPPRC/SLIRP complex 
(0.48uM). The RNA substrate (0.25uM) was a 40nt upstream segment corresponding to the MTND3 transcript. The 
incubation times were in sets of 0min, 60min, and 120min at 37⁰C. Reactions were then quenched with 90% 
formamide/1x TBE, separated through a 15% polyacrylamide/8.3M urea gel, and stained with SYBR gold. Stained 
products were visualized by scanning with a Typhoon FLA 9500 instrument.  
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6.3.17 Time courses of in vitro polyadenylation reactions 
   
 In order to observe the rate of in vitro polyadenylation, and how this rate changes 
depending on the factors present with His-mtPAP, poly(A) reactions were assembled and 
incubated at 37⁰C for a variety of time points. The maximum time point was two hours, 
as this had previously been observed to demonstrate the a plateau in extension. The initial 
conditions compared were the time courses of wild-type His-mtPAP alone, and then with 
the addition of the LRPPRC/SLIRP complex. The results of these time courses are shown 
in Figure 6.25A. The poly(A) tails are longer at each time point when LRPPRC/SLIRP is 
present, as opposed to His-mtPAP alone. The His-mtPAP used in all the in vitro 
polyadenylation reactions shown on the two gels in Figure 6.25A was taken at the same 
time from the same thawed aliquot and added to all the reactions at once. This was done 
to enable comparison between the two gels. The differences in polyadenylation are clear. 
The results are represented graphically in Figure 6.25B, where the mean of poly(A) 
lengths at each time point was quantified via densitometry. For these time course 
experiments, the addition of LRPPRC/SLIRP averages a 40nt extension increase over the 
maximal extension achieved by mtPAP alone.  
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 As the recombinant protein had been stored at -80⁰C for several months at this 
point, a reduction of enzymatic activity over that time had to be considered. Two more 
sets of in vitro activity experiments, however, were performed after this point in time. 
One set consisted of the same time course conditions as in Figure 6.25, only utilizing the 
oligoadenylated 48nt RNA transcript as a substrate, in order to assess if using an 
oligoadenylated substrate gave a different pattern of poly(A) synthesis either rate or 
maximal extension. The other set consisted of two 120min time courses, one which only 
had SLIRP added to the reaction with His-mtPAP, and the other only having LRPPRC 
added along with His-mtPAP, in order to dissect out the individual contributions of 
LRPPRC and SLIRP to the pattern of poly(A) extension. These results are shown in 
Appendix A. They are not included here, because the poly(A) lengths produced were 
shorter than previously observed, although increases in poly(A) lengths over those 
derived from mtPAP alone were still observed with LRPPRC/SLIRP and LRPPRC 
present. As very little amount of His-mtPAP protein remained, and time had not 
permitted production of a new batch of recombinant protein, the results have not been 
replicated as of this time, but need to be repeated to evaluate the effects of each protein 
independently.  
   
  
Figure 6.25. Polyadenylation time courses with LRPPRC/SLIRP. 
A. Wild-type His-mtPAP (0.55uM) was incubated for multiple time points with and without LRPPRC/SLIRP complex 
(0.48uM) present. RNA substrate was present at 0.25uM. Incubations took place at 37⁰C. At each time point, reactions 
were quenched with 90% formamide/1x TBE, and stored at -20⁰C. Samples were later thawed, then separated through a 
15% polyacrylamide/8.3M urea gel, and stained with SYBR gold. Stained products were visualized by scanning with a 
Typhoon FLA 9500 instrument. B. The log(molecular weight) of ssRNA size standards from the gels in A were graphed 
against migration through the polyacrylamide/urea gels. A line of best fit was generated, and the slope and y-intercept 
of the line used to calculate the mean poly(A) length ranges observed.  
 
A B 
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6.3.18 RNA binding capability of LRPPRC/SLIRP and mtPAP 
 
 The LRPPRC/SLIRP complex has been reported to interact directly with 
mitochondrial mRNA (Sasarman et al., 2010; Ruzzenente et al., 2012). In light of the 
previously described in vitro data, it was important to confirm that the recombinant 
LRPPRC/SLIRP complex was interacting with the RNA substrates and investigate 
whether the presence of mtPAP affects that RNA binding capacity. The RNA binding 
capacities of the recombinant proteins were assessed by electrophoretic mobility shift 
assays (EMSAs). LRPPRC/SLIRP complex was titrated into reactions containing a 
constant amount of RNA 40-mer substrate, with and without His-mtPAP present.  
 As presented in Figure 6.26, increasing the amounts of LRPPRC/SLIRP in the 
binding reactions caused increasing shifts in the migration of the RNA substrate, 
indicating direct binding by the complex. The addition of mtPAP in addition to any of the 
reactions containing different amounts of LRPPRC/SLIRP did not appear to make any 
impact on the affinity of the complex for the RNA substrate. Binding reactions using His-
mtPAP alone did not cause any shift in migration of the RNA substrate (data not shown). 
Unpublished data shared by Dr. Henrik Spahr indicated that while LRPPRC alone seems 
to bind RNA substrates in the EMSA, SLIRP does not appear to do so. Similar to the pro-
 
 
Figure 6.26. LRPPRC/SLIRP RNA binding capacity with and without mtPAP 
present 
RNA substrate (0.25uM) was incubated with increasing amounts of LRPPRC/SLIRP in modified poly(A) buffer (see 
6.2.7). Each reaction was performed with and without wild-type His-mtPAP (0.55uM) present. These reactions were 
electrophoresed through native 6% polyacrylamide/0.5x TBE gels at 4⁰C in 0.5x TBE buffer. Gels were then stained 
with 1x SYBR gold and imaged with a Typhoon FLA 9500.   
165 
 
poly(A) effect, LRPPRC seems to be the dominant contributor within the complex to 
RNA binding in vitro.   
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6.4  Discussion 
 
6.4.1  The N478D mutation causes a disruption of polyadenylation 
  activity 
 
 One of the primary aims of the in vitro analysis of polyadenylation was to dissect 
the impact of the N478D mutation on mtPAP. Due to its location in an unresolved portion 
of the crystal structure (Bai et al., 2011), assignment of a change in function is elusive. 
The initial hypothesis was that the mutation potentially disrupted a critical protein-protein 
interaction necessary for optimal polyadenylation of mitochondrial mRNA transcripts by 
mtPAP. This arose from the fact that the mutated residue is far from the active site of the 
enzyme, as well as the putative dimerization domain or RNA binding-like (RNL) domain. 
In the context of the mtPAP dimer, the unresolved regions within the "fingers" domains 
are asymmetrically distal to the dimerization interface shared by the bound monomers. 
This placement could potentially make the residues available for interacting with other 
factors, and is represented with a cartoon in Figure 6.27 for clarity. The analysis with far-
UV CD spectroscopy was consistent with this hypothesis, as the mutation did not appear 
to disrupt the secondary structure of the enzyme. 
 
 
Figure 6.27. Locations of unresolved regions containing the N478D mutation in 
mtPAP dimer 
Cartoon image of mtPAP dimer. Each monomer has the major domains labeled with different colors. For the 
monomer on the left, the domains are Palm (cyan), RNL (orange), and Fingers (green). For the monomer on the right, 
the domains are Palm (yellow), RNL (blue), and Fingers (purple). The catalytic residues are labeled pink, towards the 
center of the monomers. The unresolved domains, which contain the asparagine 478 residue, are circled on the image. 
The structure is available from the Protein Data Bank, PDB: 3QP1, reported by Bai et all., 2011. This image was 
generated using the Chimera 1.8.0 software, available from UCSF. 
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 If this hypothesis was correct, the activity of the wild-type enzyme in vitro would 
be predicted to be less than optimal in adding poly(A) tails on to RNA substrates, as the 
necessary interacting-factor would not be present. The mutant would exhibit the same 
behavior, as the enzyme activity itself would not be disrupted. Only the interacting 
residues, presumably including the N478D residue, would be disrupted, but with the 
interacting factor not being present in the reaction in the first place, this change would not 
be observed. However, as clearly demonstrated in Figure 6.20, as well as many others, the 
His-mtPAP enzyme alone can generate poly(A) tails that are close to the range of lengths 
observed in vivo. The mutant polymerase only generates a short oligo(A) tail, indicating 
that the mutation effects protein-intrinsic properties governing its polyadenylation 
activity. One could postulate that LRPPRC, or the LRPPRC/SLIRP complex, is the 
missing interacting factor, due to the effect of longer poly(A) tails being generated in 
their presence, but this increase in extension is still exerted on the mutant mtPAP. This 
argues against the mtPAP-LRPPRC/SLIRP protein-protein interaction explanation of the 
N478D mutation's impact. Clear differences are seen between the wild-type and mutant 
protein activities, and these differences are similar to the MPAT data of endogenous 
transcripts. However, the many differences between an in vitro assay and in vivo results 
must be kept in mind. There may be residues required for potential interactions with 
mtPAP, but the data presented thus far does not support asparagine 478 of mtPAP being 
one of them.  
 As demonstrated in Figures 6.20 and 6.22, the mutant His-mtPAP generates 
significantly shorter poly(A) tails, even in the presence of LRPPRC/SLIRP. One potential 
explanation for this diminished polyadenylation capability is a defect in processivity. 
Precise confirmation of a processivity defect is reported as being difficult to establish, and 
the ability to distinguish discrete substrate binding events in this experimental system is 
not possible. In this scenario, the mutation may affect the ability of the polymerase to 
interact with substrates, be it the RNA polymer or ATP. If binding of the RNA is the root 
problem, this could take the form of disruption of interactions necessary for translocation 
(if this occurs) along the extending RNA polymer as mtPAP adds adenine 
ribonucleotides, or by disrupting the ability of the enzyme to associate initially with the 3' 
end. Similarly, a decreased affinity for ATP could lead to shorter adenylate tails, even if 
the RNA binding/association capabilities were intact. As EMSA results with wild-type 
His-mtPAP and RNA substrate did not show conclusive binding, it is difficult to make 
comparisons between wild-type and mutant RNA binding affinities.  
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 Alternative possibilities are defects in catalytic activity, arising from a number of 
sources. Bai et al. predicted that the structure of mtPAP, while existing in a more closed 
conformation than canonical poly(A) polymerases in the absence of substrate, may yet 
adopt a more closed architecture upon substrate binding (Bai et al., 2011). It is possible 
that the N478D mutation decreases the ability of the polypeptide to perform this 
conformational change. At this juncture we cannot distinguish the difference between a 
decrease in processivity or catalytic rate. Both states could produce the shorter oligo(A) 
tails observed. So while this study increased our understanding of the N478D mtPAP 
mutant, the precise impact of the substitution is still elusive.    
 
  
6.4.2  The LRPPRC/SLIRP complex increases polyadenylation  
  extension length 
 
 Chujo et al. reported that LRPPRC was a critical requirement for mtPAP to 
efficiently polyadenylate RNA substrates, with only oligoadenylation (length not 
specified) occurring in its absence. The results from my study presented here are in 
contrast to that claim, and are consistent with other reports in the literature (Nagaike, 
2005; Bai et al., 2011). In our assay, mtPAP is capable of independently generating 20-
30nt poly(A) tails, significantly longer than the oligo(A) tails observed with LRPPRC 
knock downs. The addition of LRPPRC or LRPPRC/SLIRP caused further extension of 
the tail, potentially through an increase the processivity of mtPAP. Chujo et al. report that 
this effect is dose-dependent for LRPPRC, with increases observed up to 1.25uM 
LRPPRC. The results of my study partially contrast with this observation. The longer 
poly(A) tails in the presence of LRPPRC was the same at concentrations of either 0.5uM 
and 1.25uM, indicating that beyond quantities equimolar with mtPAP (0.55uM) the effect 
is likely saturated. For concentrations of LRPPRC less than equimolar with mtPAP, a 
dose-dependent effect may be observable. Our results are consistent with LRPPRC being 
the dominant effecter of the poly(A) extension within the LRPPRC/SLIRP complex. In 
my preliminary data, when His-mtPAP was paired with SLIRP alone, the further 
extension of poly(A) tails beyond that generated by mtPAP alone was not observed. 
However, the effect from the combined LRPPRC/SLIRP complex is greater than 
LRPPRC only paired with His-mtPAP. As Chujo et al. do not show their data on the 
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effect of SLIRP alone, it is difficult to know how consistent my results are compared to 
theirs. 
 The critical question is, how does LRPPRC and LRPPRC/SLIRP affect 
polyadenylation activity? A hypothesis posed by Chujo et al. is that LRPPRC acts to 
prevent mRNA 3'-end secondary or tertiary structure forming, presenting mtPAP with an 
optimal substrate. The 40nt RNA substrates used in the high-resolution poly(A) assays 
are not predicted to be highly structured at the 3'-end, nor predicted to adopt any complex 
structure in general. LRPPRC and LRPPRC/SLIRP were both able to exert their effects 
on poly(A) tails when presented with the RNA 40-mers. While LRPPRC may be involved 
with 3' unwinding in vivo, it does not appear a property required in vitro for promotion of 
polyadenylation. These results from our laboratory are particularly relevant, as the RNA 
substrates both 40nt oligomers and 248/277nt larger RNA fragments actually correspond 
to the 3' sequences from MTATP6 and MTND3, rather than "mimicking the 3' terminal 
 
 
 
 
 
 
 
 
Figure 6.28. Hypothetical mechanism of LRPPRC/SLIRP and mtPAP 
interaction 
A. In a manner potentially similar to the nuclear mechanism of PAP, PAPBN1 and CPSF, mtPAP, LRPPRC and 
SLIRP may constitute a complex assembling on the 3' ends of mt-mRNAs. The complex would coordinate the 
extension of poly(A) tails, facilitating a processive elongation of the tail to a certain length, which then forces 
disassembly of the complex and dissociation of mtPAP. B. Without the presence of LRPPRC or LRPPRC/SLIRP, 
mtPAP is free to adenylate in a non-coordinated manner. This allows the enzyme opportunities to extend poly(A) 
tails further than observed in vivo (above). The mt-mRNA coding region is shown in black, and the poly(A) tail is 
colored red.  
A 
B 
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region of mt-mRNAs" (Chujo et al., 2012). Extended poly(A) tails in the presence of 
LRPPRC/SLIRP were observed when using an RNA 40-mer corresponding to an 
upstream fragment of MTND3, further suggesting that the effect may not be constituted 
by mt-mRNA-specific 3' structure unwinding. However, our results do agree with one 
principle of the hypothesis presented by Chujo et al., which is that the LRPPRC effects 
does not appear to be sequence-specific.  
 It is possible that LRPPRC, SLIRP, and mtPAP all interact in some fashion at the 
3' end of RNA, and perhaps the increased stabilization that occurs from that interaction 
allows more efficient polyadenylation. In poly(A) reactions from the low-resolution in 
vitro assay, when other factors were absent, His-mtPAP generated the strongest signal for 
poly(A) that were similar to those observed physiologically but also generated tails 
significantly exceeding this range. One explanation is the enzyme is capable of much 
higher processivity and extensions, but this capability is curbed by protein-protein 
interactions in vivo. Without the length-limiting system present in vitro, the polymerase's 
intrinsic capacity for generating poly(A) tails can go to its limit. Another explanation is 
the "longer lengths" observed are merely an artifact of the polyacrylamide/urea gel 
electrophoresis. As this gel-type is strongly denaturing, it is unlikely that the RNA is 
aggregating or persisting in higher order structures.  
 A consistent effect observed was the disappearance or reduction of these 
presumably longer poly(A) tails upon introduction of LRPPRC or LRPPRC/SLIRP. The 
protein or complex may in fact act as a length-regulating factor, even as it affects poly(A) 
tail length within the physiological range. In a manner similar to CPSF's role in nuclear 
polyadenylation, the interaction of LRPPRC, SLIRP, and mtPAP may coordinate and 
control the extension of the poly(A) tail so that it "loops" out, or coils into a globular 
structure (Kuhn et al., 2009). This is in contrast to mtPAP acting alone, which when 
untethered by protein-protein interaction, can extend much further. However this 
extension may be less processive and occur at a slower rate. Both of these scenarios are 
represented in Figure 6.28. The "looping" extension of the poly(A) tail may be mediated 
by the continuous contact between mtPAP and LRPPRC/SLIRP as nucleotides are added, 
and the physiological length is the number of nucleotides added to the 3' end that cause 
the contact to break. This could be from torsion of the poly(A) tail, or other disruptive 
forces that occur as tail length grows.   
 While there are other reports indicating that LRPPRC and/or SLIRP can fulfill 
other roles in mitochondria, such as stabilizing non-translated mt-mRNAs (Ruzzenente et 
al., 2012), this discussion is limited to the observations made in vitro. There are 
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consistent effects observed with just the three proteins together which are difficult to 
resolve, independent of ancillary functions for the proteins in mitochondria and in other 
cellular compartments.  
     
 
6.4.3  The role of SLIRP 
 
 A curiosity that persists is the role of SLIRP in polyadenylation. The results 
presented in this study clearly show that there is an additive effect on poly(A) length 
extension from SLIRP complexing with LRPPRC. However it is also true that LRPPRC 
appears to exert the vast majority of this effect. Both LRPPRC and SLIRP have been 
reported to possess RNA binding domains, and LRPPRC/SLIRP binds mt-mRNA coding 
regions (Baughman et al., 2009; Sasarman et al., 2010; Chujo et al., 2012). It is possible 
that SLIRP is more involved with the RNA interactions, while LRPPRC interacts with 
mtPAP. Thus when complexed, the two roles of the factors synergistically promote 
polyadenylation. The complex has been reported to not bind poly(A) sequences (Chujo et 
al., 2012). Again, the LRPPRC/SLIRP complex may be more analogous to the nuclear 
CPSF complex, as opposed to the canonical nuclear poly(A) binding protein PABPN1 
(Kuhn et al., 2009). However, while not part of this study, the unpublished results from 
Nils-Goran Larsson's lab indicate that SLIRP does not appear to shift the size of RNA 
substrates in EMSA gels, while LRPPRC and LRPPRC/SLIRP clearly cause shifts. This 
argues against SLIRP acting as more of an RNA binding mediator in the context of 
polyadenylation. His-mtPAP did not cause shifts in EMSA gels either, nor did it affect the 
shifts generated by LRPPRC/SLIRP (Figure 6.26).  
 If there is a mitochondrial poly(A) binding protein, it is not currently identified. It 
is quite possible this potential player in the process could alter the dynamics of 
polyadenylation yet more from that observed in vitro. The necessity of investigating what 
other factors may be involved with polyadenylation in mitochondria, and elucidating 
more specific aspects of potential LRPPRC and SLIRP interactions with mtPAP, was 
clear. Towards that end, experiments undertaken to explore mtPAP interacting partners 
are presented in the next chapter.  
 
6.4.4  Oligoadenylation of mitochondrial mRNAs 
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 The in vitro results using the mutant enzyme argue against the existence of a 
separate oligoadenylase generating the oligo(A) tails on mt-mRNAs. The oligo(A) tail 
was observed in experiments knocking out or down LRPPRC, and siRNA-mediated 
depletion of mtPAP. If a separate oligo(A) polymerase exists, and was generating the 5-
10nt tails present in vivo, one might predict the N478D mtPAP would not be adding any 
further nucleotides, as the short tail observed would have been a product of another 
factor. This is clearly not the case, as the N478D His-mtPAP enzyme generates short 
oligo(A) tails that match the lengths (5-10nt) observed in vivo for the 1432A>G 
homozygous mutant fibroblasts.  
 Utilization of oligoadenylated RNA substrates by mtPAP did not show different 
polyadenylation profiles from those generated from RNA with a naked 3' terminus. The 
oligo(A) extension has previously been hypothesized to act as a primer for further 
polyadenylation by mtPAP. The results of this study do not support this assertion. None 
of the experiments with mtPAP polyadenylating oligo(A) RNA indicated higher activity, 
rate, or processivity.  
 A potential explanation of the various conditions leading to oligo(A) tails, could 
be the involvement of deadenylases. Overexpression of PDE12 led to reduction in 
poly(A) tail lengths on mt-mRNAs, and siRNA knock-down of hPNPase led to small 
extensions of the tails. Expression of a wild-type PAPD1 transgene in fibroblasts caused 
extra extension of mt-mRNA poly(A) tails (Chapter 5). These data suggest that part of the 
regulation of mt-mRNA poly(A) tail length may partially be the result of opposing 
adenylase and deadenylase activities. Perhaps if mtPAP/LRPPRC/SLIRP interact at the 3' 
end of mt-mRNAs, they prevent deadenylases from degrading the tail. When mtPAP is 
knocked down, or mutated (as in the case of the N478D enzyme), a low level of activity 
remains. When LRPPRC is removed, the three proteins do not coordinate at the 3' end of 
mt-mRNA. Thus, mtPAP polyadenylates, then dissociates, allowing degradation to occur, 
or the deadenylating factor is capable of displacing mtPAP in the first place. This is 
speculation, but if true would reconcile multiple lines of evidence. More research into this 
area is necessary.  
 In summary, this series of in vitro experiments has provided insight into the 
enzymatic capabilities and substrate specificities of both the wild-type and N478D mutant 
mtPAP. In addition, the length extensions observed in the presence of LRPPRC and 
LRPPRC/SLIRP aid in clarifying the dynamic environment at play during mt-mRNA 
polyadenylation, and the effects these trans-acting factors can exert. While questions 
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remain, the results of this study are critical to furthering our understanding of post-
transcriptional mechanisms and their downstream impact.  
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Investigating mtPAP interacting factors 
 
7.1  Introduction 
 
 Polyadenylation in the nucleus is a dynamic and multifaceted process, carried out 
by multi-component protein machinery. The nuclear poly(A) polymerase requires 
multiple factors to bind its RNA substrate at the right location, boost processivity, and 
coordinate extension (Mandel et al., 2008; Kuhn et al., 2009). The mitochondrial poly(A) 
polymerase appears to be capable of several of these tasks unaccompanied, however there 
are proteins that have been reported to interact with mtPAP and be important for function 
(Chujo et al., 2012; Ruzzenente et al., 2012; Kazak et al., 2013). While many aspects of 
mitochondrial polyadenylation can be reconstituted in vitro, it is unlikely that the 
currently identified factors, i.e. mtPAP, LRPPRC, SLIRP, and PABPC5 act alone. 
However, from the current literature it is unclear how polyadenylation is coupled with 
mechanisms such as transcriptional processing or ribosome loading. While the vast 
majority of polyadenylation in the nucleus is physically separated by cellular structures 
from the translation machinery, this partitioning is not in place in mitochondria. It is 
possible, therefore, that transcriptional processing is more tightly coupled with the 
translation apparatus, and mtPAP could be functionally tied to one process or the other in 
novel ways not observed in the nucleus. 
 Towards this end, my experiments were designed with the aim of identifying 
factors that interact with mtPAP, and are potentially involved with polyadenylation 
events. Several lines of investigation were designed to provide details of possible 
interactions and associations. Recently, the existence of mitochondrial RNA granules 
(MRGs) has been reported (Jourdain et al., 2013), marked by the presence of the protein 
GRSF1. Significant portions of RNA processing occur in these granules, with 
demonstrated interactions of GRSF1 and RNase P. This mitochondrial subcompartment 
presents an attractive location for investigating the localization of mtPAP. Experiments 
were designed to identify whether mtPAP is also present in the MRGs, and if so, this 
would provide details of some factors that the enzyme could physically encounter.  
 Due to the potential for polyadenylation in mitochondria occurring as an event 
tightly coupled with translation, associations with mtPAP and the mitochondrial ribosome 
were also examined. Direct binding partners of mtPAP were to be investigated through 
immunoprecipitation experiments. The in vitro data using recombinant wild-type and 
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mutant mtPAP had shown that longer poly(A) tails were generated in the presence of 
LRPPRC and the LRPPRC/SLIRP complex. This led to the hypothesis that these proteins 
may be directly interacting in some fashion in order to facilitate/regulate the poly(A) 
extensions observed. Thus, direct binding associations between mtPAP and LRPPRC and 
SLIRP were particularly examined, in order to find evidence supporting this potential 
model. As the effects on gene expression resulting from oligo(A) tails in fibroblasts had 
not explicitly revealed a role for the tail beyond stop codon completion, investigation of 
modulatory factors for polyadenylation was performed to increase our understanding of 
the molecular mechanisms involved. This chapter presents the results of these lines of 
inquiry.  
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7.2  Materials and methods 
 
7.2.1  Immunoprecipitation 
 
Isolated crude mitochondria were prepared as detailed in 2.2.6.2. 20ul of magnetic 
Dynabead Protein G beads (Novex) per IP reaction were washed 3x with 100mM Na-
phosphate pH 8.1 buffer. The beads were then suspended in 70ul 100mM Na-phosphate 
pH 8.1 buffer, and 10ug of α-mtPAP mouse monoclonal antibody (GeneTex GTX70156) 
was added to the solution, to generate the Protein G-Ig complex. This mixture was rotated 
at room temperature for 1 hour. While the antibody and beads were incubating, crude 
mitochondria were lysed by suspension in 150ul chilled lysis buffer (50mM Tris 7.4, 
150mM NaCl, 1mM EDTA, 1% Triton X-100, 1mM PMSF, 10mM MgCl2), then 
incubated on ice for 30 minutes. The insoluble fraction of the mitochondrial lysate was 
then pelleted by centrifugation at 16,000g at 4⁰C, for 15 minutes. The supernatant was 
collected, and protein concentration determined via Bradford assay. The magnetic 
bead/antibody complexes were then washed 3x with chilled lysis buffer. Equal amounts 
of lysate protein (800ug) were added to immunoprecipitation reactions if several samples 
were to be analyzed. Mitochondrial supernatant was incubated with the magnetic 
bead/antibody complexes at 4⁰C, rotating, for 1 hour. The beads/antibodies/antigen 
complexes were then collected and washed 5x with chilled lysis buffer. To elute the target 
antigen and co-immunoprecipitants, the bead/antibodies/antigen complexes were 
suspended in 1x Laemmli buffer, and heated to 70⁰C for 10 minutes, shaking at 1000rpm 
in an Eppendorf thermomixer. Immunoprecipitation samples were then either stored at -
80⁰C, or directly loaded onto 12% SDS-polyacrylamide gels for analysis by 
immunoblotting.  
 
For investigating protein-protein interactions mediated by RNA, the co-IP procedure was 
carried out as detailed above, with the following alterations: In the samples that were to 
have RNA removed, the mitochondrial lysate (800ug) had 5ug of RNase A introduced 
and was incubated at 10⁰C for 15min. For RNA-protected samples, all buffers and 
solutions were made up with DEPC-treated H2O, and the isolated mitochondria were 
lysed in 150ul chilled lysis buffer that included 100U of SUPERase-In (Invitrogen) 
RNase inhibitor. For washes of the bead/antibodies/antigen complexes, lysis buffer 
contained 20U SUPERase-In/ml.      
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7.2.2  Isokinetic sucrose gradients 
 
Chilled, filter-sterilized gradient buffer was prepared (50mM Tris pH 7.2, 10mM 
MgOAc, 40mM NH4Cl, 100mM KCl, 1mM PMSF, 50ug/ml Chloramphenicol). 
Solutions of 10% and 30% sucrose were prepared in gradient buffer (0.5g sucrose in 5ml 
buffer and 1.5g sucrose in 5ml of buffer). 0.5ml of 10% sucrose solution was pipetted into 
an ultracentrifuge tube (Beckman Coulter 343778), with 0.5ml 30% sucrose injected 
under the 10% sucrose fraction using a 1ml syringe and needle. This was done gently, 
allowing 2 distinct clear fractions to be formed. The ultracentrifuge tube was then 
plugged using a rubber plug, making sure not to contact sucrose solution. On a balanced 
Gradient Master 107 (Biocomp), the sucrose fractions were mixed, using the TL55 
program, short sucrose 10%-30%, 55sec/0.85. Once mixed, the gradient was stored on a 
flat surface, undisturbed, at 4⁰C, for 1 hour. The Optima TLX ultracentrifuge (Beckman) 
was turned on, and allowed to cool to 4⁰C. During the centrifuge cooling period, cells 
were harvested from a confluent T75 flask and pelleted as detailed in 2.2.6.2. On ice, the 
cell pellets were lysed in 80ul lysis buffer (50mM Tris 7.4, 150mM NaCl, 1mM EDTA, 
1% Triton X-100, 1mM PMSF, 10mM MgCl2, 1x protease inhibitors). The lysate was 
incubated at 4⁰C, rotating, for 30 minutes. Then the non-soluble fraction of the cell lysate 
was pelleted by centrifugation at 4⁰C, for 10 minutes, at 12,000g. The supernatant was 
collected, and protein concentration determined via Bradford assay. The plug on the 
gradient was carefully removed, and 900ug of lysate carefully loaded on top of the 
sucrose gradient, making sure not to disrupt gradient. The tube was then placed in the 
ultracentrifuge. The ultracentrifuge was set to deliver 100,000g for 2 hours 15 minutes at 
4⁰C (acceleration = 1, and deceleration = 4). Upon finishing centrifugation, 100ul 
fractions were taken from the gradient, starting at the top (10% sucrose) and moving 
towards the bottom (30% sucrose). In total, 11-12 fractions were typically collected. 
These fractions were then analyzed by SDS-PAGE and immunoblotting.       
 
7.2.3  Mass spectrometry analysis of immunoprecipitated samples  
 
Immunoprecipitation (IP) experiments were carried out using an α-mtPAP antibody 
(GeneTex GTX70156), as described above. The IP samples were then separated by 12% 
SDS-PAGE, and stained with Coomassie brilliant blue. Stained bands suspected of 
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corresponding to mtPAP and unknown proteins were carefully excised from the gel, 
deposited in microtubes, and stored at -20⁰C. Analysis by mass spectrometry of mtPAP 
co-immunoprecipitation samples was carried out by the Radboud Proteomics Centre in 
Nijmegan, the Netherlands.  
 
7.2.4  Immunofluorescent microscopy  
 
Analysis of mtPAP localization was performed by Alexis Jourdain at the University of 
Geneva. 143B.206 osteosarcoma cells were either transiently transfected with a FLAG-
tagged mtPAP construct (pcDNA5/FRT/TO-mtPAPFLAG, see 5.2.1) and mtPAP 
detected using α-FLAG antibodies (Sigma F1804), or the endogenous mtPAP was 
detected using α-mtPAP antibodies (GeneTex GTX70156). The cells were fixed using 
4% paraformaldehyde. Immunodetection was carried out in PBS + 0.1% Triton X-100 + 
3% w/v BSA, with antibodies targeting the FLAG-tag, mtPAP, or GRSF1. Essentially as 
described in (Jourdain et al., 2013). 
 
7.2.5  Stable transfection of HEK293 Flp-In
TM
 T-REx
TM
 cells with 
  FLAG-tagged mtPAP 
 
HEK293 Flp-In
TM
 T-REx
TM
 (hereafter referred to as HEK293) cells were seeded in 6-
well tissue culture plates (Corning) 1 day before performing transfections. These cells are 
normally cultured with 10ug/ml Blasticidin
S
 and 100ug/ml zeocin. These antibiotics were 
omitted for the transfection steps. For transfection, two aliquots were mixed of 1.8ug 
pOG44 (1.8ul of 1 ug/ul), which encodes the Flp recombinase, and 0.2ug (4ul of 50ug/ul) 
pcDNA5/FRT/TO-mtPAPFLAG in 100ul of DMEM, for a total of 2ug DNA.  
The two aliquots were used to mix ratios of DNA:Superfect of 1:5 and 1:7.5 
 
1:5 ratio - 2ug DNA (100ul) + 10ul SuperFect (Qiagen) 
1:7.5 ratio - 2ug DNA (100ul) + 14ul SuperFect 
 
To the DNA/SuperFect mix, 600ul of complete DMEM was added, mixed gently 5x by 
pipetting, and allowed to incubate at room temperature for 10 minutes. At this point cells 
were washed 1x with Dulbecco’s A-PBS, then the DNA/SuperFect mix was added to the 
wells. The cells were incubated with the mix for 3 hours at 37⁰C. After the incubation, the 
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DNA/SuperFect mix was removed and replaced with fresh warmed complete DMEM. 
After 24 hours in complete DMEM, Hygromycin
B
 was introduced to the culture media at 
a final concentration of 100ug/ml. Stable transfectants were selected, generally over a 2 
week period, and individual lines generated by isolating clonal colonies.  
 
HEK293 cells expressing N478D mtPAP-FLAG were generated according to the same 
protocol, utilizing the 1432A>G mutated version of the pcDNA5/FRT/TO-mtPAP-FLAG 
construct. This mutation was introduced using the Quikchange II Site-Directed 
Mutagenesis kit (6.2.2) with Mut-mtPAPF and Mut-mtPAPR primers (2.2.4.4). Protein 
expression was induced by 1ug/ml of tetracycline introduced into the culture media. 
Confirmation of tagged-protein expression was completed by immunoblotting using α-
FLAG antibodies. 
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7.3  Results 
 
7.3.1  Identification of mtPAP interaction partners by   
  immunoprecipitation and mass spectrometry 
 
 In order to explore the possibility of proteins directly binding to mtPAP, 
immunoprecipitation (IP) experiments were carried out, utilizing a mouse monoclonal 
antibody recognizing mtPAP. The initial cells used to establish these IP conditions and 
efficacy of the antibody for IP were HEK293 cells, as they are enriched in mitochondria 
relative to fibroblasts. Crude mitochondria were isolated from the HEK293 rather than 
whole cell lysate to enrich the levels of mitochondrial proteins in the input material for 
the IP. Controls for the IP consisted of beads coated with either a goat α-MNK1 antibody 
for an IgG control, or beads without antibody bound. Immunoblotting for mtPAP was 
carried to confirm effective immunoprecipitation by the α-mtPAP mouse monoclonal 
antibody. Once confirmed, the Coomassie staining and mass spectrometry was then 
performed as described below. 
 To parse the interactions mediated via binding to RNA transcripts, some 
mitochondrial lysates were 
incubated with RNase A 
prior to incubating with 
bead/antibody complexes. 
Non-RNase A treated 
lysates were processed in 
an RNA-protective 
fashion. This included 
usage of DEPC-treated 
H2O and introduction of 
RNase inhibitors.    
 The initial IP 
samples were separated 
via SDS-PAGE, and 
stained with Coomassie 
brilliant blue, in order to 
identify major protein 
 
 
 
 
Figure 7.1. Coomassie staining of mtPAP co-IP 
samples 
Coomassie Brilliant Blue stained 12% SDS-PAGE of proteins isolated from 
IP reactions using antibody against mtPAP. Preparation treated with RNase 
A is shown in lane 3, those processed in an RNA-protected manner are 
shown in lane 2. The gel was imaged using white light settings on the 
ChemiDoc MP (Bio-Rad).   
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species present in the sample, as well as obtain an approximation of their abundance. 
These results are shown in Figure 7.1. Beyond the two stained bands corresponding to the 
IgG heavy and light chains of the α-mtPAP antibody, there were only two major bands 
observed at approximately between 60 and 70 kDa, in all co-IP samples. A band appeared 
at a slightly increased size, smearing up from the IgG heavy chain in a non-RNase A 
treated co-IP sample. These three bands, termed "smeared", "65kDa", and "70kDa", were 
carefully excised from the gel, placed into microtubes, and stored at -20⁰C. The gel slices 
were then sent to the Nijmegen Proteomics Facility at the Radboud University Nijmegen 
Medical Center for analysis via mass spectrometry.  
 The results of the analysis by mass spectrometry are shown in Table 7.1. The most 
significant protein identified in the "65kDa" and "70kDa" gel slices is ATAD3A, with 
ATAD3B and ATAD3C present to lesser extents. These proteins are most highly 
represented in the gel slice corresponding to 70kDa. In the "65kDa" gel slice, ATAD3A is 
also highly represented, and the next most abundant protein is mtPAP. This suggests a 
strong association of ATAD3 with mtPAP. Both mtPAP and ATAD3 have predicted 
masses of approximately 66kDa, and may be overlapping in terms of staining on the gel 
due to similar migration. The emPAI values obtained for other proteins identified in the 
Table 7.1. Analysis of mtPAP co-immunoprecipitation by mass spectrometry.  
 
 
GROUP RANK PROTEIN emPAI 65 kDa bandemPAI 70 kDa bandemPAI Smear
1 1
gi|283436222|ref|NP_001164006.1| 
ATPase family AAA domain-containing protein 3A isoform 2 [Homo sapiens] 3.262158829 14.31740464 1.346228848
2 1
gi|75677353|ref|NP_114127.3| 
ATPase family AAA domain-containing protein 3B [Homo sapiens] 1.301807313 5.210169419 0.675474919
8 1
gi|194018490|ref|NP_001034300.2| 
ATPase family AAA domain-containing protein 3C [Homo sapiens] 1.11348904 4.956621435 0.496235656
3 1
gi|119395750|ref|NP_006112.3| 
keratin, type II cytoskeletal 1 [Homo sapiens] 1.894266125 1.768902684 1.030917621
6 1
gi|31542947|ref|NP_002147.2| 
60 kDa heat shock protein, mitochondrial [Homo sapiens] 2.16227766 1.319447866 0
7 1
gi|190194365|ref|NP_060579.3| 
poly(A) RNA polymerase, mitochondrial precursor [Homo sapiens] 2.403414883 1.189906295 0.554137221
9 1
gi|55956899|ref|NP_000217.2| 
keratin, type I cytoskeletal 9 [Homo sapiens] 0.865663579 0.957341781 0.333521432
22 1
gi|136429|sp|P00761.1|
TRYP_PIG Trypsin   1.335721469 0.832980711 0.832980711
5 1
gi|195972866|ref|NP_000412.3| 
keratin, type I cytoskeletal 10 [Homo sapiens] 1.371373706 0.77827941 1.487902367
4 1
gi|47132620|ref|NP_000414.2| 
keratin, type II cytoskeletal 2 epidermal [Homo sapiens] 0.843422992 0.715437896 0.910952975
15 1
gi|4508005|ref|NP_003440.1| 
tripartite motif-containing protein 26 [Homo sapiens] 0 0.479833198 0
12 1
gi|167466173|ref|NP_005337.2| 
heat shock 70 kDa protein 1A/1B [Homo sapiens] 0 0.458594012 0
35 1
gi|16751921|ref|NP_444513.1| 
dermcidin preproprotein [Homo sapiens] 0 0.389495494 0.389495494
16 1
gi|4757732|ref|NP_004199.1| 
apoptosis-inducing factor 1, mitochondrial isoform 1 precursor [Homo sapiens] 0 0.371686619 0
31 1
gi|24497605|ref|NP_057637.2| 
nuclear pore glycoprotein p62 [Homo sapiens] 0 0.258925412 0
21 1
gi|56237027|ref|NP_006537.3| 
insulin-like growth factor 2 mRNA-binding protein 1 isoform 1 [Homo sapiens] 0 0.216483949 0
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co-IP samples did not suggest significance. Mitochondrial HSP60 was indentified in the 
"65kDa" slice, but this was not investigated further. The "smear" gel slice was likely to be 
the result of keratin contamination from sample handling. 
 
7.3.2  Immunoblot analysis of mtPAP co-immunoprecipitations 
 
 The limitation of using immunoblotting for identifying protein-protein interactions 
is the necessity of assuming what the targets may be and of there being sufficient amounts 
to be detectable. Since these experiments were initiated prior to performing mass 
spectrometry on co-IP samples, the priority factors to probe for were LRPPRC and 
SLIRP, based largely on the in vitro data with recombinant proteins, where these factors 
had been reported to interact with mtPAP, and the knockout experiments performed in 
transgenic mice. Once the mtPAP co-IP samples were analyzed by mass spectrometry, 
confirming the presence of ATAD3, this protein became the next priority. These resulting 
western data are shown in Figure 7.2 There was very weak signal at the 130 kDa size in 
the co-IP sample (Figure 7.2A, lane 3). The signal was significantly diminished compared 
to input, and sandwiched between two non-specific bands (marked by *). SLIRP was not 
detected in the co-IP sample, surprisingly, considering it is reported to show robust 
binding of LRPPRC. ATAD3 was also detected as immunoprecipitated by mtPAP (lane 
3), in correspondence with the mass spectrometry data.  
A 
 
 
Figure 7.2. Immunoblot analysis of mtPAP co-immunoprecipitation. 
Eluates from the immunoprecipitations with MNK-1 IgG control (lane 2) and mtPAP (lane 3) antibodies were 
decorated with antibodies as indicated. Specific band corresponding to LRPPRC is labeled with black arrow. Non-
specific bands are labeled with asterisks. TOM20 was used as a control for input (lane 1) contamination.  
B 
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 To examine whether potential interactions of LRPPRC and ATAD3 with mtPAP 
were mediated by RNA binding, RNase A-treated mitochondrial lysates were subjected to 
immunoprecipitation using the anti-mtPAP antibody, and analyzed by immunoblotting 
and compared to RNA-protected lysates. As shown in Figure 7.2B, neither the weak 
signal at 130kDa nor ATAD3 levels present in the co-IP samples changed upon RNase A 
treatment of the mitochondrial lysates. This suggested that if ATAD3 or LRPPRC 
possibly interact with mtPAP, these interaction may not be established through shared 
RNA binding.  
 To further confirm possible interactions between mtPAP, LRPPRC, and ATAD3, 
FLAG-tagged mtPAP was expressed in HEK293 cells, and the Sigma M2 α-FLAG 
monoclonal antibody used to immunoprecipitate mtPAP. It was expected that the initially 
observed interactions would be recapitulated using the FLAG-IP approach. However, 
previous attempts to use the α-FLAG antibody with FLAG-tagged mtPAP in the 
lentivirus-transduced fibroblasts (Chapter 5) produced poor results. As the system using 
HEK293 cells is well established in our lab, the FLAG-IP was carried out and analyzed 
by immunoblotting. Clones of the HEK293 line expressing tetracycline-inducible mtPAP-
 
 
 
Figure 7.3. Expression and co-immunoprecipitation of mtPAP-FLAG 
A.. Western analysis was performed to determine expression of FLAG-tagged mtPAP in clonal HEK293 cells 
transfected with pcDNA5/FRT/TO-mtPAP-FLAG following 3 days induction (tetracycline 1ug/ml). B. 
Mitochondria from "clone 2" were used for α-FLAG co-IP. Input (lane 1) and eluate (lane 3) were immunoblotted 
against mtPAP, LRPPRC, and ATAD3. TOM20 was used as a control for input contamination.   
A 
B 
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FLAG were tested to determine expression levels (Fig 7.3A lanes 2, 4, 6). Good 
expression was identified in all 3 clones and clone 2 was selected for the FLAG-IP. The 
results, shown in Figure 7.3B, demonstrate interactions of LRPPRC and ATAD3 were not 
observed.  
 To rule out the possibility of the N478D mutation disrupting the potential 
interactions with either LRPPRC or ATAD3, co-IP experiments were performed using 
crude mitochondria isolated from control and 1432A>G mutant fibroblasts. The total 
input of mitochondrial lysate (Fig 7.4 lanes 1 and 2) was substantially less than used in 
the co-IP experiments 
utilizing HEK293 cells, 
with 250ug of fibroblast 
mitochondrial lysate versus 
900ug HEK293 
mitochondrial lysate. This 
likely had an impact on 
visualization of LRPPRC in 
the co-IP samples, as it 
could not be detected for the 
control (Fig 7.4 lane 4) and 
so it was not possible to 
determine if the level was 
affected in the mutant cell 
line (Fig 7.4 lane 3). ATAD3 is clearly present in the eluates of both the co-IP samples, 
and the level does not differ between wild-type or mutant fibroblasts (Fig 7.4 lanes 3 and 
4) and not detectable in the IgG control (lane 5).  
 
  
 
7.3.3  Investigating mtPAP associations with the mitochondrial  
  ribosome 
 
 
 
Figure 7.4. Wild-type versus N478D mtPAP co-
immunoprecipitation 
Mitochondrial lysate (250ug) was prepared from control (Lane 2) and 
homozygous 1432A>G (lane 1) fibroblasts. Eluates from 
immunoprecipitation reactions were probed for the presence of LRPPRC 
and ATAD3. TOM20 was used as a control for input contamination.  
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 The processes of mitochondrial transcription and translation have been 
hypothesized to be tightly coupled, based on data from S. cerevisiae (Shadel, 2004). To 
investigate the possibility of mtPAP interacting with factors involved in translation, the 
sedimentation profile of mtPAP was examined, along with components of the 
mitochondrial ribosome. In addition, the previously indentified factors, LRPPRC and 
ATAD3, were examined. Any potential changes as a result of the N478D mutation were 
also to be determined. The material used for the gradients was mitochondrial lysate 
isolated from control and 1432A>G mutant fibroblasts. The analysis of the sedimentation 
profiles consisted of immunoblotting fractions taken from the sucrose gradients.  
 Figure 7.5 shows that in both wild type and mutant cell lines mtPAP migrates 
primarily with the free fraction (fraction #1). No significant shift in fraction migration 
occurs as a result of the N478D mutation. DAP3 and MRPL3 were blotted as indicators 
of migration for the small and large subunits of the mitoribosome, respectively. Neither of 
these markers appeared to change migration status in the mutant fibroblasts. Further, the 
signal for wild-type and N478D mtPAP does not co-migrate with the markers for either 
the small or large subunits of the mitoribosome.  
 
 
Figure 7.5. Migration of mtPAP in isokinetic sucrose density gradients 
Fibroblast whole cell lysate (900ug) was separated through a 1ml 10-30% sucrose gradient. Fractions were analyzed by 
immunoblotting using MRPL3 and DAP3 as indicators of the large and small mitoribosomal subunits, respectively. The 
position in the gradient of mtPAP and the proteins identified as associated were also determined. The left panel 
corresponds to analysis of wild-type fibroblasts, and the right panel corresponds to analysis of the homozygous 
1432A>G mutant fibroblasts.  
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 Both LRPPRC and ATAD3 show changes in their positions in the mutant 
fibroblasts compared to wild-type. In the control cells the majority of the signal for 
ATAD3 is in fraction 2, with the remaining signal spread between fractions 3 and 6. In 
the mutant cells, ATAD3 appears to be in complexes of higher molecular weights as the 
strongest signal has shifted to fractions 5 and 6. For LRPPRC, the majority of the wild 
type signal is in fractions 1-4, although there is very weak signal throughout all the 
fractions. In the mutant fibroblasts the signal is distributed in fractions 1-6. For both wild-
type and mutant, SLIRP is only found within the free fraction (fraction 1).  
 These sucrose gradients did not visualize significant amounts of monosome, as is 
common for most cell lines. Thus, any changes resulting from the N478D mutation on 
assembly of the monosome could not be observed. The signals for MRPL3 and DAP3 are 
more intense for the mutant cells, due to exposure times necessary for visualization. This 
was consistent with the de novo protein synthesis data from wild-type and mutant 
fibroblasts, which also did not indicate any major uniform translation defects, making 
significant ribosome disruption unlikely as translation of all mtDNA-encoded peptides 
would be affected.   
 
7.3.4  Localization of mtPAP in mitochondrial RNA granules 
 
 The discovery of mitochondrial RNA granules as discrete foci of RNA processing 
(Jourdain et al., 2013) presented a logical location for mt-mRNA polyadenylation to take 
place . My host lab established a collaboration with Professor Jean-Claude Martinou's 
laboratory at the University of Geneva to carry out co-localization studies with mtPAP, 
and GRSF1 as a marker for the RNA granules. The immunofluorescence microscopy was 
performed by Alexis Jourdain, the lead author of the paper reporting the existence of the 
granules (Jourdain et al., 2013). The pcDNA5/FRT/TO-mtPAPFLAG construct was sent 
to Professor Martinou's lab to be transiently expressed in 143B.206 osteosarcoma cells, as 
Mr Jourdain was most confident of identifying the localization of mtPAP using α-FLAG 
antibodies in these cells. The mouse monoclonal α-mtPAP antibody was also sent to their 
lab to also allow examination of the endogenous localization of mtPAP. It was hoped that 
these two approaches would ideally produce mutually supportive results.  
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 The microscopy data for localization of wild-type endogenous and FLAG-tagged 
mtPAP are shown in Figure 7.6. Both the FLAG-tagged and endogenous mtPAP co-
localize with GRSF1, indicating the presence of mtPAP in the mitochondrial RNA 
granules. To further support this evidence, both endogenous and FLAG-tagged mtPAP 
co-localized with FASTKD2, another marker of mitochondrial RNA granules (personal 
correspondence, unpublished data).    
 In continuing to evaluate the precise impact of the N478D mutation, the 
localization of mutant mtPAP was also examined. The 1432A>G mutation was 
introduced into the pcDNA5/FRT/TO-mtPAPFLAG construct, and this was sent to 
Professor Martinou's lab for transient expression in 143B.206 cells. As shown in Figure 
 
 
 
 
Figure 7.6. mtPAP is present in mitochondrial RNA granules.  
A. Endogenous mtPAP was detected using α-mtPAP antibodies, and HA-tagged GRSF1 detected using α-HA 
antibodies, in 143B.206 cells. Fluorescent dye-conjugated secondary antibodies were used for visualization, and the 
signals merged to determine co-localization of mtPAP and GRSF1. B. 143B.206 cells were transiently transfected 
with the pcDNA5/FRT/TO-mtPAP-FLAG construct, and α-FLAG antibodies were utilized for detecting FLAG-
tagged mtPAP. The FLAG signal was then merged with signal from HA-tagged GRSF1.    
A 
B 
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7.7, the N478D FLAG-tagged mtPAP also appears to co-localize with GRSF1. However, 
the ability of the N478D mtPAP monomer to heterodimerize with the wild-type monomer 
is unknown. The presence of mtPAP in discrete mitochondrial foci does not seem to 
differ significantly with either the wild-type or N478D mtPAP-FLAG detected, so it is 
suggestive that the mutant enzyme is present in RNA granules as is the wild-type.  
 
 
  
 
 
 
Figure 7.7. N478D mtPAP-FLAG co-localizes with mitochondrial RNA granules.  
143B.206 cells were transiently transfected with a pcDNA5/FRT/TO-mtPAPFLAG construct harboring the 1432A>G 
mutation, and α-FLAG antibodies for detecting FLAG-tagged mtPAP. The FLAG image was then merged with the 
image from HA-tagged GRSF1. 
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7.4  Discussion 
 
 The most abundant protein found in the mtPAP co-IP samples was ATAD3. In 
addition to implications of involvement in chemoresistance and anti-apoptotic properties 
(Hubstenberger et al., 2008; Fang et al., 2010), this protein has been reported to be 
involved in multiple levels of mitochondrial gene expression. Reports have reported 
ATAD3 as associated with nucleoid, affecting ribosome and translation, and involvement 
in organelle fission machinery (He et al., 2007; Gilquin et al., 2010; He et al., 2012). 
These reports also indicate that ATAD3 interacts with the mitochondrial inner and outer 
membranes. These varied reports of ATAD3 involvement make precise connections with 
mtPAP or polyadenylation difficult. ATAD3A appeared to be the dominant type of 
ATAD3 present in the co-IP samples, as opposed to ATAD3B and ATAD3C, although 
both of these were present at high levels in the IP, as judged by MS EMPAI values and 
western. ATAD3B has been reported as a negative regulator of ATAD3A (Merle et al., 
2012). A large amount of ATAD3A is present in mtPAP co-IP samples. As ATAD3A has 
been reported to oligomerize (Gilquin et al., 2010), this may explain how such large 
amounts of the protein, relative to mtPAP, can be present in the co-IP samples. The 
reasons for the observed shift in position on the sucrose gradient in the presence of the 
N478D mtPAP are unclear. The possibility of a mutation causing increased interaction of 
ATAD3 with the mitoribosome is low, unless it normally associates with unincorporated 
subunits and these are increased in the presence of N478D mtPAP. However, there are no 
further data to support this hypothesis.   
 If the hypothesis that human mitochondrial transcription and translation are tightly 
coupled is true, perhaps ATAD3A serves as a linker for these processes. It may 
coordinate spatial localization of transcription and translation machinery, as it interacts 
with components of both, and is anchored to the inner mitochondrial membrane. The 
robust effect on de novo protein synthesis upon RNAi knock-down (He et al., 2012) 
supports this. The fragmented morphology also reported with RNAi knock-down (Gilquin 
et al., 2010) likely does not involve polyadenylation, and may simply reflect other roles 
that ATAD3 fulfills.  
 It is important to note the lack of ATAD3 signal in the FLAG-IP reactions. This 
may implicate ATAD3 as a non-specific interaction, rather than a physiologically relevant 
binding partner of mtPAP. An important experiment to perform would be 
immunoprecipitating ATAD3, and then blotting for the presence of mtPAP.  
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 The hypothesized protein-protein interaction with LRPPRC was not supported by 
the IP and sucrose gradient data. The observed signal at 130kDa in HEK293 co-IP 
samples was not present at the levels expected for robust interaction with mtPAP. This 
does not conclusively disprove an interaction between LRPPRC and mtPAP, but if such 
an interaction exists, it may be very transient. The approach of excising Coomassie 
stained bands from co-IP samples separated by SDS-PAGE had the major limitation of 
not allowing examination of all the other proteins present at other points of migration 
through the gel. Analysis by mass spectrometry of the total co-IP sample would be more 
informative, particularly for identifying if LRPPRC is present at appreciable levels.  
 LRPPRC is clearly present in the free fraction of the sucrose gradient, like 
mtPAP. However, this is not evidence of a direct interaction, moreover LRPPRC is 
spread throughout several fractions of the gradient. Without visualization of the 
monosome, the impact of the N478D mutation on ribosome assembly is difficult to 
examine. The slight shift in position on the gradient observed in mutant fibroblasts may 
not be physiologically relevant. LRPPRC is commonly identified in mitochondrial protein 
immunoprecipitations. This may reflect bona fide interactions, or the ‘sticky’ nature of 
the protein generating a non-specific contaminant. While the model of direct interaction 
between LRPPRC/mtPAP is attractive, based on the in vitro polyadenylation data 
(Chapter 6), there is little published evidence to support it beyond those experiments.  
 The presence of mtPAP in mitochondrial RNA granules is not entirely 
unexpected, as it is logical to associate polyadenylation events spatially and temporally 
with transcript processing and maturation. This is what occurs in the human nucleus, with 
cleavage and polyadenylation intimately coupled. The localization experiments have also 
confirmed that the N478D mutation does not interfere with mtPAP being directed to the 
granules. This is consistent with the in vitro experiments using N478D mtPAP that 
suggested a potential defect in processivity of the enzyme rather than mis-localization. 
Future work should investigate whether RNA polymerase is present closely associated 
with the granules, perhaps with further co-IP and mass spectrometry analysis, with 
emphasis on searching for factors involved with transcription and maturation.  
 The localization to RNA granules also confirms mtPAP to be present and active in 
the mitochondrial matrix, as it is present with proteins that have been identified as 
residing in the matrix. The microscopy images appear to show mtPAP as present in 
discrete mitochondrial foci, rather than present diffusely in the matrix. If the enzyme were 
also fulfilling roles in the cytosol, a much more even distribution throughout the cell 
would be expected. This conflicts with a previous report that stated that mtPAP (then 
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referred to as TUTase 1) is present in the cytosol and responsible for oligouridylation of 
histone mRNA (Mullen and Marzluff, 2008). There remains a possibility that small, near-
undetectable amounts of mtPAP are located in the cytosol, and responsible for 
oligouridylation of the histone mRNAs. However, a later report mentions, via 
unpublished data, that the effects of TUTase 1 on histone mRNAs was an indirect result 
of a cell growth defect (Su et al., 2013). That report provides additional evidence that 
mtPAP may not be directly involved with cytosolic polynucleotide tails, and is probably 
exclusively a mitochondrial factor.   
 In conclusion, this chapter indicates that a novel candidate for interaction with 
MTPAP is ATAD3. In particular, the ATAD3A was the most abundant of the three 
ATAD3 isoforms. Characterization of this interaction is ongoing.  
 
 
  
193 
 
 
 
 
 
 
 
Chapter 8 
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Concluding remarks and future directions 
 
 The two major questions these studies aimed to address were: what is the role of 
the human mitochondrial poly(A) tail, and what is the impact of the mtPAP N478D 
mutation? Despite the rigorous investigations performed, neither of these questions have 
been completely resolved. However, over the course of this thesis work, major strides 
have been made in elucidating their answers. The results presented here represent the first 
report of the effects of a physiological, rather than an artificial loss of polyadenylation in 
human mitochondria, and how the loss of the mitochondrial poly(A) tail can cause the 
oxidative defects underlying the neurodegenerative pathologies reported as a consequence 
of a PAPD1 mutation (chapters 4 and 5). The effect of LRPPRC enhancing the mtPAP 
polyadenylation activity was confirmed and clarified via the in vitro investigations 
(chapter 6). In addition, the novel interaction of mtPAP and ATAD3 was uncovered 
(chapter 7).   
 The establishment of fibroblast lines harboring the 1432A>G PAPD1 mutation in 
culture was designed to allow a more physiologically relevant system for assessing the 
function of mitochondrial polyadenylation. Free from non-specific effects resulting from 
targeted intervention, the cells would ideally provide valuable mechanistic insights as to 
the role of the poly(A) tail in mitochondrial gene expression. As a result of the studies 
detailed in this thesis work, numerous insights have been made. The various perturbations 
of transcript and translation processes catalogued have presented a complex picture of the 
effects of truncating the poly(A) tail. Particular results stand out, in terms of raising more 
questions. The non-uniform changes with increases, decreases, or non-effect observed on 
mt-mRNA stability are perplexing. No single trend emerges from the specific impact on 
each of the transcripts. It is unclear whether the varying effects are a result of the tail 
performing multiple functions, or if the mt-mRNAs behave differently based on as yet 
unknown qualities.  
 For some transcripts there is also a disconnect between mt-mRNA levels and the 
steady state levels of the encoded polypeptide. There are differences in de novo protein 
synthesis and translation product turnover for different gene products. It is intriguing to 
speculate how the profound loss of a poly(A) extension at the 3’ terminus of the mt-
mRNA could affect its translatability and even more so the turnover of the resulting 
polypeptide. It is possible that small perturbations in translation processes can cause 
major defects, as reflected in the steady-state protein levels and assembly of the 
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respiratory complexes. These disconnects between transcript stability and protein 
synthesis represent major deficits in our understanding, mechanistically speaking. More 
work is necessary to dissect the molecular processes underlying these results. The data 
from complex IV gene expression stand out amidst the complicated results. From 
shortening of the poly(A) tail to decreased steady-state levels of the mRNA transcripts, to 
decreased protein synthesis, to decreased steady-state protein levels, culminating in a 
profound loss of fully assembled complex IV. This is the only complex to show such a 
linear progression of downstream effects from oligoadenylation of the mt-mRNAs, and 
presents a compelling argument for a role in transcript stabilization for the poly(A) tail in 
mitochondria.    
 The experiments performed here, particularly the transduction of the mutant 
patient fibroblasts with wild type PAPD1, confirmed the pathogenicity of the 1432A>G 
PAPD1 mutation. As an extension of these observations, this work aimed to characterize 
the explicit impact of the mutation on the polymerase. Studying the characteristics of the 
recombinant mutant protein in isolation provided many clues as to the exact consequences 
of the defect. Gel filtration analysis revealed that the dimerization status of N478D 
mtPAP is not disrupted. The in vitro N478D mtPAP activity data generated supported the 
hypothesis that the mutation is disrupting activity, directly or indirectly, as western data 
from the fibroblast lines had established that the stability of the mutant protein was 
unaffected. No data indicated that the mutation affected any of the currently identified 
protein-protein interactions. My in vitro data indicated that the wild type protein was able 
to act on a naked RNA end and did not require an oligo(A) tail as a substrate, suggesting 
that another enzyme is not required to generate the oligo(A) tail as a prerequisite for a 
poly(A) extension. Wild type mtPAP was also able to extend from an oligo(A) tail. The 
mutant protein had similar recognition and was able to act on both naked and 
oligoadenylated 3’ termini, although without the same level of extension activity. The 
reduced poly(A) tail length could therefore be through a defect in processivity, or changes 
in affinity for substrate. If the poly(A) polymerase disengages from the RNA transcript 
too easily, extension of the poly(A) tail could be compromised, as seen in the data from 
the mutant protein. The ability to isolate the exact structural or catalytic consequences of 
the mutation were beyond the scope of this work. What is clear is the N478D polymerase 
can still add to the 3' termini of RNA substrates, whether they are ‘naked’ or 
oligoadenylated but only in a severely compromised fashion. The lengths observed in 
vitro correspond to the lengths identified on the MPAT assay in the homozygous mutant 
fibroblasts. This provides evidence against the hypothetical oligo(A) polymerase in 
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mitochondria. It also leaves the question as to why the mutant cannot successively re-
associate with the oligo(A) tail it generates to extend the 3’ modification in an additive 
fashion. 
 Due to time restrictions, multiple avenues of investigation that were identified 
from results presented in this thesis were not explored. An aspect of transcriptional 
processing that was not investigated was the roles of the various nucleases may have in 
regulating the length of the poly(A) tail. hSUV3, PNPase, PDE12, and still undiscovered 
RNases may all play a role in regulating polyadenylation, as well as in regulating 
transcript stabilities. Depleting these factors in the mutant PAPD1 cells may produce 
effects that are informative on which of the factors affect the poly(A) tails. This might be 
particularly informative in the patient fibroblasts transduced with the wild-type PAPD1 
transgene, where extra extension of the poly(A) tail was observed by MPAT assays. 
These putative RNase regulators of poly(A) tail length may act in concert with each other 
as well. There must be an in vivo system that monitors/regulates the particular length of 
the poly(A) tail. The in vitro data reported here suggests that mtPAP is capable of 
extensions longer than the approximately 45nt poly(A) tail found on mt-mRNAs. My data 
suggested that this might be modulated in the presence of the LRPPRC/SLIRP complex. 
However, as mentioned earlier, more work is necessary to rule out any assay artifact. This 
emphasizes the need for further experiments examining the processes governing poly(A) 
length.  
 While the patient fibroblasts proved to be valuable models for investigating 
mitochondrial polyadenylation, it is pertinent to note that the affected tissue in the 
patients was primarily neuronal. Investigating potential differences in how the mtPAP 
mutation impacts various cell types would be informative. Possible avenues of exploring 
this area include generating transgenic mice homozygous for the mutant PAPD1 gene, or 
de-differentiating the patient fibroblasts, and then differentiating them into specific cell 
types of interest. 
 The identification, reported here, of ATAD3 interacting with mtPAP bears further 
exploration. The most pertinent experiment, as related to this body of work, would be 
assessing the poly(A) tail lengths in cell lines carrying ATAD3 mutations or cells 
depleted of ATAD3. This would reveal if interactions between the two proteins 
physiologically affects polyadenylation activity. Inclusion of recombinant ATAD3, 
particularly ATAD3A, in the in vitro poly(A) assays may also offer evidence of impact 
on poly(A) extension.  
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 Several experiments remain to be performed to complete this area of work and 
allow manuscript preparation. Of critical importance is the enzymatic activity of complex 
V in homozygous 1432A>G PAPD1 mitochondria. Depletion at steady-state of the ATP6 
and putatively of ATP8 subunits would be expected to cause major assembly and activity 
issues for the complex, yet analysis via blue native PAGE suggests wild-type levels of 
assembly. A final experiment that I would like to perform is the immunoprecipitation of 
mtPAP from the in vitro reactions containing LRPPRC, to search for any evidence of 
protein-protein interaction.  
 In summary, this thesis work has shown that the shorter oligo(A) tails on human 
mitochondrial transcripts results in pathogenic molecular consequences, and revealed 
insights into the regulation of polyadenylation. These types of investigations are critical 
to fully elucidate the mechanisms governing transcript stability and translation effects in 
the presence of shortened poly(A) tails. Further studies based on the data generated for 
this thesis will allow progress to be made in understanding multifaceted mitochondrial 
disease states, and developing treatments for patients with defects in these specific 
pathways. The story still remains incomplete, and further research is required but the data 
presented here represents an advance in understanding the complexity of mitochondrial 
post-transcriptional maturation and gene expression.  
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Appendix A:  
Additional in vitro polyadenylation time courses 
I.   
  
 
 
 
 
 
  
A 
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Figure 6.25. Individual contributions of LRPPRC and SLIRP to in vitro 
polyadenylation activity. 
Wild-type His-mtPAP (0.55uM, lanes 2-8 A and B) was incubated for multiple time points with A) LRPPRC 
(0.5uM) and B) SLIRP (0.5uM) present. Single 2hr time point control reactions including LRPPRC/SLIRP complex 
(0.5uM) were provided for comparison. Incubations took place at 37⁰C. The 40nt RNA transcript (0.25uM) was 
used as the substrate. At each time point, reactions were quenched with 90% formamide/1x TBE, and stored at -
20⁰C. Samples were later thawed, then separated through a 15% polyacrylamide/8.3M urea gel, and stained with 
SYBR gold. Stained products were visualized by scanning with a Typhoon FLA 9500 instrument.  
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II. 
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Figure 6.26. Polyadenylation time courses using oligo(A) RNA substrate. 
Wild-type His-mtPAP (0.55uM) was incubated for the same time points as in Figure 6.24 without (A) and with (B) 
LRPPRC/SLIRP complex (0.5uM) present. Oligoadenylated 48nt RNA substrate was present at 0.25uM. Incubations 
took place at 37⁰C. At each time point (0 to 120min), reactions were quenched with 90% formamide/1x TBE, and 
stored at -20⁰C. Samples were later thawed, then separated through a 15% polyacrylamide/8.3M urea gel, and stained 
with SYBR gold. Stained products were visualized by scanning with a Typhoon FLA 9500 instrument. 
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III. 
Lentiviral vector backbone, with PAPD1 (accession number: NM_018109.1) cloned in 
(Cat #: LP-W1687-Lv121, Lot #: GC10312K1105).  
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Appendix C 
 
MTCO1 MPAT results pre and post WT PAPD1 expression 
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MTCO1 MPAT results pre and post expression of WT 
PAPD1 
A. Initial gene-specific PCR results forRNA14 and MTCO1. B. Results of the 
MTCO1 MPAT analysis performed on RNA extracted from fibroblasts pre and 
post treatment with LVPAPD1.  
